WO2006041641A2 - Therapeutic agents with decreased toxicity - Google Patents

Therapeutic agents with decreased toxicity Download PDF

Info

Publication number
WO2006041641A2
WO2006041641A2 PCT/US2005/033952 US2005033952W WO2006041641A2 WO 2006041641 A2 WO2006041641 A2 WO 2006041641A2 US 2005033952 W US2005033952 W US 2005033952W WO 2006041641 A2 WO2006041641 A2 WO 2006041641A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
xaa
conjugate molecule
molecule according
sabm
Prior art date
Application number
PCT/US2005/033952
Other languages
French (fr)
Other versions
WO2006041641A3 (en
Inventor
Mark S. Dennis
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Priority to MX2007003907A priority Critical patent/MX2007003907A/en
Priority to EP05810079A priority patent/EP1796718A2/en
Priority to JP2007535700A priority patent/JP2008515889A/en
Priority to AU2005294723A priority patent/AU2005294723A1/en
Priority to CA002583137A priority patent/CA2583137A1/en
Priority to BRPI0516577-6A priority patent/BRPI0516577A/en
Publication of WO2006041641A2 publication Critical patent/WO2006041641A2/en
Publication of WO2006041641A3 publication Critical patent/WO2006041641A3/en
Priority to IL182261A priority patent/IL182261A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • This invention relates to novel therapeutic agents with decreased toxicity in vivo, compositions comprising the same, methods for decreasing the toxicity of therapeutic agents in vivo and methods for treating patients comprising administering the novel therapeutic agents.
  • ADC antibody-drug conjugates
  • Toxins used in antibody-toxin conjugates include bacterial toxins such as diphtheria toxin, plant toxins such as ricin, small molecule toxins such as geldanamycin (Mandler et al (2000) J. of the Nat. Cancer Inst. 92(19):1573-1581; Mandler et al (2000) Bioorganic & Med. Chem. Letters 10:1025-1028; Mandler et al (2002) Bioconjugate Chem. 13:786-
  • auristatin peptides More recently, auristatin peptides, auristatin E (AE) and monomethylauristatin (MMAE) and synthetic analogs of dolastatin (WO 02/088172), have been conjugated to full length antibodies (e.g., Klussman, et al (2004), Bioconjugate Chemistry 15(4):765-773; Doronina et al (2003) Nature Biotechnology 21(7):778-784;
  • ZEVALIN® is an antibody-radioisotope conjugate composed of a murine IgGl kappa monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes and In or Y radioisotope bound by a thiourea linker- chelator (Wiseman et al (2000) Eur. J. Nucl. Med. 27(7):766-77; Wiseman et al (2002) Blood 99(12):4336-42; Witzig et al (2002) J. CHn. Oncol. 20(10):2453-63; Witzig et al (2002) J.
  • ZEVALIN® has activity against B-cell non-Hodgkin's Lymphoma (NHL), administration results in severe and prolonged cytopenias in most patients.
  • MYLOT ARGTM (gemtuzumab ozogamicin, Wyeth Pharmaceuticals), an antibody drug conjugate composed of a CD33 antibody linked to calicheamicin, was approved in 2000 for the treatment of acute myeloid leukemia by injection (Drugs of the Future (2000) 25(7):686; US Patent Nos. 4970198; 5079233; 5585089; 5606040; 5693762; 57391 16; 5767285; 5773001 ).
  • Cantuzumab mertansine (Immunogen, Inc.), an antibody drug conjugate composed of the huC242 antibody linked via the disulfide linker SPP to the maytansinoid drug moiety, DMl (Xie et al (2004) J. ofPha ⁇ m. and Exp. Ther. 308(3):1073-1082), is advancing into Phase II trials for the treatment of cancers that express
  • CanAg such as colon, pancreatic, gastric, and others.
  • MLN-2704 (Millennium Pharm., BZL Biologies, Immunogen Inc.)
  • PSMA anti-prostate specific membrane antigen
  • DMl maytansinoid drug moiety
  • glycosylation sites have been introduced to the molecules (Keyt et.al., 1994, PNAS USA 91:3670-74), and molecules have been conjugated with PEG (Clark et.al., 1996, J. Biol. Chem., 271: 21969- 77; Lee et. al, 1999, Bioconjugate Chem. 10:973-981; Tanaka et. al., 1991, Cancer Res. 51:3710-14) to increase size and increase elimination half-times. Some have attempted to use human serum albumin to improve the therapeutic use of the drug.
  • albumin has been attached to small molecules (Syed etal., 1997, Blood 89:3243-3252; Burger et.al., 2001 Int. J. Cancer 92:718-724; Wosikowski K, et al., Clin Cancer Res. 2003 May 9(5): 1917-26); CD4 (Yeh et.al., 1992, PNAS USA 89: 1904-1908); the Fc portion of an IgG (Ashkenazi et.al.(1997) Curr.Opin in Immunol.
  • albumin binding polypeptides have also been investigated. Extended in vivo half-times of human soluble complement receptor type 1 (sCRl) fused to the albumin binding domains from Streptococcal protein G have been reported (Makrides et al. 1996 /. Pharmacol. Exptl. Ther. 277:532-541). Labelled albumin binding domains of protein G have been described (EP 0486,525). Several phage diplay-derived albumin binding peptides have been described by applicant. See WO 01/45746, United States Patent
  • serum albumin binding peptides associate with serum albumin non-covalently in vivo.
  • the serum albumin binding peptides are necessarily a step removed from the in vivo cycling mechanism of serum albumin itself.
  • the invention described below addresses the unexpectedly advantageous utility of albumin binding peptides in the context of a conjugate with a targeting agent/cytoxic agent.
  • the present invention relates to a conjugate molecule comprising a covalently linked combination of at least one serum albumin-binding moiety (SABM), targeting agent (TA) and cytotoxic agent (CA).
  • SABM serum albumin-binding moiety
  • TA targeting agent
  • CA cytotoxic agent
  • the conjugate molecule comprises 2 or more CAs.
  • the conjugate molecule comprises 2 or more TAs.
  • the SABM comprises an amino acid sequence that is at " least 50% identical to the sequence of DICLPRWGCLW (SEQ ID NO:8) and wherein the amino acid sequence has two Cys residues with five amino acid residues in between the Cys residues.
  • the amino acid sequence has a percent identity to SEQ ID NO:8 that is selected from the group consisting of at least 60% identity, at least 70% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, at least 98% identity and at least 99% identity.
  • the SABM comprises a variant of the amino acid sequence of DICLPRWGCLW (SEQ ID NO:8), wherein between 1-5 residues of any of one of the residues of SEQ ID NO:8
  • NO:8 is substituted with a different amino acid residue, except for the Cys residues.
  • the SABM comprises a linear or a cyclic amino acid sequence selected from the group consisting of :
  • Val-Cys-Tyr-Xaa-Xaa-Xaa-Ile-Cys-Phe [SEQ ID NO: 2] Cys-Tyr-Xaal-Pro-Gly-Xaa-Cys [SEQ ID NO: 3] Asp-Xaa-Cys-Leu-Pro-Xaa-Trp-Gly-Cys-Leu-Trp [SEQ ID NO: 4] Trp-Cys-Asp-Xaa-Xaa-Leu-Xaa-Ala-Xaa-Asp-Leu-Cys [SEQ ID NO: 5]; Asp-Leu- Val-Xaa-Leu-Gly-Leu-Glu-Cys-Trp [SEQ ID NO: 6] ;
  • SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3and SEQ ID NO: 4 comprise additional amino acids at the N- terminus (Xaa) x and additional amino acids at the C-terminus (Xaa) z , wherein Xaa is an amino acid and x and z are a whole number greater or equal to 0 (zero), generally less than 100, preferably less than 10 and more preferably 0, 1, 2, 3, 4 or 5 and more preferably 4 or 5 and Xaajis selected from the group consisting of He, Phe, Tyr, and VaI
  • the invention relates to the use of an albumin binding peptide comprising the sequence DICLPRWGCLW [SEQ ID NO 8]
  • the SABM comprises any one of the ammo acid sequences selected from the group consisting of SEQ ID NOs 7-20,27- 154 and 157-421
  • the SABM comprises the amino acid sequence selected from the group consisting of SEQ ID NOs 7, 8 9, 10, 1 1 ,
  • the SABM comprises the following amino acid sequence
  • the SABM comprises any one of the peptide sequences described m Tables 1-9
  • all the above-mentioned SABM sequences bind to serum albumin with a K ⁇ that is about 100 ⁇ M or less
  • the K ⁇ is selected from the group consisting of about 10 ⁇ M or less, about 1 ⁇ M or less, about 500 nM or less, about 10OnM or less, about 5OnM or less and about 1OnM or less
  • the TA is a polypeptide comprising an amino acid sequence that can bind to a target cell surface protein, wherein the TA comprises an amino acid sequence that is a hgand for the cell surface protein, an adhesion or an antibody, or a fragment of any one of the above that can bind to the cell surface protein
  • the cell surface protein to be targeted is a B cell surface marker
  • the receptor to be targeted is selected from the group consisting of
  • the TA is an antibody directed against any one of those receptors According to a preferred embodiment, the antibody is in the form of any one of the following a Fab, F(ab) 2 , scFv and a diabody According to another embodiment, the TA comprises a VH or VL sequence described herein (e g , an anti-HER2 antibody comprising the antigen- binding portions of SEQ ID NO 428 and 429)
  • the anti-HER2 antibody comprises the variable regions of SEQ ID NO 428 and 429
  • the anti-HER2 antibody comprises a variant of the light chain variable sequence of SEQ ID NO 428, wherein at least one or more of the ammo acids selected from the group consisting of Q27(V L ), D28(V L ), N30(V L ), T31(V L ), A32(V L ), Y49(V L ), F53(V L ), Y55(V L ), R66(V L ), H91(V L ), Y92((V L ), and T94(V L ), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine
  • the anti-HER2 antibody comprises a variant of the light chain variable sequence of SEQ ID NO 428, wherein at least one or more amino acids of the variable region have a substitution selected from the group consisting of D28(V L )Q, D28(V L L ),
  • the anti-HER2 antibody comprises a variant of the heavy chain variable sequence of SEQ ID NO:429, wherein at least one or more of the amino acids selected from the group consisting of W95(V H ), D98(V H ), F100(V H ), Y100a(V H ), and Y102(V H ), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.
  • the anti-HER2 antibody comprises a variant of the heavy chain variable sequence of SEQ ID NO:429, wherein the variable region comprises at least one or more substitutions selected from the group consisting of W95(V H )Y, D98(V H )W, D98(V H )R, D98(V H )K, D98(V H )H, F100(V H )P, F100(V H )L, F100(V H )M, F100(V H )W, Y100a(V H )F, Y102(V H )V, Y102(V H )K, and Y102(V H )L.
  • the variable region comprises at least one or more substitutions selected from the group consisting of W95(V H )Y, D98(V H )W, D98(V H )R, D98(V H )K, D98(V H )H, F100(V H )P, F100(V H )L, F100(
  • the anti-HER2 antibody comprises a variant of the heavy chain variable sequence of SEQ ID NO:429, wherein the variable region comprises at least the substitutions F100(V H )P and Y102(V H )K. According to one embodiment, the anti-HER2 antibody comprises a variant of the heavy chain variable sequence of SEQ ID NO:429, wherein the variable region comprises at least the substitutions of F100(V H )P and Y102(V H )L.
  • the anti-HER2 antibody comprises variants of the light chain variable sequence SEQ ID NO:428 and heavy chain variable sequence SEQ ID NO:429, wherein at least one or more of the amino acids selected from the group consisting of D28(VL), N30(V L ), T31(V L ), A32(V L ), Y49(V L ), F53(V L ), Y55(V L ), R66(V L ), H91(V L ), Y92(V L ), T94(V L ), W95(V H ), D98(V H ), F100(V H ); Y100a(V H ), and Y102(V H ), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.
  • the anti-HER2 antibody comprises variants of the light chain variable sequence SEQ ID NO:428 and heavy chain variable sequence SEQ ID NO:429 comprising at least one or more of the following substitutions D28(V L )Q; D28(V L )G; N30(V L )S; T31(V L )S; A32(V L )G; Y49(V L )W, Y49(V L )D, Y49(V L )V; F53(V L )W, F53(V L )V, F53(V L )Q, Y55(V L )W, R66(V L )N, H91(V L )F, H91(VL)Y, Y92(V L )W, T94(V L )S, W95(V H )Y, D98(V H )W, D98(V H )R, D98(V H )K, D98(V H )H, F100
  • the anti-HER2 antibody comprises variants of the light chain variable sequence SEQ ID NO:428 and heavy chain variable sequence SEQ ID NO:429 comprising at least the following substitutions Y49(V L )D, F53(V L )W, Y55(V L )W, FIOO(VH)P, and Y102(V H )K.
  • the anti-HER2 antibody comprises variants of the light chain variable sequence SEQ ID NO:428 and heavy chain variable sequence SEQ ID NO:429 comprising at least the following substitutions Y49(V L )D, F53(V L )W, Y55(VL)W, FIOO(VH)P, and
  • the anti-HER2 antibody is any anti-HER2 antibody disclosed in United States Patent Publication No. 2003/0228663 Al, filed April 9, 2003; WO 03/087131; Carter et al, (1992) PNAS 89:4285-4289 which publications are expressly incorporated by reference herein.
  • the TA has an additional bioactivity other than the ability to bind to a protein on the outer surface of a cell.
  • the other bioactivity is the ability to block ligand-mediated cellular signaling through the cell.
  • the other bioactivity is the ability to induce apoptosis of the targeted cell.
  • the TA is a polypeptide that binds to a protein on a cell of interest with a Kd selected from the group consisting of lOuM or less, 1 uM or less, 500nm or less, lOOnm or less and 10 nm or less.
  • tne protein on me ceil or interest to wnicn tne i A Din ⁇ s is overexpressed in cancer cells as compared to normal cells.
  • the cell being targeted by the TA is a pathogenic cell, such as a tumor cell.
  • the cytotoxic agent is monomethylauristatin (MMAE).
  • the conjugate molecule comprises a linker moiety located between said SABM and targeting agent or cytotoxic agent.
  • the linker moiety comprises the amino acid sequence: GGGS (SEQ ID NO:422).
  • the SABM binds to human albumin.
  • the SABM is conjugated to the N- or C-terminal region of a variable heavy or variable light chain of a TA.
  • the present invention provides compositions comprising the conjugate molecule admixed with a pharmaceutical carrier.
  • the present invention also provides a the use of the conjugate molecule in the manufacture of a medicament.
  • the present invention also provides methods for reducing the toxicity of a therapeutic agent comprising the step of producing a therapeutic agent with a serum albumin binding moiety (SABM) conjugated to the therapeutic agent.
  • the method can further comprise the step of comparing the toxicity of the therapeutic agent having the SABM with the therapeutic agent without the SABM.
  • the method further comprises the step of measuring the toxicity of the therapeutic agent:SABM conjugate.
  • the present invention provides methods of reducing the toxicity of a therapeutic agent in a mammal comprising administering to the mammal a therapeutically effective amount of the conjugate molecule according to this invention.
  • the method further comprises the step of measuring the toxicity of the therapeutic agentSABM conjugate.
  • the mammal is suffering from an autoimmune disease or a cancer.
  • the present invention provides methods of treating a tumor in a mammal comprising the step of treating a mammal having the tumor with a therapeutically effective amount of a conjugate molecule of this invention that binds to the tumor cells or vasculature surrounding the tumor.
  • the present invention also provides methods of treating an autoimmune disorder in a mammal comprising the step of treating a mammal having the autoimmune disorder with a therapeutically effective amount of a conjugate molecule of this invention.
  • the conjugate molecules bind to B-cells that contribute to or cause the autoimmune disorder.
  • the present invention also provides methods of treating a cell proliferative disorder in a mammal comprising the step of treating a mammal having the autoimmune disorder with a therapeutically effective amount of a conjugate molecule of this invention.
  • the present invention provides a method for depleting B cells in a mammal comprising the step of treating the mammal with a therapeutically effective amount of a conjugate molecule of this invention that binds to the B cell.
  • the methods of treatment of this invention further comprises the step of measuring the toxicity of the conjugate molecule in a mammal.
  • toxicity is manifested as any one of the group consisting of weight loss, hematopoietic toxicity, renal toxicity, liver toxicity, gastrointestinal toxicity, decreased mobilization of hematopoietic progenitor cells from bone marrow into the peripheral blood, anemia, myelosuppression, pancytopenia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, stomatitis, alopecia, headache, and muscle pain.
  • the present invention also provides articles of manufacture comprising a container, a composition within the container comprising a conjugate molecule of this invention, a package insert containing instructions to administer a therapeutically effective dose.
  • Figure 1 shows the tumor volume over time post injection of a control vehicle (circles), Herceptin®- vc-Pab-MMAE (squares), Ab.Fab4D5-H-vc-PAB-MMAE (diamonds), Fab3D4-vc-PAB-MMAE (triangles) and Ab.FabControl-vc-P AB-MMAE (empty circles).
  • Figure 2 shows the group change in body weight post administration of Herceptin®-vc ⁇ MMAE (squares), Herceptin®- F(ab') 2 4D5-vc-MMAE (crosses), free MMAE (circles).
  • Figure 3 shows the group change in body weight post administration of Herceptin®- vc-MMAE (diamonds), Fab4D5-vc-MMAE (triangles), AB .Fab4D5-H- vc-MMAE (circles) and PBS (squares).
  • Figure 4 shows the amino acid sequence of a light chain variable domain of a humanized anti-HER2 antibody [SEQ ID NO:428] and a heavy chain variable domain of a humanized anti-HER2 antibody [SEQ ID NO:429].
  • serum albumin binding peptide or “serum albumin binding moiety” (“SABM”) refers to a compound or a polypeptide comprising an amino acid sequence that binds to serum albumin.
  • the SABM binds to a human serum albumin.
  • the SABM comprises at least one of any one of the sequences recited in the Listing of Sequences that binds to rabbit, rat, mouse or human serum albumin.
  • the SABM comprises at least one of any one of the sequences recited in the Listing of Sequences that binds to multiple species of serum albumin.
  • the SABM comprises at least one of any one of the sequences recited in Tables 1-9 that binds to any one or combination of rabbit, rat, mouse and human serum albumin.
  • the SABM comprises at least one of any one of the sequences recited in the Tables 1-9 that binds to multiple species of serum albumin.
  • multispecies binders include those SABM's that bind at least human and rat serum albumin; those that bind at least human, rat and rabbit serum albumin; those that bind at least human and rabbit serum albumin; and those that bind at least human and mouse serum albumin.
  • the SABM peptide is a non-naturally occurring amino acid sequence that can bind albumin.
  • SABMs within the context of the present invention can be constrained (that is, having some element of structure as, for example, the presence of amino acids which initiate a beta-turn or beta- pleated sheet, or for example, cyclized by the presence of disulfide-bonded Cys residues) or unconstrained (linear) amino acid sequences of less than about 50 amino acid residues, and preferably less than about 40 amino acids residues.
  • SABMs less than about 40 amino acid residues, preferred are the SABMs of between about 10 and about 30 amino acid residues and especially the SABMs of about 20 amino acid residues.
  • the skilled artisan will recognize that it is not the length of a particular SABM but its ability to bind an albumin that distinguishes the SABM of the present invention.
  • a “targeting agent” or "TA” of the present invention will bind a target molecule on the surface of a cell with sufficient affinity and specificity if the TA "homes" to, "binds” or “targets” a target molecule such as a specific cell type bearing the target molecule in vitro and preferably in vivo (see, for example, the use of the term “homes to,” “homing,” and “targets” in Pasqualini and Ruoslahti, 1996 Nature, 380:364-366 and Arap et al., 1998 Science, 279:377-380).
  • the TA will bind a target molecule with an affinity characterized by a dissociation constant, K 11 , of less than about 10 microM, preferably less than about 100 nM and less than about 10 nM.
  • K 11 dissociation constant
  • polypeptides or small molecules having an affinity for a target molecule of less than about 1 nM and preferably between about 1 pM and 1 nM are equally likely to be TAs within the context of the present invention.
  • the TA is a polypeptide (e.g., an antibody).
  • a TA that binds a particular target molecule as described above can be isolated and identified by any of a number of techniques known in the art.
  • TAs are amino acid sequences as described above that may contain naturally as well as non-naturally occurring amino acid residues, such as phage-display derived antibodies. So-called “peptide mimetics” and
  • peptide analogs that include non-amino acid chemical structures that mimic the structure of a particular amino acid or peptide, can be TAs within the context of the invention. Such mimetics or analogs are characterized generally as exhibiting similar physical characteristics such as size, charge or hydrophobicity present in the appropriate spatial orientation as found in their peptide counterparts.
  • a specific example of a peptide mimetic compound is a compound in which the amide bond between one or more of the amino acids is replaced by, for example, a carbon-carbon bond or other bond as is well known in the art (see, for example Sawyer, 1995, In: Peptide Based Drug Design pp. 378-422, ACS, Washington DC ).
  • B cell surface marker or “B cell surface antigen” herein is an antigen expressed on the surface of a B cell which can be targeted with an antagonist which binds thereto.
  • Exemplary B cell surface markers include the CDlO, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD40, CD53, CD72, CD73, CD74,
  • CDw75, CDw76, CD77, CDw78, CD79a, CD79b, CD80, CD81, CD82, CD83, CDw84, CD85 and CD86 leukocyte surface markers for descriptions, see The Leukocyte Antigen Facts Book, 2nd Edition. 1997, ed. Barclay et al. Academic Press, Harcourt Brace & Co., New York).
  • B cell surface markers include RP105, FcRH2, CD79A, C79B, CR2, CCR6, CD72, P2X5, HLA-DOB, CXCR5, FCER2, BR3, BTLA, NAG14 (aka LRRC4), SLGC16270 (ala LOC283663), FcRHl, IRTA2, ATWD578 (aka MGC15619), FcRH3,
  • IRTAl FcRH6 (aka LOC343413) and BCMA (aka TNFRSF17).
  • the B cell surface marker of particular interest is preferentially expressed on B cells compared to other non-B cell tissues of a mammal and may be expressed on both precursor B cells and mature B cells.
  • the preferred B cell surface markers herein are CD20 and CD22.
  • the "CD20" antigen is non-glycosylated phosphoprotein found on the surface of greater than 90% of B cells from peripheral blood or lymphoid organs. CD20 is expressed during early pre-B cell development and remains until plasma cell differentiation. CD20 is present on both normal B cells as well as malignant B cells. Other names for CD20 in the literature include "B-lymphocyle-restricted antigen" B 1 and "Bp35". The CD20 antigen is described in Clark et al.
  • CD22 antigen also known as BL-CAM or Lyb8, is a type 1 integral membrane glycoprotein with molecular weight of about 130 (reduced) to 14OkD (unreduced). It is expressed in both the cytoplasm and cell membrane of B-lymphocytes. CD22 antigen appears early in B-cell lymphocyte differentiation at approximately the same stage as the CD19 antigen. Unlike other B-cell markers, CD22 membrane expression is limited to the late differentiation stages comprised between mature B cells (CD22+) and plasma cells (CD22-). The CD22 antigen is described, for example, in Wilson et al. J. Exp. Med. 173:137 (1991) and Wilson et al. J. Immunol. 150:5013 (1993).
  • the "CD19” antigen refers to an antigen identified, for example, by the HD237-CD19 or B4 antibody
  • CD19 is found on Pro-B, pre-B, immature and mature, activated and memory B cells, up to a point just prior to terminal differentiation into plasma cells. Neither CD 19 nor CD20 is expressed on hematopoietic stem cell or plasma cell. Binding of an antagonist to CD 19 may cause internalization of the CD 19 antigen.
  • the amino acid sequence of human CD 19 is shown in The Leukocyte Antigen Facts Book, Barclay et al. supra, page 180, and also EMBL Genbank accession no.
  • B cell depletion refers to a reduction in B cell levels in an animal or human after drug or antibody treatment, as compared to the level before treatment. B cell levels are measurable using well known assays such as by getting a complete blood count, by FACS analysis staining for known B cell markers, and by methods such as described in the Experimental Examples. B cell depletion can be partial or complete.
  • the depletion of CD20 expressing B cells is at least 25%.
  • B cells are generally depleted for the duration of time when the drug is circulating in the patient's body and the time for recovery of B cells.
  • amino acid within the scope of the present invention is used in its broadest sense and is meant to include naturally occurring L alpha-amino acids or residues.
  • the commonly used one and three letter abbreviations for naturally occurring amino acids are used herein (Lehninger, A.L., 1975, Biochemistry, 2d ed., pp. 71-92, Worth Publishers, New York).
  • the term includes D-amino acids as well as chemically modified amino acids such as amino acid analogs, naturally occurring amino acids that are not usually incorporated into proteins such as norleucine, and chemically synthesized compounds having properties known in the art to be characteristic of an amino acid.
  • analogs or mimetics of phenylalanine or proline that allow the same conformational restriction of the peptide compounds as natural Phe or Pro, are included within the definition of amino acid.
  • Such analogs and mimelics are reterred to herein as "functional equivalents" of an amino acid.
  • Other examples of amino acids are listed by Roberts and Vellaccio, 1983, In: The Peptides: Analysis, Synthesis, Biology, Gross and Meiehofer, eds., Vol. 5 p. 341, Academic Press, Inc., N. Y., which is incorporated herein by reference.
  • SABMs and TAs synthesized, for example, by standard solid phase synthesis techniques, are not limited to amino acids encoded by genes.
  • amino acids which are not encoded by the genetic code, include, for example, those described in International Publication No. WO 90/01940 such as, for example, 2-amino adipic acid (Aad) for GIu and Asp; 2-aminopimelic acid (Apm) for GIu and Asp; 2- aminobutyric (Abu) acid for Met, Leu, and other aliphatic amino acids; 2-aminoheptanoic acid (Ahe) for Met, Leu and other aliphatic amino acids; 2-aminoisobutyric acid (Aib) for GIy; cyclohexylalanine (Cha) for VaI, and Leu and He; homoarginine (Har) for Arg and Lys; 2,3-diaminopropionic acid (Dpr) for Lys, Arg and His; N-ethylglycine (EtGIy) for GIy, Pro, and Ala; N-ethylglycine (EtGIy
  • SABMs and TAs within the context of the present invention may be "engineered”, i.e., can be non- native or non-naturally occurring TAs.
  • non-native or “non-naturally occurring” is meant that the amino acid sequence of the particular SABM is not found in nature. That is to say, amino acid sequences of non- native or non-naturally occurring TAs or SABMs need not correspond to an amino acid sequence of a naturally occurring protein or polypeptide.
  • TAs or SABMs of this variety may be produced or selected using a variety of techniques, including those well known to the skilled artisan. For example, constrained or unconstrained peptide libraries may be randomly generated and displayed on phage utilizing art standard techniques, for example, Lowman et al, 1998, Biochemistry 37:8870-8878.
  • SABMs and TAs and cytotoxic agents when used within the context of the present invention, can be “conjugated” to eachother.
  • conjuggated is used in its broadest sense to encompass all methods of covalent attachment or joining that are known in the art.
  • the SABM is a protein and the TA is an amino acid extension C- or N-terminus to the SABM.
  • a short amino acid linker sequence may lie between the protein therapeutic and the SABM.
  • the SABM, optional linker and TA will be encoded by a nucleic acid comprising a sequence encoding SABM operably linked (in the sense that the DNA sequences are contiguous and in reading frame) to an optional linker sequence encoding a short polypeptide as described below, and a sequence encoding the TA.
  • the SABM is considered to be "conjugated" to the TA optionally via a linker sequence.
  • the SABM amino acid sequence may interrupt or replace a section of the TA amino acid sequence, provided, of course, that the insertion of the SABM amino acid sequence does not interfere with the function of the protein therapeutic.
  • the SABM will be linked, e.g., by chemical conjugation to the TA or other therapeutic optionally via a linker sequence.
  • the SABM will be linked to the TA via a side chain of an amino acid somewhere in the middle of the TA that doesn't interfere with TA's ability to recognize the target activity.
  • the SABM is considered to be "conjugated" to the TA.
  • the term “antibody” is used in the broadest sense and specifically covers monoclonal antibodies
  • polyclonal antibodies including full length monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.
  • multispecific antibodies e.g., bispecific antibodies
  • antibody fragments so long as they exhibit the desired biological activity.
  • Fully fragments of the antibodies of the invention comprise a portion of an intact antibody, generally including the antigen binding or variable region of the intact antibody or the Fc region of an antibody which retains FcR binding capability.
  • antibody fragments include linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
  • the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that can be present in minor amounts. Monoclonal antibodies are highly specific, each being directed against one or two antigenic site(s), typically one site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which are derived from animals against an antigen so that several different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins.
  • the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567).
  • the “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in
  • the monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in ' antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Methods of making chimeric antibodies are known in the art.
  • Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity-determining region (CDR) of the recipient are replaced by residues from a CDR of a non- human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity.
  • CDR complementarity-determining region
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence although the FR regions may include one or more amino acid substitutions that improve binding affinity.
  • the number of these amino acid substitutions in the FR are typically no more than 6 in the H chain, and in the L chain, no more than 3.
  • the humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • the humanized antibody includes a PRIMATIZED ® antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by, e.g., immunizing macaque monkeys with the antigen of interest. Methods of making humanized antibodies are known in the art.
  • Human antibodies can also be produced using various techniques known in the art, including phage- display libraries. Hoogenboom and Winter, J. MoI. Biol., 227:381 (1991); Marks et al., J. MoI. Biol., 222:581 (1991). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies. Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985);
  • immunoadhesin designates antibody-like molecules which combine the binding specificity of a heterologous protein (an “adhesin”) with the effector functions of immunoglobulin constant domains.
  • the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is
  • heterologous an immunoglobulin constant domain sequence
  • the adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand.
  • the immunoglobulin constant domain sequence in the immunoadhesin can be obtained from any immunoglobulin, such as IgG-I, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-I and IgA-2), IgE, IgD or IgM.
  • a “fusion protein” and a “fusion polypeptide” refer to a polypeptide having at least two portions covalently linked together, where each of the portions is a polypeptide having a different property.
  • the property may be a biological property, such as activity in vitro or in vivo.
  • the property may also be a simple chemical or physical property, such as binding to a target molecule, catalysis of a reaction, etc.
  • the portions may be linked directly by a single peptide bond or through a peptide linker containing one or more amino acid residues. Generally, the portions and the linker will be in reading frame with each other.
  • an "isolated" polypeptide or antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the polypeptide or antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes, in preferred embodiments, the antibody will be purified ( 1 ) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or. preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
  • Humanized anti-ErbB2 (HER2) antibodies include huMAb4D5-l , huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN7) as described in Table 3 of U.S. Pat. No. 5,821,337 expressly incorporated herein by reference; humanized 520C9 (WO93/21319) and humanized 2C4 antibodies as described in copending application Ser. No. 09/81 1115, and antibodies comprising the variable regions of anti-HER2 variants disclosed in WO 03/08713 land United States Patent Publication No. 2003/0228663, incorporated herein by reference. Throughout the disclosure, the terms "huMAb4D5-8" and "hu4D5-8" are used interchangeably.
  • cytotoxic agent refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells.
  • the cytotoxic agent should be capable of being internalized and/or capable of inhibiting cell growth from outside the cell without necessarily binding to the cell surface.
  • the agent is a small molecule.
  • the active portion of the cytotoxic agent is 110OkD or less.
  • the term is intended to include radioactive isotopes
  • chemotherapeutic agents e.g. methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin, or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, (e.g., MMAE) including fragments and/or variants thereof, and the various antitumor or anticancer agents or grow inhibitory agents disclosed below.
  • chemotherapeutic agents e.g. methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin, or other
  • chemotherapeutic agent is a chemical compound useful in the treatment of cancer.
  • examples of chemotherapeutic agents include alkylating agents such as thiotepa and CYTOXAN® cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophyc
  • calicheamicin especially calicheamicin gammall and calicheamicin omegall
  • dynemicin including dynemicin A
  • bisphosphonates such as clodronate
  • an esperamicin as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores
  • aclacinomysins actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6 ⁇ diazo-5-oxo-L-norleucine, ADRIAMYCIN® doxorubicin (including morph
  • AB RAXANETM Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel American Pharmaceutical Partners, Schaumberg, Illinois
  • TAXOTERE® doxetaxel Rhone- Poulenc Rorer, Antony, France
  • chloranbucil GEMZAR® gemcitabine
  • 6- thioguanine mercaptopurine
  • methotrexate platinum analogs such as cisplatin and carboplatin
  • vinblastine platinum
  • platinum etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; CPT-I l; topoisomerase inhibitor RFS 2000; difluorometlhylornithine (DMFO); retin
  • a “growth inhibitory agent” when used herein refers to a compound or composition which inhibits growth of a cell in vitro and/or in vivo.
  • the growth inhibitory agent may be one that significantly reduces the percentage of cells in S phase.
  • growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce GI arrest and M-phase arrest.
  • Classical M-phase blockers include the vincas (vincristine and vinblastine), TAXOL® paclitaxel, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin.
  • DNA alkylating agents such as tanoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1 , entitled “Cell cycle regulation, oncogenes, and antieioplastic drugs” by Murakaini et al. (W B Saunders: Philadelphia, 1995), especially p. 13.
  • growth inhibitory agents include an epidermal growth factor receptor (EGFR) antagonist (e.g., a tyrosine kinase inhibitor), HERl /EGFR inhibitor (e.g., erlotinib (TarcevaTM), platelet derived growth factor inhibitors (e.g., GleevecTM (Imatinib Mesylate)), a COX-2 inhibitor (e.g., celecoxib), and other bioactive and organic chemical agents, etc.
  • EGFR epidermal growth factor receptor
  • HERl /EGFR inhibitor e.g., erlotinib (TarcevaTM)
  • platelet derived growth factor inhibitors e.g., GleevecTM (Imatinib Mesylate)
  • COX-2 inhibitor e.g., celecoxib
  • therapeutically effective amount refers to an amount of a conjugate molecule effective to
  • conjugate or “treat” a disease or disorder in a subject.
  • conjugate molecule may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
  • Treatment refers to amelioration or alleviation of a disease or disorder. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
  • a subject is successfully "treated” for a cancer or an autoimmune disease if, after receiving a therapeutic amount of a conjugate according to the methods of the present invention, the subject shows observable and/or measurable reduction in or absence of one or more signs and symptoms of the particular disease.
  • reduction in the number of cancer cells or absence of the cancer cells reduction in the tumor size; inhibition (i.e., slow to some extent and preferably stop) of tumor metastasis; inhibition, to some extent, of tumor growth; increase in length of remission, and/or relief to some extent, one or more of the symptoms associated with the specific cancer; reduced morbidity and mortality, and improvement in quality of life issues.
  • Reduction of the signs or symptoms of a disease may also be felt by the patient.
  • Treatment can achieve a complete response, defined as disappearance of all signs of cancer, or a partial response, wherein the size of the tumor is decreased, preferably by more than 50 percent, more preferably by 75%.
  • a patient is also considered treated if the patient experiences stable disease.
  • the cancer patients are still progression-free in the cancer after one year, preferably after 15 months. These parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician of appropriate skill in the art.
  • the subject shows improvement from the illness while experiencing less side effects than a subject who may be treated received with the same conjugate molecule lacking the SABM.
  • cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
  • examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies.
  • squamous cell cancer e.g., epithelial squamous cell cancer
  • lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, melanoma, multiple myeloma and B-cell lymphoma, brain, as well as head and neck cancer, and associated metastases.
  • squamous cell cancer e.g., epithelial squamous cell cancer
  • cell proliferative disorder and “proliferative disorder” refer to disorders that are associated with some degree -of abnormal cell proliferation.
  • the cell proliferative disorder is cancer.
  • Tumor refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
  • B-cell regulated autoimmune diseases include arthritis (rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), psoriasis, dermatitis including atopic dermatitis; chronic autoimmune urticaria, polymyositis/dermatomyositis, toxic epidermal necrolysis, systemic scleroderma and sclerosis, responses associated with inflammatory bowel disease (IBD) (Crohn's disease, ulcerative colitis), respiratory distress syndrome, adult respiratory distress syndrome (ARDS), meningitis, allergic rhinitis, encephalitis, uveitis, colitis, glomerulonephritis, allergic conditions, eczema, asthma, conditions involving infiltration of T cells and chronic inflammatory responses, atherosclerosis, autoimmune myocarditis, leukocyte adhesion deficiency, systemic lupus erythematosus (SLE), lupus (
  • B cell neoplasms include CD20-positive Hodgkin's disease including lymphocyte predominant Hodgkin's disease (LPHD); non-Hodgkin's lymphoma (NHL); follicular center cell (FCC) lymphomas; acute lymphocytic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hairy cell leukemia.
  • LPHD lymphocyte predominant Hodgkin's disease
  • NHL non-Hodgkin's lymphoma
  • FCC follicular center cell lymphomas
  • ALL acute lymphocytic leukemia
  • CLL chronic lymphocytic leukemia
  • the non-Hodgkins lymphoma include low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small non-cleaved cell NHL, bulky disease NHL, plasmacytoid lymphocytic lymphoma, mantle cell lymphoma, AIDS- related lymphoma and Waldenstrom's macroglobulinemia. Treatment of relapses of these cancers are also contemplated.
  • LPHD is a type of
  • CLL Hodgkin's disease that tends to relapse frequently despite radiation or chemotherapy treatment and is characterized by CD20-positive malignant.cells.
  • CLL is one of four major types of leukemia.
  • a cancer of mature B-cells called lymphocytes, CLL is manifested by progressive accumulation of cells in blood, bone marrow and lymphatic tissues.
  • Indolent lymphoma is a slow-growing, incurable disease in which the average patient survives between six and 10 years following numerous periods of remission and relapse.
  • mammal for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc.
  • the mammal is human.
  • the subject to be treated according to this invention is a mammal.
  • a “disorder” is any condition that would benefit from treatment with the compositions comprising the conjugate molecules of the invention. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
  • “Elimination half-time” is used in its ordinary sense, as is described in Goodman and Gillman 's The Pharmaceutical Basis of Therapeutics, pp. 21-25 Alfred Goodman Gilman, Louis S. Goodman, and Alfred Gilman, eds., 6th ed. 1980. Briefly, the term is meant to encompass a quantitative measure of the time course of drug elimination.
  • the elimination of most drugs is exponential (i.e., follows first-order kinetics), since drug concentrations usually do not approach those required for saturation of the elimination process.
  • the rate of an exponential process may be expressed by its rate constant, k, which expresses the fractional change per unit of time, or by its half-time, ti/ 2 , the time required for 50% completion of the process.
  • the units of these two constants are time "1 and time, respectively.
  • the conjugate molecules of this invention have a longer half-life and lower toxicity than conjugate molecules that lack the SABM.
  • Transfection refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for . example, CaPO 4 precipitation and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.
  • Transformation means introducing DNA into an organism so that the DNA is replicable, either as an-extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells.
  • pulmonary administration refers to administration of a formulation of the invention through the lungs by inhalation.
  • inhalation refers to intake of air to the alveoli. In specific examples, intake can occur by self-administration of a formulation of the invention while inhaling, or by administration via a respirator, e.g., to an patient on a respirator.
  • respirator e.g., to an patient on a respirator.
  • inhalation used with respect to a formulation of the invention is synonymous with "pulmonary administration.”
  • parenteral refers to introduction of a compound of the invention into the body by other than the intestines, and in particular, intravenous (i.v.), intraarterial (La.), intraperitoneal (i.p.), intramuscular (i.m.), intraventricular, and subcutaneous (s.c.) routes.
  • an aerosol refers to suspension in the air.
  • aerosol refers to the particlization of a formulation of the invention and its suspension in the air.
  • an aerosol formulation is a formulation comprising a compound of the present invention that is suitable for aerosolization, i.e., particlization and suspension in the air, for inhalation or pulmonary administration.
  • SABMs within the context of the present invention bind albumin.
  • Preferred SABMs that bind serum albumin include linear and cyclic peptides, preferably cyclic peptide compounds comprising the following formulae or are' peptides that compete for binding serum albumin of a particular mammalian species with peptides of the following formulae: Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaaaaa
  • Phe-Cys-Xaa-Asp-Trp-Pro-Xaa-Xaa-Xaa-Ser-Cys [SEQ ID NO: 1] Val-Cys-Tyr-Xaa-Xaa-Xaa-ne-Cys-Phe [SEQ ID NO: 2] Cys-Tyr-Xaai-Pro-Gly-Xaa-Cys [SEQ ID NO: 3] and Asp-Xaa-Cys-Leu-Pro-Xaa-Trp-Gly-Cys-Leu-Trp [SEQ ID NO: 4] Preferred are peptide compounds of the foregoing general formulae comprising additional amino acids at the N-terminus (Xaa) x and additional amino acids at the C-terminus (Xaa) z , wherein Xaa is an amino acid and x and z are a whole number greater or equal to 0 (zero), generally less than 100, preferably
  • SABMs that bind a serum albumin are identified as described herein in the context of the following general formulae:
  • Trp-Cys-Asp-Xaa-Xaa-Leu-Xaa-Ala-Xaa-Asp-Leu-Cys (SEQ ID NO: 5) and Asp-Leu- Val-Xaa-Leu-Gly-Leu- Glu-Cys-Trp [SEQ ID NO: 6] where additional amino acids may be present at the N-terminal end (Xaa) x and additional amino acids may be present at the C-terminal end (Xaa) z , and where Xaa is an amino acid and x and z are a whole number greater or equal to zero, generally less than 100, preferably less than 10 and more preferably 0, 1, 2, 3, 4 or 5 and more preferably 4 or 5. According to this aspect of the invention reference is made to the Examples below and particularly the
  • Tables contained therein showing especially exemplary peptides and appropriate amino acids for selecting peptides ligands that bind a mammalian serum albumin.
  • Table 7 for selecting SABMs that bind across several species of serum albumin.
  • Preferred compounds according to this aspect of the invention include: DLCLRDWGCLW (SEQ ID NO:7)
  • DICLPRWGCLW (SEQ ID NO:8)
  • QRLMEDICLPRWGCLWEDDE (SEQ ID NO: 10)
  • SABMs of the present invention bind human serum albumin and can be identified by their ability to compete for binding of human serum albumin in an in vitro assay with SABMs having the general formulae shown below, where additional amino acids may be present at the N-terminal end (Xaa) x and at the C-terminal end (Xaa) z :
  • Xaa is an amino acid
  • x and z are preferably 4 or 5
  • Xaai is selected from the group consisting of Re, Phe, Tyr, and VaI.
  • the SABMs of the present invention will compete with any of the SABMs represented in SEQ ID NO: 7 - 20 described herein above and preferably will compete with SEQ ID NO: 10 for binding human serum albumin.
  • the term “compete” and “ability to compete” are relative terms.
  • the terms when used to describe the SABMs of the present invention, refer to SABMs that produce a 50% inhibition of binding of, for example the peptide represented by SEQ ID NO: 10, when present at 50 ⁇ M, preferably when present at 1 ⁇ M, more preferably 100 nM, and preferably when present at 1 nM or less in a standard competition assay as described herein.
  • SABMs having an affinity for a serum albumin of less than about 1 nM and preferably between about 1 pM and 1 nM are equally likely to be SABMs within the context of the present invention.
  • a peptide or other compound may determine whether a peptide or other compound has the ability to compete with a SABM for binding to albumin employing procedures that include, but are not limited to, competitive assay systems using techniques such as radioimmunoassays (RIA), enzyme immunoassays (EIA), preferably the enzyme linked immunosorbent assay (ELISA), "sandwich” immunoassays, immunoradiometric assays, fluorescent immunoassays, and immunoelectrophoresis assays, to name but a few.
  • RIA radioimmunoassays
  • EIA enzyme immunoassays
  • ELISA enzyme linked immunosorbent assay
  • "sandwich” immunoassays immunoradiometric assays
  • fluorescent immunoassays preferably the enzyme linked immunosorbent assays
  • immunoelectrophoresis assays to name but a few.
  • the selected SABM will be labeled with a detectable moiety (the detectably labeled SABM hereafter called the "tracer") and used in a competition assay with a candidate compound for binding albumin.
  • detectable labels are available that can be preferably grouped into the following categories: ⁇ (a) Radioisotopes, such as S, C, I, H, and I.
  • the SABM can be labeled with the radioisotope using techniques described in Coligen et al, 1991, eds., Current Protocols in Immunology, Volumes 1 and 2, Wiley-Interscience, New York, N. Y., for example. Radioactivity can be measured using scintillation counting.
  • Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, lissamine, phycoerythrin, and Texas Red are available.
  • the fluorescent labels can be conjugated to the peptide compounds using the techniques disclosed in Current Protocols in Immunology, supra, for example. Fluorescence can be quantified using a fluorimeter.
  • the enzyme preferably catalyzes a chemical alteration of the chromogenic substrate that can be measured using various techniques.
  • the enzyme may catalyze a color change in a substrate, that can be measured spectrophotometrically.
  • the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above.
  • the chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light that can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor.
  • enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRP), alkaline phosphatase, beta-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like.
  • luciferases e.g., firefly luciferase and bacterial luciferase
  • enzyme-substrate combinations include, for example:
  • HRP Horseradish peroxidase
  • a dye precursor e.g. ABTS, orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB)
  • OPD orthophenylene diamine
  • TMB 3,3',5,5'-tetramethyl benzidine hydrochloride
  • alkaline phosphatase AP
  • para-nitrophenyl phosphate as chromogenic substrate
  • ⁇ -D-galactosidase ⁇ -D-GaI
  • a chromogenic substrate e.g. p-nitrophenyl- ⁇ -D- galactosidase
  • fluorogenic substrate 4-methylumbelliferyl- ⁇ -D-galactosidase
  • the tracer is incubated with immobilized target in the presence of varying concentrations of unlabeled candidate compound.
  • Increasing concentrations of successful candidate compound effectively compete with binding of the tracer to immobilized target.
  • the concentration of unlabeled candidate compound at which 50% of the maximally-bound tracer is displaced is referred to as the "IC50" and reflects the IgG binding affinity of the candidate compound. Therefore a candidate compound with an IC50 of 1 HiM displays a substantially weaker interaction with the target than a candidate compound with an IC 50 of 1 ⁇ M.
  • mut mutated sequence
  • a control peptide
  • Assays were performed under conditions where EC 5 o(con)/EC 5 o(mut) will approximate K d (con)/K d (mut).
  • the invention provides compounds "having the ability to compete" for albumin such as human serum albumin binding in an in vitro assay as described.
  • the compound has an IC 50 for the target such as human serum albumin of less than 1 ⁇ M.
  • Preferred among these compound are compounds having an IC 50 of less than about 100 nM , and preferably less than about 10 nM or less than about 1 nM.
  • the compounds display an IC 50 for the target molecule such as or human serum albumin of less than about 100 pM and more preferably less than about 10 pM.
  • a preferred in vitro assay for the determination of a candidate compound's ability to compete with a SABM described herein is as follows and is described more fully in the Examples.
  • the candidate compound is a peptide.
  • the ability of a candidate compound to compete with a labeled SABM tracer for binding to human serum albumin is monitored using an ELISA. Dilutions of a candidate compound in buffer are added to microtiter plates coated with human serum albumin (as described in the Example Sections) along with tracer for 1 hour. The microtiter plate is washed with wash buffer and the amount of tracer bound to human serum albumin measured.
  • the SABM is linked to a TAxytotoxic agent to form a conjugate molecule that comprises at least one of each component (i.e., at least three different components).
  • Each component can be optionally joined to each other via a flexible linker domain.
  • the SABM domain may be joined via its N- or C-terminus to the N- or C-terminus of the TA.
  • nucleic acid encoding a SABM will be operably linked to nucleic acid encoding the TA sequence, optionally via a linker domain.
  • the construct encodes a fusion protein wherein the C-terminus of the SABM is joined to the N-terminus of the TA.
  • fusions where, for example, the N-terminus of the SABM is joined to the N- or C-terminus of the TA also are possible.
  • the SABM domain may be inserted within the TAs molecule rather than being joined to the TAs at its N-or C-terminus. This configuration may be used to practice the invention so long as the functions of the SABM domain and the TAs are preserved.
  • a SABM may be inserted into a non-binding light chain CDR of an immunoglobulin without interfering with the ability of the immunoglobulin to bind to its target.
  • Regions of TAs molecules that can accommodate SABM domain insertions may be identified empirically ⁇ i.e., by selecting an insertion site, randomly, and assaying the resulting conjugate for the function of the TAs ), or by sequence comparisons amongst a family of related TAs molecules ⁇ e.g., for TAs s that are proteins) to locate regions of low sequence homology. Low sequence homology regions are more likely to tolerate insertions of SABMs domains than are regions that are well-conserved.
  • the three-dimensional structure may provide guidance as to SABM insertion sites. For example, loops or regions with high mobility (i.e., large temperature or "B" factors) are more likely to accommodate SABM domain insertions than are highly ordered regions of the structure, or regions involved in ligand binding or catalysis.
  • the SABM domain is optionally linked to the TAs via a linker.
  • the linker component of the conjugate molecule of the invention does not necessarily participate, but may contribute to the function of the conjugate molecule. Therefore, the linker domain is defined as any group of molecules that provides a spatial bridge between the TAs and the SABM domain.
  • the linker domain can be of variable length and makeup, however, it is the length of the linker domain and not its structure that is important for creating the spatial bridge.
  • the linker domain preferably allows for the SABM of the conjugate molecule to bind, substantially free of steric and/or conformational restrictions to the target molecule.
  • the length of the linker domain is dependent upon the character of the two "functional" domains of the conjugate molecule, Le., the SABM and the TAs .
  • the linker domain may be a polypeptide of variable length.
  • the amino acid composition of the polypeptide determines the character and length of the linker.
  • the linker molecule comprises a flexible, hydrophilic polypeptide chain.
  • Exemplary linker domains comprise one or more GIy and/or Ser residues, such as those described in the Example sections below.
  • the present invention encompasses a composition of matter comprising an isolated nucleic acid, preferably DNA, encoding a SABM or a conjugate molecule comprising a SABM and a polypeptide TAs as described herein.
  • DNAs encoding the peptides of the invention can be prepared by a variety of methods known in the art. These methods include, but are not limited to, chemical synthesis by any of the methods described in Engels et al. 1989, Agnew. Chem. Int. Ed. Engl. 28:716-734 (the entire disclosure of which is incorporated herein by reference) such as the triester, phosphite, phosphoramidite, and H-phosphonate chemical synthesis methods.
  • codons preferred by the expression host cell are used in the design of the encoding DNA.
  • DNA encoding the peptides can be altered to encode one or more variants by using recombinant DNA techniques, such as site specific mutagenesis (Kunkel et ai, 1991 , Methods EnzymoL, 204:125-139; Carter et al. 1986, Nucl. Acids Res. 13:4331; ZoWe ⁇ etal. 1982, Nucl. Acids Res. 10:6487), cassette mutagenesis (Wells et al. 1985, Gene 34:315), restriction selection mutagenesis (Carter, 1991 , In: Directed Mutagenesis: A Practical Approach, MJ. McPherson, ed., IRL Press, Oxford), and the like.
  • the nucleic acid encodes a SABM capable of binding a target molecule.
  • Target molecules include, for example, extracellular molecules such as various serum factors, including but not limited to, plasma proteins such as serum albumin, immunoglobulins, apolipoproteins or transferrin, or proteins found on the surface of erythrocytes or lymphocytes, provided, of course, that binding of the SABM to the cell surface protein does not substantially interfere with the normal function of the cell.
  • Preferred for use in the present invention are SABMs that bind serum albumin with a desired affinity, for example, with high affinity, or with an affinity that facilitates useful tissue uptake and diffusion of a bioactive molecule that is fused to the SABM.
  • the nucleic acid encodes a conjugate molecule comprising a SABM sequence and an TAs .
  • the TAs may comprise any polypeptide compound useful as a therapeutic or diagnostic agent, e.g., enzymes, hormones, cytokines, antibodies, or antibody fragments.
  • the nucleic acid molecule according to this aspect of the present invention encodes a conjugate molecule and the nucleic acid encoding the SABM sequence is operably linked to (in the sense that the DNA sequences are contiguous and in reading frame) the nucleic acid encoding the biologically active agent.
  • these DNA sequences may be linked through a nucleic acid sequence encoding a linker domain amino acid sequence.
  • the invention further comprises an expression control sequence operably linked to the DNA molecule encoding a peptide of the invention, an expression vector, such as a plasmid, comprising the DNA molecule, where the control sequence is recognized by a host cell transformed with the vector, and a host cell transformed with the vector.
  • an expression vector such as a plasmid
  • plasmid vectors contain replication and control sequences derived from species compatible with the host cell.
  • the vector ordinarily carries a replication site, as well as sequences that encode proteins capable of providing phenotypic selection in transformed cells.
  • suitable vectors include pBR322 (ATCC No. 37,017), phGH107
  • Prokaryotic host cells containing the expression vectors of the present invention include E, coli Kl 2 strain 294 (ATCC NO. 31,446), E. coli strain JMlOl (Messing et al. 1981 , Nucl. Acid Res. 9:309), E. coli strain B, E. coli Strain _1776 (ATCC No. 31537), E.
  • E. co// W3110 F-, gamma-, prototrophic, ATCC No. 27,325)
  • E. coli strain 27C7 W3110, tonA, phoA El 5, (argF-lac)169, ptr3, degP41, ompT, kan r ) (U.S. Patent No. 5,288,931, ATCC No. 55,244)
  • Bacillus subtilis Salmonella typhimurium, Serratia marcesans, and Pseudomonas species.
  • eukaryotic organisms such as yeasts, or cells derived from multicellular organisms can be used as host cells.
  • yeast host cells such as common baker's yeast or
  • suitable vectors include episomally-replicating vectors based on the 2-micron plasmid, integration vectors, and yeast artificial chromosome (YAC) vectors.
  • yeast artificial chromosome YAC
  • suitable vectors include baculoviral vectors.
  • suitable expression vectors include vectors derived from the Ti plasmid of Agrobacterium tumefaciens.
  • Examples of useful mammalian host cells include monkey kidney CVl line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al 1977, J. Gen Virol 36:59); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin 1980, Proc. Natl. Acad. Sci. USA, 77:4216); mouse Sertoli cells (TM4, Mather 1980, Biol. Reprod. 23:243-251); monkey kidney cells (CVl)
  • ATCC CCL 70 African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (Wl 38, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al 1982, Annals N. Y. Acad. ScL 383:44-68); MRC 5 cells; FS4 cells; and a human hepatoma cell line (Hep G2).
  • useful vectors include vectors derived from SV40, vectors derived from cytomegalovirus such as the pRK vectors, including pRK5 and pRK7 (Suva et al. 1987, Science 237:893-896; EP 307,247 (3/15/89), EP 278,776 (8/17/88)) vectors derived from vaccinia viruses or other pox viruses, and retroviral vectors such as vectors derived from Moloney's murine leukemia virus (MoMLV).
  • DNA encoding the peptide of interest is operably linked to a secretory leader sequence resulting in secretion of the expression product by the host cell into the culture medium.
  • secretory leader sequences examples include STII, ecotin, lamB, herpes GD, lpp, alkaline phosphatase, invertase, and alpha factor. Also suitable for use herein is the 36 amino acid leader sequence of protein A (Abrahmsen et al 1985, EMBO J. 4:3901).
  • Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
  • Prokaryotic host cells used to produce the present peptides can be cultured as described generally in Sambrook et aL, supra.
  • the mammalian host cells used to produce peptides of the invention can be cultured in a variety of media.
  • Commercially available media such as Ham's FlO (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells.
  • any of the media described in the art for example, Ham and Wallace, 1979, Meth. Em. 58:44; Barnes and Sato 1980, Anal. Biochem. 102:255, U.S. Patent Nos. 4,767,704;
  • GentamycinTM drug is included at appropriate concentrations that would be known to those skilled in the art.
  • the culture conditions such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
  • the host cells referred to in this disclosure encompass cells in in vitro culture as well as cells that are within a host animal.
  • Another method of producing the SABMs of the invention involves chemical synthesis. This can be accomplished by using methodologies well known in the art (see Kelley and Winkler, 1990, In: Genetic
  • SABMs of the invention can be prepared conveniently using solid-phase peptide synthesis. Merrifield, 1964, J. Am. Chem. Soc. 85:2149; Houghten, 1985, Proc. Natl. Acad. ScL USA 82:5132. Solid- phase peptide synthesis also can be used to prepare the conjugate molecule compositions of the invention if the TAs is or comprises a polypeptide.
  • Solid-phase synthesis begins at the carboxy terminus of the nascent peptide by coupling a protected amino acid to an inert solid support.
  • the inert solid support can be any macromolecule capable of serving as an anchor for the C-terminus of the initial amino acid.
  • the macromolecular support is a cross-linked polymeric resin (e.g., a polyamide or polystyrene resin) as shown in Figures 1-1 and 1-2, on pages 2 and 4 of Stewart and Young, supra.
  • the C-terminal amino acid is coupled to a polystyrene resin to form a benzyl ester.
  • a macromolecular support is selected such that the peptide anchor link is stable under the conditions used to deprotect the alpha-amino group of the blocked amino acids in peptide synthesis.
  • a base- labile alpha-protecting group is used, then it is desirable to use an acid-labile link between the peptide and the solid support.
  • an acid-labile ether resin is effective for base-labile Fmoc-amino acid peptide synthesis as described on page 16 of Stewart and Young, supra.
  • a peptide anchor link and ⁇ - protecting group that are differentially labile to acidolysis can be used.
  • an aminomethyl resin such as the phenylacetamidomethyl (Pam) resin works well in conjunction with Boc-amino acid peptide synthesis as described on pages 1 1 - 12 of Stewart and Young, supra.
  • the alpha-amino protecting group of the initial amino acid is removed with, for example, trifluoroacetic acid (TFA) in methylene chloride and neutralized in, for example, triethylamine (TEA).
  • TFA trifluoroacetic acid
  • TAA triethylamine
  • the next alpha-amino and side chain protected amino acid in the synthesis is added.
  • the remaining alpha-amino and, if necessary, side chain protected amino acids are then coupled sequentially in the desired order by condensation to obtain an intermediate compound connected to the solid support.
  • some amino acids may be coupled to one another to form a fragment of the desired peptide followed by addition of the peptide fragment to the growing solid phase peptide chain.
  • the condensation reaction between two amino acids, or an amino acid and a peptide, or a peptide and a peptide can be carried out according to the usual condensation methods such as the axide method, mixed acid anhydride method, DCC (NjN'-dicyclohexylcarbodiimide) or DIC (N,N'-diisopropylcarbodiimide) methods, active ester method, p-nitrophenyl ester method, BOP (benzotriazole-1-yl-oxy-tris [dimethylamino] phosphonium hexafluorophosphate) method, N-hydroxysuccinic acid imido ester method, etc., and Woodward reagent K method.
  • an intermediate compound is produced that contains each of the amino acid residues located in the desired sequence in the peptide chain wherein individual residues still carry side-chain protecting groups. These protecting groups can be removed substantially at the same time to produce the desired polypeptide product following removal from the solid phase.
  • benzyloxycarbonyl (abbreviated Z), isonicotinyloxycarbonyl (iNOC), o-chlorobenzyloxycarbonyl [Z(2C1)], p-nitrobenzyloxycarbonyl [Z(NO 2 )], p- methoxybenzyloxycarbonyl [Z(OMe)], t-butoxycarbonyl (Boc), t-amyloxycarbonyl (Aoc), isobornyloxycarbonyl, adamantyloxycarbonyl, 2-(4-biphenyl)-2-propyloxycarbonyl (Bpoc), 9- fluorenylmethoxycarbonyl (Fmoc), methylsulfonyethoxycarbonyl (Msc), trifluoroacetyl, phthalyl, formyl, 2- nitrophenylsulphenyl (NPS), diphenyl
  • Protective groups for the carboxy functional group are exemplified by benzyl ester (OBzI), cyclohexyl ester (Chx), 4-nitrobenzyl ester (ONb), t-butyl ester (Obut), 4-pyridylmethyl ester (OPic), and the like. It is often desirable that specific amino acids such as arginine, cysteine, and serine possessing a functional group other than amino and carboxyl groups are protected by a suitable protective group.
  • the guanidino group of arginine may be protected with nitro, p-toluenesulfonyl, benzyloxycarbonyl, adamantyloxycarbonyl, p-methoxybenzesulfonyl, 4-methoxy-2,6-dimethylbenzenesulfonyl (Nds), 1 ,3,5-trimethylphenysulfonyl (Mts), and the like.
  • the thiol group of cysteine can be protected with p-methoxybenzyl, trityl, and the like.
  • the peptide can be cleaved away from the solid support, recovered, and purified.
  • the peptide is removed from the solid support by a reagent capable of disrupting the peptide-solid phase link, and optionally deprotects blocked side chain functional groups on the peptide.
  • the peptide is cleaved away from the solid phase by acidolysis with liquid hydrofluoric acid (HF), which also removes any remaining side chain protective groups.
  • HF liquid hydrofluoric acid
  • the acidolysis reaction mixture contains thio-cresol and cresol scavengers.
  • the resin is washed with ether, and the free peptide is extracted from the solid phase with sequential washes of acetic acid solutions. The combined washes are lyophilized, and the peptide is purified.
  • the conjugate molecules may comprise TAs that are organic compounds having diagnostic or therapeutic utility, or alternatively, fusions between a SABM and a polypeptide TAs in configurations that cannot be encoded in a single nucleic acid.
  • TAs that are organic compounds having diagnostic or therapeutic utility
  • fusions between a SABM and a polypeptide TAs in configurations that cannot be encoded in a single nucleic acid examples include fusions between the amino terminus of a SABM and the amino terminus of the TAs , or fusions between the carboxy-terminus of a SABM and the carboxy-terminus of the TAs .
  • Chemical conjugation may be employed to prepare these embodiments of the conjugate molecule, using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate
  • SPDP iminothiolane
  • imidoesters such as dimethyl adipimidate HCl
  • active esters such as disuccinimidyl suberate
  • aldehydes such as glutaraldehyde
  • bis-azido compounds such as bis (p-azidobenzoyl) hexanediamine
  • bis-diazonium derivatives such as bis-(p-diazoniumbenzoyl)- ethylenediamine
  • diisocyanates such as toluene, 2,6-diisocyanate
  • bis-active fluorine compounds such as l,5-difluoro-2,4-dinitrobenzene.
  • SABMs may be cyclized by formation of a disulfide bond between cysteine residues.
  • Such peptides can be made by chemical synthesis as described above and then cyclized by any convenient method used in the formation of disulfide linkages.
  • peptides can be recovered from solid phase synthesis with sulfhydryls in reduced form, dissolved in a dilute solution wherein the intramolecular cysteine concentration exceeds the intermolecular cysteine concentration in order to optimize intramolecular disulfide bond formation, such as a peptide concentration of 25 mM to 1 uM, and preferably 500 uM to 1 uM, and more preferably 25 uM to 1 uM, and then oxidized by exposing the free sulfhydryl groups to a mild oxidizing agent that is sufficient to generate intramolecular disulfide bonds, e.g., molecular oxygen with or without catalysts such as metal cations, potassium ferricyanide, sodium tetrathionate, and the like.
  • a mild oxidizing agent that is sufficient to generate intramolecular disulfide bonds, e.g., molecular oxygen with or without catalysts such as metal cations, potassium ferricyanide, sodium te
  • the peptides can be cyclized as described in Pelton et al, 1986, J. Med. Chem. 29:2370-2375. Cyclization can be achieved by the formation, for example, of a disulfide bond or a lactam bond between a first and a second residue capable of forming a disulfide bond, for example, Cys, Pen, Mpr, and Mpp and its 2-amino group-containing equivalents. Residues capable of forming a lactam bridge include, for example, Asp, GIu, Lys, Om, ⁇ -diaminobutyric acid, diaminoacetic acid, aminobenzoic acid, and mercaptobenzoic acid.
  • the compounds herein can be cyclized for example via a lactam bond that can utilize the side chain group of a non-adjacent residue to form a covalent attachment to the N-terminus amino group of
  • compositions which comprising the conjugate molecules of the invention may be administered in any suitable manner, including parental, topical, oral, or local (such as aerosol or transdermal), or any combination thereof.
  • compositions of the present invention comprise any of the conjugate molecules noted above with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier for example, for oral administration, a solid carrier is preferred; for i.v. administration, a liquid salt solution carrier is generally used.
  • compositions of the present invention include pharmaceutically acceptable components that are compatible with the subject and the protein of the invention. These generally include suspensions, solutions, and elixirs, and most especially biological buffers, such as phosphate buffered saline, saline, Dulbecco's Media, and the like. Aerosols may also be used, or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like (in the case of oral solid preparations, such as powders, capsules, and tablets).
  • the term "pharmaceutically acceptable” generally means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • the formulation of choice can be accomplished using a variety of the aforementioned buffers, or even excipients including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like.
  • "PEGylation" of the compositions may be achieved using techniques known to the art (see for example International Patent Publication No WO92/16555, U S Patent No 5,122,614 to Enzon, and International Patent Publication No WO92/00748)
  • a preferred route of administration of the present invention is in the aerosol 01 inhaled form
  • the compounds of the present invention, combined with a dispersing agent or dispersant, can be administered in an aerosol formulation as a dry powder or in a solution or suspension with a diluent
  • the term "dispersant” refers to an agent that assists aerosohzation of the compound or absorption of the protein in lung tissue, or both
  • the dispersant is pharmaceutically acceptable Suitable dispersing agents are well known in the art, and include but are not limited to surfactants and the like
  • surfactants that are generally used in the art to reduce surface induced aggregation of a compound, especially a peptide compound, caused by atomization of the solution forming the liquid aerosol, may be used
  • Nonlimiting examples of such surfactants are surfactants such as polyoxyethylene fatty acid esters and alcohols, and polyoxyethylene sorbitan fatty acid esters
  • Amounts of surfactants used will vary, being generally within the range of from about 0 001% to about 4% by weight of the formulation
  • the surfactant is polyoxyethylene sorbitan monooleate or sorbitan trioleate Suitable surfactants are well known in the art, and can be selected on the basis of desired properties,
  • the liquid or dry formulations can comprise additional components, as discussed further below
  • the liquid aerosol formulations generally contain the conjugate molecules and a dispersing agent in a physiologically acceptable diluent
  • the dry powder aerosol formulations of the present invention consist of a finely divided solid form of the conjugate molecule and a dispersing agent
  • the formulation must be aerosolized That is, it must be broken down into liquid or solid particles in order to ensure that the aerosolized dose actually reaches the alveoli
  • the mass median dynamic diameter will be 5 micrometers or less in order to ensure that the drug particles reach the lung alveoli (Wearley, 1991, Cut Rev in Ther Drug Came) Systems 8 333)
  • the term "aerosol particle" is used herein to describe the liquid or solid particle suitable for pulmonary administration, i e , that will reach the alveoli
  • Other considerations such as construction of the delivery device, additional components in the formulation and particle characteristics are important
  • any form of aerosohzation known in the art including but not limited to nebuhzation, atomization or pump aerosohzation of a liquid formulation, and aerosohzation of a dry powder formulation, can be used m the practice of the invention
  • a delivery device that is uniquely designed for administration of solid formulations is envisioned Often, the aerosohzation of a liquid or a dry powder formulation will require a propellant
  • the propellant may be any propellant generally used in the art Specific nonlimiting examples of such useful propellants are a chloroflourocarbon, a hydrofluorocarbon, a hydochlorofluorocarbon, or a hydrocarbon, including triflouromethane, dichlorodiflouromethane, dichlorotetrafuoroethanol, and 1 ,1,1 ,2-tetraflouroethane, or combinations thereof.
  • the device for aerosolization is a metered dose inhaler.
  • a metered dose inhaler provides a specific dosage when administered, rather than a variable dose depending on administration.
  • Such a metered dose inhaler can be used with either a liquid or a dry powder aerosol formulation.
  • Metered dose inhalers are well known in the art.
  • the liquid aerosol formulations of the present invention will typically be used with a nebulizer.
  • the nebulizer can be either compressed air driven or ultrasonic. Any nebulizer known in the art can be used in conjunction with the present invention such as but not limited to: Ultravent, Mallinckrodt, Inc. (St. Louis, MO); the Acorn II nebulizer (Marquest Medical Products, Englewood CO). Other nebulizers useful in conjunction with the present invention are described in U.S. Patent Nos. 4,624,251 issued November 25, 1986;
  • the formulation may include a carrier.
  • the carrier is a macromolecule which is soluble in the circulatory system and which is physiologically acceptable where physiological acceptance means that those of skill in the art would accept injection of said carrier into a patient as part of a therapeutic regime.
  • the carrier preferably is relatively stable in the circulatory system with an acceptable elimination half-time.
  • macromolecules include but are not limited to soya lecithin, oleic acid, and sorbetan trioleate, with sorbitan trioleate preferred.
  • the formulations of the present embodiment may also include other agents useful for protein stabilization or for the regulation of osmotic pressure.
  • agents include but are not limited to salts, such as sodium chloride, or potassium chloride, and carbohydrates, such as glucose, galactose, or mannose, and the like.
  • the present pharmaceutical formulation will be used as a dry powder inhaler formulation comprising a finely divided powder form of the SABM and a dispersant.
  • the form of the compound will generally be a lyophilized powder. Lyophilized forms of conjugate molecule can be obtained through standard techniques.
  • the dry powder formulation will comprise a finely divided dry powder containing one or more compounds of the present invention, a dispersing agent and also a bulking agent.
  • Bulking agents useful in conjunction with the present formulation include such agents as lactose, sorbitol, sucrose, or mannitol, in amounts that facilitate the dispersal of the powder from the device.
  • Example 1 Materials For these studies, a Fab of a humanized antibody that binds to the extracellular domain of pi 85 HER2 (HER2) was recombinantly engineered to include an albumin binding peptide (AB).
  • AB albumin binding peptide
  • the humanized Fab had been derived from the murine monoclonal antibody muMAb4D5 (herein 4D5), which monoclonal antibody was produced by a hybridoma deposited with the American Type Culture Collection in Manassas, Virginia, and has ATCC accession number CRL 10463.
  • QRLMEDICLPRWGCLWEDDF (SEQ ID NO: 1) was joined via a nucleic acid sequence encoding a linker sequence, GGGS (SEQ ID NO:422), to a nucleic acid sequence encoding the Fab.
  • the nucleic acid sequence encoding the linker was joined to the heavy chain C-terminal KTHT residues of the Fab.
  • an anti- tissue factor Fab containing the variable region of the D3H44 antibody fused to an AB through its light chain was constructed by recombinant DNA engineering. See Presta, L., et al., (2001) Thromb. Haemost. 85:379- 389 for D3H44 amino acid sequence.
  • a fusion protein ("AB.Fab4D5-H" or "rhuABFabATFL")
  • a fusion protein ("AB.Fab4D5-H" or "rhuABFabATFL")
  • MMAE monomethylauristatin
  • the fusion proteins were attached to MMAE via a valine-citrulline (val-cit or vc) dipeptide Linker reagent having a maleimide moiety and a para- aminobenzylcarbamoyl (PAB) spacer.
  • PAB para- aminobenzylcarbamoyl
  • the fusion proteins were attached to MMAE via, for example, conjugation with an MMAE modified with an activated derivative of maleimidocaproyl through their lysines using succinimidyl acetylthioacetate (Sata) to generate free thiols followed by conjugation to valine-citrulline-MMAE ("vc-MMAE").
  • the ratio of MMAE on the resulting AB.Fab4D5-H was generally an average around 1:1 with ratios as high as 4:1 and as low as 0:1 such that between 0-4 MMAE moieties were randomly distributed on exposed lysines, the overall average being about 1 MMAE per AB.Fab4D5-H.
  • MMAE-conjugated molecules or a phosphate buffer saline were administered on day 0 of the study and tumor measurements were performed twice weekly for 17 days.
  • a known efficacious MMAE conjugate, Herceptin®-MC-vc-PAB-MMAE was run for comparison at a dose of 1245 ⁇ g/m2 MMAE.
  • Log Cell Kill analyses based on tumor doubling times were conducted. The Log Cell Kill analysis uses a mathematical computation of tumor growth delay based on the time it takes for tumors to double in size after treatment begins compared to controls. The mathematical equation is:
  • Example 3 Toxicity of IgG-MMAE, Ffab'VMMAE conjugates and free MMAE
  • the ⁇ g MMAE/m2 was calculated using 718 as the MW of MMAE and
  • the ⁇ g MMAE/m2 was calculated using 718 as the MW of MMAE and 100000 as the MW of Herceptin® F(ab')2.
  • the body surface area was calculated as follows: [ ⁇ (body weight in grams to 0.667 power) x 1 ] .8 J/10000].
  • the dose solutions were administered by a single intravenous bolus tail-vein injection on Study Day 1 at a dose volume of 10 mL/kg (diluted in PBS). General clinical observations were performed daily. Morbidity and mortality checks were performed twice daily (AM and PM). The body weights of the animals were measured pre-dose on Study Day 1 and daily thereafter.
  • Whole blood was collected into EDTA containing tubes for hematology parameters (e.g., mean serum AST levels, ALT levels, GGT levels and billirubin levels) and differential cell counts (e.g., mean white blood cell counts and platlet counts).
  • Whole blood was collected into serum separator tubes for clinical chemistry parameters. Blood samples were collected pre-dose on Study Day -4, on Study Day 3 and on Day 5 at necropsy.
  • mice on dose groups 4 and 5 (27.14 mg/kg Herceptin® F(ab')2-val-cit-MMAE and 516 ug/kg free MMAE, respectively) were moribund. All group 4 and 5 animals were severely lethargic and most had a yellow discharge in the urogenital area. The animals in these dose groups were necropsied on Day 3. On study day 5 animals in dose group 3 (10.83 mg/kg Herceptin® F(ab')2-val-cit-MMAE) also had yellow discharges in the urogenital area.
  • Herceptin® F(ab')2 -vc-MMAE group 3 showed transient elevations of liver function tests on day 3, which returned to baseline levels by day 5. However, platelet and white blood cell counts remained decreased on day
  • the morphologic changes were least severe in group 3 (low dose Herceptin® F(ab')2) and most severe in groups 4 and 5 (high dose Herceptin® F(ab')2 and free MMAE).
  • the changes included bone marrow hypocellularity, thymic atrophy with marked apoptotic activity, increased numbers of mitotic and apoptotic cells in intestinal mucosa with variable extent of mucosal degeneration and atrophy and increased numbers of mitotic and apoptotic cells among hepatocytes and biliary epithelium. Animals of groups 2, 4 and 5 also showed evidence of hepatocyte dropout and occasional areas of hepatic necrosis.
  • Herceptin® F(ab')2-val-cit-MMAE (lysine) caused acute toxicity in a dose-dependent fashion.
  • Animals in the high dose Herceptin® F(ab')2-val-cit-MMAE showed a significantly greater weight loss compared with animals receiving the same amount of drug as Herceptin®- val-cit-MMAE.
  • the findings are consistent with the administration of agents that inhibit tubulin formation (Wood KW, Cornwell WD, and Jackson JR. Past and future of the mitotic spindle as an oncology target.
  • MMAE Herceptin®-monomethylauristatin
  • mice Female rats were administered equivalent doses (2105ug MMAE/m 2 ) via tail-vein injections at a dose volume of 10 ml/kg (diluted in PBS). All dose solutions were administered as a single bolus injection.
  • blood samples (approximately 500 ul) were generally collected via the retro-orbital sinus under isofluorane anesthesia on Study Days -3 (pre-dose) and Day 3 for clinical chemistry and hematology. Blood was also collected on Day 5 at necropsy via the inferior vena cava under ketamine anesthesia. Clinical observations and body weight recordings were performed once daily and cageside mortality checks were conducted twice daily (am/pm). Animals which were moribund were euthanized. During necropsy on Study Day 5, the blood of the rats were collected via the abdominal aorta for clinical chemistry and hematology.
  • mice in dose groups 3 and 4 had moderate pilo-erection and many of the animals were lethargic.
  • Two animals in the 14.25 mg/kg rhuFab4D5-val-cit-MMAE dose group were moribund on day 4 and were necropsied.
  • the auristatin E conjugated full length antibody (Herceptin®-MC-val-cit-P AB-MMAE, group 2) showed the same toxicity profile as seen in previous studies: Liver function tests were elevated on days 3 and 5 and showed, with the exception of GGT, evidence of recovery by day 5. The same animals showed progressive neutro- and thrombocytopenia during the 5-day study.
  • Animals in group 4 and 6 showed profound thrombo- and leukocytopenia on day 5. The levels are lower than those seen in animals of group 2 and animals in group 6 seem to do slightly better than animals in group 4. The results of the histopathological evaluation correlate very well with the clinical observations (body weight measurements) and the clinical pathology data. Animals in groups 2, 3, 4 and 6 show a markedly hypocellular bone marrow; signs of regeneration are only present in animals of group 3. In contrast, animals in group 5 show bone marrows of near normal cellularity. Similar findings are observed in the thymus: Animals of groups 2, 4 and 6 show marked atrophy and apoptotic activity, whereas animals of groups 3 and 5 show mild atrophy without significant apoptotic activity.
  • Figure 3 indicates that the albumin binding peptide can alter the toxicity of a drug conjugate.
  • Ab.Fab4D5-H-vc-MMAE (containing the albumin binding peptide) was significantly less toxic in rats than Fab4D5-vc-MMAE at Study Day 5.
  • Dose groups 2, 4, and 6 (20.2 mg/kg Herceptin®-val-cit-MMAE, 14.24 mg/kg rhuFab4D5-val-cit-MMAE, and 19.62 mg/kg rhuFab4D5-H-val-cit-MMAE, respectively) all received 2105 ug/M2 MMAE.
  • the group average decrease in body weight in Group 2 and 4 animals was more severe than group 6 animals.
  • Binding affinities between SA peptides and album were obtained using a BIAcore 3000 (BIAcore, Inc., Piscataway, NJ). Albumin was captured in a CM5 chip using amine coupling at approximately 5000 resonance units (RU). SA peptides (0, 0.625, 1.25, 2.5, 5, and lO ⁇ M were injected at a flow rate of 20 ⁇ l/minute for 30 seconds. The bound peptides were allowed to disassociate for 5 minutes before matrix regeneration using 1OmM glycine, pH 3.
  • the signal from an injection passing over an uncoupled cell was subtracted from that of an immobilized cell to generate sensongrams corresponding to the amount of peptide bound as a function of time.
  • the running buffer, PBS containing 0.05% TWEEN-20T was used for all sample dilutions.
  • BIAcore kinetic evaluation software (v 3.1 ) was used to determine the dissociation constant (Kj) from the association and dissociation rates, using a one to one binding model.
  • ELISA In assessing the binding capacity between proteins, ELISA has been the method of choice. The ease of developing a highly specific and quantitative assay has resulted in ELISA wide application. However, in the format where protein is immobilized directly on the solid surface, the potential artifact due to denaturing or obscuring binding epitope can occur.
  • the first format involved the adsorption of albumin to the well surface and the bound Fab is detected with goat-anti-huFab-HRP.
  • the second format involves the binding of Fab-H with albumin in solution and determines the dissociation constant (Kd).
  • Kd dissociation constant
  • the basic principle of the second assay is to allow the binding, of a constant concentration of Fab-H to varying amount of albumin, to reach equilibrium in solution, and determine the un-bound Fab-H in ELISA well coated with albumin.
  • the Kd value can be determined by analyzing the data using Scatchard Analysis (Munson et al, 1980, Anal. Biochem.,
  • Rat Albumin - Lyophilized form Cat. No. A6414
  • Rabbit Albumin- Lyophilized form Cat. No. A0639 lmg/ml Albumin solution was prepared by dissolving 10 mg in 10ml of PBS. The solution is stored at 4°C.
  • Assay Buffer PBS + 0.5%Chicken Egg Albumin (Sigma #A5503)+).5% Tween 20, PH 7.4)
  • Fab-Hx was removed by washing the well with 0.05% PBS/Tween20 and the bound Fab-Hx molecules were detected by I hour incubation with Goat anti-human Fab'2-HRP for at 25°C. Bound HRP was then measured with a solution of tetramethylbenzidine (TMB VH 2 OT . After 15 minutes incubation, the reaction was quenched by the addition of 1 M phosphoric acid. The absorbance at 450 nm was read with a reference wavelength of 650 nm. Kd (Solution Binding with Preincubation) ELISA Assay
  • a fixed concentration of Fab-H (determined in above binding ELISA) was first incubated in solution with varying concentrations of albumin in Assay Buffer. After >2 hours of incubation at room temperature, 100 ⁇ l of the mixture was transferred to Albumin coated ELISA plates. The concentration of free Fab-Hx was then determined by the direct binding ELISA as described above.
  • Fab-H was incubated with rabbit albumin at 1 hr., 2 hr. and overnight, and then the reaction mixtures were assayed in the binding ELISA. Equilibrium was reached after 2 hours incubation.
  • the Ab- albumin mixture was incubated with coated albumin in the well for 15, 30, 45, 60 and 120 minute. Based on this assay, it was determined that 30 minutes was the minimum amount of time required to bind all the free Fab-H.

Abstract

The present invention relates to therapeutic agents with reduced toxicity comprising a serum albumin binding peptide (SABP), a targeting agent and a cytotoxic agent. The present invention also relates to methods for reducing the toxicity agents and methods of treatment using the therapeutic agents with reduced toxicity.

Description

THERAPEUTIC AGENTS WITH DECREASED TOXICITY
This application is a non-provisional application filed under 37 CFR 1.53(b)(l), claiming priority under 35 USC 119(e) to provisional application numbers 60/641,534 filed on January 5, 2005 and 60/616,507 filed on October 5, 2004, the contents of which are incorporated herein by reference.
FIELD OF THE INVENTION
This invention relates to novel therapeutic agents with decreased toxicity in vivo, compositions comprising the same, methods for decreasing the toxicity of therapeutic agents in vivo and methods for treating patients comprising administering the novel therapeutic agents.
BACKGROUND OF THE INVENTION
Attempts have been made to use antibody-drug conjugates (ADC), to locally deliver cytotoxic or cytostatic agents, i.e. drugs that kill or inhibit tumor cells in the treatment of cancer (Payne, G. (2003) Cancer Cell 3:207-212; Syrigos and Epenetos (1999) Anticancer Research 19:605-614; Niculescu-Duvaz and Springer (1997) Adv. Drug Del. Rev. 26:151-172; US 4975278). Theoretically, the drug moiety will be targeted to the tumors and be internalized, wherein systemic administration of these unconjugated drug agents may result in unacceptable levels of toxicity to normal cells (Baldwin et al., (1986) Lancet pp. (Mar. 15, 1986):603-05; Thorpe, (1985) "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review," in Monoclonal Antibodies '84: Biological And Clinical Applications, A. Pinchera et al. (ed.s), pp. 475-506). Both polyclonal antibodies and monoclonal antibodies have been used in to make ADCs (Rowland et al., (1986) Cancer Immunol. Immunother., 21 :183-87). Drugs used in these methods include daunomycin, doxorubicin, methotrexate and vindesine (Rowland et al., (1986) supra). Toxins used in antibody-toxin conjugates include bacterial toxins such as diphtheria toxin, plant toxins such as ricin, small molecule toxins such as geldanamycin (Mandler et al (2000) J. of the Nat. Cancer Inst. 92(19):1573-1581; Mandler et al (2000) Bioorganic & Med. Chem. Letters 10:1025-1028; Mandler et al (2002) Bioconjugate Chem. 13:786-
791), maytansinoids (EP 1391213; Liu et al., (1996) Proc. Natl. Acad. ScL USA 93:8618-8623), and calicheamicin (Lode et al (1998) Cancer Res. 58:2928; Hinman et al (1993) Cancer Res. 53:3336-3342). More recently, auristatin peptides, auristatin E (AE) and monomethylauristatin (MMAE) and synthetic analogs of dolastatin (WO 02/088172), have been conjugated to full length antibodies (e.g., Klussman, et al (2004), Bioconjugate Chemistry 15(4):765-773; Doronina et al (2003) Nature Biotechnology 21(7):778-784;
Francisco et al (2003) Blood 102(4): 1458-1465; US 2004/0018194; WO 04/032828; Mao, et al (2004) Cancer Res. 64(3):781-788; Bhaskar et al (2003) Cancer Res. 63:6387-6394; WO 03/043583; Mao et al (2004) Cancer Res. 64:781-788). Variants of auristatin E are also disclosed in US 5767237; US 6124431. ZEVALIN® (ibritumomab tiuxetan, Biogen Idee Inc.) is an antibody-radioisotope conjugate composed of a murine IgGl kappa monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes and In or Y radioisotope bound by a thiourea linker- chelator (Wiseman et al (2000) Eur. J. Nucl. Med. 27(7):766-77; Wiseman et al (2002) Blood 99(12):4336-42; Witzig et al (2002) J. CHn. Oncol. 20(10):2453-63; Witzig et al (2002) J. Clin. Oncol. 20(15):3262-69). Although ZEVALIN® has activity against B-cell non-Hodgkin's Lymphoma (NHL), administration results in severe and prolonged cytopenias in most patients. MYLOT ARG™ (gemtuzumab ozogamicin, Wyeth Pharmaceuticals), an antibody drug conjugate composed of a CD33 antibody linked to calicheamicin, was approved in 2000 for the treatment of acute myeloid leukemia by injection (Drugs of the Future (2000) 25(7):686; US Patent Nos. 4970198; 5079233; 5585089; 5606040; 5693762; 57391 16; 5767285; 5773001 ). Cantuzumab mertansine (Immunogen, Inc.), an antibody drug conjugate composed of the huC242 antibody linked via the disulfide linker SPP to the maytansinoid drug moiety, DMl (Xie et al (2004) J. ofPhaτm. and Exp. Ther. 308(3):1073-1082), is advancing into Phase II trials for the treatment of cancers that express
CanAg, such as colon, pancreatic, gastric, and others. MLN-2704 (Millennium Pharm., BZL Biologies, Immunogen Inc.), an antibody drug conjugate composed of the anti-prostate specific membrane antigen (PSMA) monoclonal antibody linked to the maytansinoid drug moiety, DMl, is under development for the potential treatment of prostate tumors. Various methods have been tried to improve the half life of small molecule or biological therapeutics.
For example, glycosylation sites have been introduced to the molecules (Keyt et.al., 1994, PNAS USA 91:3670-74), and molecules have been conjugated with PEG (Clark et.al., 1996, J. Biol. Chem., 271: 21969- 77; Lee et. al, 1999, Bioconjugate Chem. 10:973-981; Tanaka et. al., 1991, Cancer Res. 51:3710-14) to increase size and increase elimination half-times. Some have attempted to use human serum albumin to improve the therapeutic use of the drug. For example, albumin has been attached to small molecules (Syed etal., 1997, Blood 89:3243-3252; Burger et.al., 2001 Int. J. Cancer 92:718-724; Wosikowski K, et al., Clin Cancer Res. 2003 May 9(5): 1917-26); CD4 (Yeh et.al., 1992, PNAS USA 89: 1904-1908); the Fc portion of an IgG (Ashkenazi et.al.(1997) Curr.Opin in Immunol. 9: 195-200), IL-2 (Yao, Z et al., (2004 May) Cancer Immunol Immunother.53(5y.404-I0) and the bridge between an anti-gp72 antibody and a methotrexate molecule (Affleck, K et al., (1992) Br J Cancer.65(6):838-44).
The use of albumin binding polypeptides have also been investigated. Extended in vivo half-times of human soluble complement receptor type 1 (sCRl) fused to the albumin binding domains from Streptococcal protein G have been reported (Makrides et al. 1996 /. Pharmacol. Exptl. Ther. 277:532-541). Labelled albumin binding domains of protein G have been described (EP 0486,525). Several phage diplay-derived albumin binding peptides have been described by applicant. See WO 01/45746, United States Patent
Publication No. 2004/0001827, and Dennis, MS, et al., (2002) JBC 277(38):35035-43. In theory, serum albumin binding peptides associate with serum albumin non-covalently in vivo. As such, the serum albumin binding peptides are necessarily a step removed from the in vivo cycling mechanism of serum albumin itself. The invention described below addresses the unexpectedly advantageous utility of albumin binding peptides in the context of a conjugate with a targeting agent/cytoxic agent.
SUMMARY OF THE INVENTION
The present invention relates to a conjugate molecule comprising a covalently linked combination of at least one serum albumin-binding moiety (SABM), targeting agent (TA) and cytotoxic agent (CA). According to one embodiment, the conjugate molecule comprises 2 or more CAs. According to embodiment, the conjugate molecule comprises 2 or more TAs.
According to one embodiment of this invention, the SABM comprises an amino acid sequence that is at" least 50% identical to the sequence of DICLPRWGCLW (SEQ ID NO:8) and wherein the amino acid sequence has two Cys residues with five amino acid residues in between the Cys residues. According to one embodiment, the amino acid sequence has a percent identity to SEQ ID NO:8 that is selected from the group consisting of at least 60% identity, at least 70% identity, at least 80% identity, at least 85% identity, at least 90% identity, at least 95% identity, at least 98% identity and at least 99% identity.
According to another embodiment, the SABM comprises a variant of the amino acid sequence of DICLPRWGCLW (SEQ ID NO:8), wherein between 1-5 residues of any of one of the residues of SEQ ID
NO:8 is substituted with a different amino acid residue, except for the Cys residues.
According to another embodiment, the SABM comprises a linear or a cyclic amino acid sequence selected from the group consisting of :
Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa Phe-Cys-Xaa-Asp-Trp-Pro-Xaa-Xaa-Xaa-Ser-Cys [SEQ ID NO: 1]
Val-Cys-Tyr-Xaa-Xaa-Xaa-Ile-Cys-Phe [SEQ ID NO: 2] Cys-Tyr-Xaal-Pro-Gly-Xaa-Cys [SEQ ID NO: 3] Asp-Xaa-Cys-Leu-Pro-Xaa-Trp-Gly-Cys-Leu-Trp [SEQ ID NO: 4] Trp-Cys-Asp-Xaa-Xaa-Leu-Xaa-Ala-Xaa-Asp-Leu-Cys [SEQ ID NO: 5]; Asp-Leu- Val-Xaa-Leu-Gly-Leu-Glu-Cys-Trp [SEQ ID NO: 6] ;
CXXGPXXXXC [SEQ ID NO:21] XXXXCXXGPXXXXCXXXX [SEQ ID NO:22] CXXXXXXCXXXXXXCCXXXCXXXXXXC [SEQ ID NO:23] CCXXXCXXXXXXC [SEQ ID NO:24] CCXXXXXCXXXXCXXXXCC [SEQ ID NO:25]
CXCXXXXXXXCXXXCXXXXXX [SEQ ID NO:26] XXXXXDXCLPXWGCLWXXXX [SEQ ID NO: 155] XXXXDXCLPXWGCLWXXX [SEQ ID NO: 156] DXCLPXWGCLW [SEQ ID NO:423] XXXXD I CLPRW G CLW XXX [SEQID NO:424],
XXXXXDICLPRWGCLWXXXX[SEQIDNO^]
XXEMCYFPGICWMXX[SEQIDNO:426]
XXDLCLRDWGCLWXX[SEQIDNO^V] wherein X is any amino acid residue. According to one preferred embodiment, SABM sequence of the above general formulae, particularly
SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3and SEQ ID NO: 4, comprise additional amino acids at the N- terminus (Xaa)x and additional amino acids at the C-terminus (Xaa)z, wherein Xaa is an amino acid and x and z are a whole number greater or equal to 0 (zero), generally less than 100, preferably less than 10 and more preferably 0, 1, 2, 3, 4 or 5 and more preferably 4 or 5 and Xaajis selected from the group consisting of He, Phe, Tyr, and VaI In one embodiment, the invention relates to the use of an albumin binding peptide comprising the sequence DICLPRWGCLW [SEQ ID NO 8] According to one embodiment, the SABM comprises any one of the ammo acid sequences selected from the group consisting of SEQ ID NOs 7-20,27- 154 and 157-421 According one preferred embodiment, the SABM comprises the amino acid sequence selected from the group consisting of SEQ ID NOs 7, 8 9, 10, 1 1 , 12, 13, 14 15, 16, 17, 18, 19 and 20
According to another embodiment , the SABM comprises the following amino acid sequence
Xaa, - Cys - Xaaj - Cys - Xaak, wherein the sum of i, j, and k is about 25 or less and Xaa is any amino acid residue According to one preferred embodiment, the sum of i, j, and k is about 18 residues or less According to another preferred embodiment, the the sum of i, j, and k is about 11 residues or less According to another embodiment, the SABM comprises any one of the peptide sequences described m Tables 1-9
According to one embodiment of this invention, all the above-mentioned SABM sequences bind to serum albumin with a K^ that is about 100 μM or less According to another embodiment, the K^ is selected from the group consisting of about 10 μM or less, about 1 μM or less, about 500 nM or less, about 10OnM or less, about 5OnM or less and about 1OnM or less
According to another embodiment, the TA is a polypeptide comprising an amino acid sequence that can bind to a target cell surface protein, wherein the TA comprises an amino acid sequence that is a hgand for the cell surface protein, an adhesion or an antibody, or a fragment of any one of the above that can bind to the cell surface protein According to one embodiment, the cell surface protein to be targeted is a B cell surface marker According to another embodiment, the receptor to be targeted is selected from the group consisting of
HER2, CD20, EGFR, PDGFR, BR3, FIt-I, KDR and EphB2 According to another embodiment, the TA is an antibody directed against any one of those receptors According to a preferred embodiment, the antibody is in the form of any one of the following a Fab, F(ab)2, scFv and a diabody According to another embodiment, the TA comprises a VH or VL sequence described herein (e g , an anti-HER2 antibody comprising the antigen- binding portions of SEQ ID NO 428 and 429)
According to one embodiment, the anti-HER2 antibody comprises the variable regions of SEQ ID NO 428 and 429 According to one embodiment, the anti-HER2 antibody comprises a variant of the light chain variable sequence of SEQ ID NO 428, wherein at least one or more of the ammo acids selected from the group consisting of Q27(VL), D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92((VL), and T94(VL), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine According to one embodiment, the anti-HER2 antibody comprises a variant of the light chain variable sequence of SEQ ID NO 428, wherein at least one or more amino acids of the variable region have a substitution selected from the group consisting of D28(VL)Q, D28(VL)G, N30(VL)S, 131(VL)S, A32(VL)G, Y49(VL)W, Y49(VL)D, Y49(VL)V, F53(VL)W, F53(VL)V, F53(VL)Q, Y55(VL)W, R66(VL)N, H91(VL)F, H91(VL)Y, Y92(VL)W, and T94(VL)S According to one embodiment, the anti-HER2 antibody comprises a variant of the light chain variable sequence of SEQ ID NO 428, wherein the variable region comprises at least three substitutions Y49(VL)D, F53(VL)W, and Y55(VL)W According to one embodiment, the anti-HER2 antibody comprises a variant of the light chain variable sequence of SEQ ID NO:428, wherein the variable region comprises at least three substitutions N30(VL)S, Hg I (V1 )F, and Y92(VL)W.
According to one embodiment, the anti-HER2 antibody comprises a variant of the heavy chain variable sequence of SEQ ID NO:429, wherein at least one or more of the amino acids selected from the group consisting of W95(VH), D98(VH), F100(VH), Y100a(VH), and Y102(VH), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine. According to one embodiment, the anti-HER2 antibody comprises a variant of the heavy chain variable sequence of SEQ ID NO:429, wherein the variable region comprises at least one or more substitutions selected from the group consisting of W95(VH)Y, D98(VH)W, D98(VH)R, D98(VH)K, D98(VH)H, F100(VH)P, F100(VH)L, F100(VH)M, F100(VH)W, Y100a(VH)F, Y102(VH)V, Y102(VH)K, and Y102(VH)L. According to one embodiment, the anti-HER2 antibody comprises a variant of the heavy chain variable sequence of SEQ ID NO:429, wherein the variable region comprises at least the substitutions F100(VH)P and Y102(VH)K. According to one embodiment, the anti-HER2 antibody comprises a variant of the heavy chain variable sequence of SEQ ID NO:429, wherein the variable region comprises at least the substitutions of F100(VH)P and Y102(VH)L. According to one embodiment, the anti-HER2 antibody comprises variants of the light chain variable sequence SEQ ID NO:428 and heavy chain variable sequence SEQ ID NO:429, wherein at least one or more of the amino acids selected from the group consisting of D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92(VL), T94(VL), W95(VH), D98(VH), F100(VH); Y100a(VH), and Y102(VH), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine. According to one embodiment, the anti-HER2 antibody comprises variants of the light chain variable sequence SEQ ID NO:428 and heavy chain variable sequence SEQ ID NO:429 comprising at least one or more of the following substitutions D28(VL)Q; D28(VL)G; N30(VL)S; T31(VL)S; A32(VL)G; Y49(VL)W, Y49(VL)D, Y49(VL)V; F53(VL)W, F53(VL)V, F53(VL)Q, Y55(VL)W, R66(VL)N, H91(VL)F, H91(VL)Y, Y92(VL)W, T94(VL)S, W95(VH)Y, D98(VH)W, D98(VH)R, D98(VH)K, D98(VH)H, F100(VH)P, F100(VH)L, FIOO(VH)M, Y100a(VH)F, Y102(VH)V, Y102(VH)K, and Y102(VH)L. According to one embodiment, the anti-HER2 antibody comprises variants of the light chain variable sequence SEQ ID NO:428 and heavy chain variable sequence SEQ ID NO:429 comprising at least the following substitutions Y49(VL)D, F53(VL)W, Y55(VL)W, FIOO(VH)P, and Y102(VH)K. According to one embodiment, the anti-HER2 antibody comprises variants of the light chain variable sequence SEQ ID NO:428 and heavy chain variable sequence SEQ ID NO:429 comprising at least the following substitutions Y49(VL)D, F53(VL)W, Y55(VL)W, FIOO(VH)P, and
Y 102(VH)L. According to another embodiment, the anti-HER2 antibody is any anti-HER2 antibody disclosed in United States Patent Publication No. 2003/0228663 Al, filed April 9, 2003; WO 03/087131; Carter et al, (1992) PNAS 89:4285-4289 which publications are expressly incorporated by reference herein.
According to one embodiment, the TA has an additional bioactivity other than the ability to bind to a protein on the outer surface of a cell. According to another embodiment, the other bioactivity is the ability to block ligand-mediated cellular signaling through the cell. According to another embodiment, the other bioactivity is the ability to induce apoptosis of the targeted cell. According to another embodiment, the TA is a polypeptide that binds to a protein on a cell of interest with a Kd selected from the group consisting of lOuM or less, 1 uM or less, 500nm or less, lOOnm or less and 10 nm or less. According to one embodiment, tne protein on me ceil or interest to wnicn tne i A Dinαs is overexpressed in cancer cells as compared to normal cells. According to another embodiment, the cell being targeted by the TA is a pathogenic cell, such as a tumor cell.
According to one preferred embodiment, the cytotoxic agent is monomethylauristatin (MMAE). According to another preferred embodiment, the conjugate molecule comprises a linker moiety located between said SABM and targeting agent or cytotoxic agent. In one embodiment, the linker moiety comprises the amino acid sequence: GGGS (SEQ ID NO:422).
According to another embodiment the SABM binds to human albumin. According to another embodiment, the SABM is conjugated to the N- or C-terminal region of a variable heavy or variable light chain of a TA.
The present invention provides compositions comprising the conjugate molecule admixed with a pharmaceutical carrier. The present invention also provides a the use of the conjugate molecule in the manufacture of a medicament.
The present invention also provides methods for reducing the toxicity of a therapeutic agent comprising the step of producing a therapeutic agent with a serum albumin binding moiety (SABM) conjugated to the therapeutic agent. The method can further comprise the step of comparing the toxicity of the therapeutic agent having the SABM with the therapeutic agent without the SABM. According to one embodiment, the method further comprises the step of measuring the toxicity of the therapeutic agent:SABM conjugate. The present invention provides methods of reducing the toxicity of a therapeutic agent in a mammal comprising administering to the mammal a therapeutically effective amount of the conjugate molecule according to this invention. According to one embodiment, the method further comprises the step of measuring the toxicity of the therapeutic agentSABM conjugate. According to one preferred embodiment, the mammal is suffering from an autoimmune disease or a cancer. The present invention provides methods of treating a tumor in a mammal comprising the step of treating a mammal having the tumor with a therapeutically effective amount of a conjugate molecule of this invention that binds to the tumor cells or vasculature surrounding the tumor. The present invention also provides methods of treating an autoimmune disorder in a mammal comprising the step of treating a mammal having the autoimmune disorder with a therapeutically effective amount of a conjugate molecule of this invention. According to one preferred embodiment, the conjugate molecules bind to B-cells that contribute to or cause the autoimmune disorder. The present invention also provides methods of treating a cell proliferative disorder in a mammal comprising the step of treating a mammal having the autoimmune disorder with a therapeutically effective amount of a conjugate molecule of this invention. According to another embodiment, the present invention provides a method for depleting B cells in a mammal comprising the step of treating the mammal with a therapeutically effective amount of a conjugate molecule of this invention that binds to the B cell.
According to one embodiment, the methods of treatment of this invention further comprises the step of measuring the toxicity of the conjugate molecule in a mammal. According to one embodiment, toxicity is manifested as any one of the group consisting of weight loss, hematopoietic toxicity, renal toxicity, liver toxicity, gastrointestinal toxicity, decreased mobilization of hematopoietic progenitor cells from bone marrow into the peripheral blood, anemia, myelosuppression, pancytopenia, thrombocytopenia, neutropenia, lymphopenia, leukopenia, stomatitis, alopecia, headache, and muscle pain.
The present invention also provides articles of manufacture comprising a container, a composition within the container comprising a conjugate molecule of this invention, a package insert containing instructions to administer a therapeutically effective dose.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the tumor volume over time post injection of a control vehicle (circles), Herceptin®- vc-Pab-MMAE (squares), Ab.Fab4D5-H-vc-PAB-MMAE (diamonds), Fab3D4-vc-PAB-MMAE (triangles) and Ab.FabControl-vc-P AB-MMAE (empty circles).
Figure 2 shows the group change in body weight post administration of Herceptin®-vc~MMAE (squares), Herceptin®- F(ab')24D5-vc-MMAE (crosses), free MMAE (circles).
Figure 3 shows the group change in body weight post administration of Herceptin®- vc-MMAE (diamonds), Fab4D5-vc-MMAE (triangles), AB .Fab4D5-H- vc-MMAE (circles) and PBS (squares).
Figure 4 shows the amino acid sequence of a light chain variable domain of a humanized anti-HER2 antibody [SEQ ID NO:428] and a heavy chain variable domain of a humanized anti-HER2 antibody [SEQ ID NO:429].
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS I. Definitions
The term "serum albumin binding peptide" or "serum albumin binding moiety" ("SABM") refers to a compound or a polypeptide comprising an amino acid sequence that binds to serum albumin. According to one preferred embodiment, the SABM binds to a human serum albumin. According to one embodiment, the SABM comprises at least one of any one of the sequences recited in the Listing of Sequences that binds to rabbit, rat, mouse or human serum albumin. According to another embodiment, the SABM comprises at least one of any one of the sequences recited in the Listing of Sequences that binds to multiple species of serum albumin. According to one embodiment, the SABM comprises at least one of any one of the sequences recited in Tables 1-9 that binds to any one or combination of rabbit, rat, mouse and human serum albumin. According to another embodiment, the SABM comprises at least one of any one of the sequences recited in the Tables 1-9 that binds to multiple species of serum albumin. Examples of multispecies binders include those SABM's that bind at least human and rat serum albumin; those that bind at least human, rat and rabbit serum albumin; those that bind at least human and rabbit serum albumin; and those that bind at least human and mouse serum albumin.
According to one preferred embodiment, the SABM peptide is a non-naturally occurring amino acid sequence that can bind albumin. SABMs within the context of the present invention can be constrained (that is, having some element of structure as, for example, the presence of amino acids which initiate a beta-turn or beta- pleated sheet, or for example, cyclized by the presence of disulfide-bonded Cys residues) or unconstrained (linear) amino acid sequences of less than about 50 amino acid residues, and preferably less than about 40 amino acids residues. Of the SABMs less than about 40 amino acid residues, preferred are the SABMs of between about 10 and about 30 amino acid residues and especially the SABMs of about 20 amino acid residues. However, upon reading the instant disclosure, the skilled artisan will recognize that it is not the length of a particular SABM but its ability to bind an albumin that distinguishes the SABM of the present invention.
A "targeting agent" or "TA" of the present invention will bind a target molecule on the surface of a cell with sufficient affinity and specificity if the TA "homes" to, "binds" or "targets" a target molecule such as a specific cell type bearing the target molecule in vitro and preferably in vivo (see, for example, the use of the term "homes to," "homing," and "targets" in Pasqualini and Ruoslahti, 1996 Nature, 380:364-366 and Arap et al., 1998 Science, 279:377-380). In general, the TA will bind a target molecule with an affinity characterized by a dissociation constant, K11, of less than about 10 microM, preferably less than about 100 nM and less than about 10 nM. However, polypeptides or small molecules having an affinity for a target molecule of less than about 1 nM and preferably between about 1 pM and 1 nM are equally likely to be TAs within the context of the present invention. Preferably, the TA is a polypeptide (e.g., an antibody). In general, a TA that binds a particular target molecule as described above can be isolated and identified by any of a number of techniques known in the art.
TAs are amino acid sequences as described above that may contain naturally as well as non-naturally occurring amino acid residues, such as phage-display derived antibodies. So-called "peptide mimetics" and
"peptide analogs", that include non-amino acid chemical structures that mimic the structure of a particular amino acid or peptide, can be TAs within the context of the invention. Such mimetics or analogs are characterized generally as exhibiting similar physical characteristics such as size, charge or hydrophobicity present in the appropriate spatial orientation as found in their peptide counterparts. A specific example of a peptide mimetic compound is a compound in which the amide bond between one or more of the amino acids is replaced by, for example, a carbon-carbon bond or other bond as is well known in the art (see, for example Sawyer, 1995, In: Peptide Based Drug Design pp. 378-422, ACS, Washington DC ).
A "B cell surface marker" or "B cell surface antigen" herein is an antigen expressed on the surface of a B cell which can be targeted with an antagonist which binds thereto. Exemplary B cell surface markers include the CDlO, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD40, CD53, CD72, CD73, CD74,
CDw75, CDw76, CD77, CDw78, CD79a, CD79b, CD80, CD81, CD82, CD83, CDw84, CD85 and CD86 leukocyte surface markers (for descriptions, see The Leukocyte Antigen Facts Book, 2nd Edition. 1997, ed. Barclay et al. Academic Press, Harcourt Brace & Co., New York). Other B cell surface markers include RP105, FcRH2, CD79A, C79B, CR2, CCR6, CD72, P2X5, HLA-DOB, CXCR5, FCER2, BR3, BTLA, NAG14 (aka LRRC4), SLGC16270 (ala LOC283663), FcRHl, IRTA2, ATWD578 (aka MGC15619), FcRH3,
IRTAl, FcRH6 (aka LOC343413) and BCMA (aka TNFRSF17).
The B cell surface marker of particular interest is preferentially expressed on B cells compared to other non-B cell tissues of a mammal and may be expressed on both precursor B cells and mature B cells. The preferred B cell surface markers herein are CD20 and CD22. The "CD20" antigen is non-glycosylated phosphoprotein found on the surface of greater than 90% of B cells from peripheral blood or lymphoid organs. CD20 is expressed during early pre-B cell development and remains until plasma cell differentiation. CD20 is present on both normal B cells as well as malignant B cells. Other names for CD20 in the literature include "B-lymphocyle-restricted antigen" B 1 and "Bp35". The CD20 antigen is described in Clark et al. PNAS (USA) 82: 1766 (1985), for example. The amino acid sequence of human CD20 is shown in The Leukocyte Antigen Facts Book, Barclay et al. supra, page 182, and also EMBL Genbank accession no. X12530 and Swissprot Pl 1836.
The "CD22" antigen, also known as BL-CAM or Lyb8, is a type 1 integral membrane glycoprotein with molecular weight of about 130 (reduced) to 14OkD (unreduced). It is expressed in both the cytoplasm and cell membrane of B-lymphocytes. CD22 antigen appears early in B-cell lymphocyte differentiation at approximately the same stage as the CD19 antigen. Unlike other B-cell markers, CD22 membrane expression is limited to the late differentiation stages comprised between mature B cells (CD22+) and plasma cells (CD22-). The CD22 antigen is described, for example, in Wilson et al. J. Exp. Med. 173:137 (1991) and Wilson et al. J. Immunol. 150:5013 (1993). The "CD19" antigen refers to an antigen identified, for example, by the HD237-CD19 or B4 antibody
(Kiesel et al. Leukemia Research II, 12: 1 119 (1987)). CD19 is found on Pro-B, pre-B, immature and mature, activated and memory B cells, up to a point just prior to terminal differentiation into plasma cells. Neither CD 19 nor CD20 is expressed on hematopoietic stem cell or plasma cell. Binding of an antagonist to CD 19 may cause internalization of the CD 19 antigen. The amino acid sequence of human CD 19 is shown in The Leukocyte Antigen Facts Book, Barclay et al. supra, page 180, and also EMBL Genbank accession no.
M28170 and Swissprot Pl 1836.
As used herein, "B cell depletion" refers to a reduction in B cell levels in an animal or human after drug or antibody treatment, as compared to the level before treatment. B cell levels are measurable using well known assays such as by getting a complete blood count, by FACS analysis staining for known B cell markers, and by methods such as described in the Experimental Examples. B cell depletion can be partial or complete.
In one embodiment, the depletion of CD20 expressing B cells is at least 25%. In a patient receiving a B cell depleting drug, B cells are generally depleted for the duration of time when the drug is circulating in the patient's body and the time for recovery of B cells.
Therefore, the term "amino acid" within the scope of the present invention is used in its broadest sense and is meant to include naturally occurring L alpha-amino acids or residues. The commonly used one and three letter abbreviations for naturally occurring amino acids are used herein (Lehninger, A.L., 1975, Biochemistry, 2d ed., pp. 71-92, Worth Publishers, New York). The correspondence between the standard single letter codes and the standard three letter codes is well known to the skilled artisan, and is reproduced here: A = Ala; C = Cys; D = Asp; E = GIu; F = Phe; G = GIy; H = His; I = He; K = Lys; L = Leu; M = Met; N = Asn; P = Pro; Q = GIn; R = Arg; S = Ser; T = Thr; V = VaI; W = Trp; Y = Tyr. The term includes D-amino acids as well as chemically modified amino acids such as amino acid analogs, naturally occurring amino acids that are not usually incorporated into proteins such as norleucine, and chemically synthesized compounds having properties known in the art to be characteristic of an amino acid. For example, analogs or mimetics of phenylalanine or proline, that allow the same conformational restriction of the peptide compounds as natural Phe or Pro, are included within the definition of amino acid. Such analogs and mimelics are reterred to herein as "functional equivalents" of an amino acid. Other examples of amino acids are listed by Roberts and Vellaccio, 1983, In: The Peptides: Analysis, Synthesis, Biology, Gross and Meiehofer, eds., Vol. 5 p. 341, Academic Press, Inc., N. Y., which is incorporated herein by reference. SABMs and TAs synthesized, for example, by standard solid phase synthesis techniques, are not limited to amino acids encoded by genes. Commonly encountered amino acids which are not encoded by the genetic code, include, for example, those described in International Publication No. WO 90/01940 such as, for example, 2-amino adipic acid (Aad) for GIu and Asp; 2-aminopimelic acid (Apm) for GIu and Asp; 2- aminobutyric (Abu) acid for Met, Leu, and other aliphatic amino acids; 2-aminoheptanoic acid (Ahe) for Met, Leu and other aliphatic amino acids; 2-aminoisobutyric acid (Aib) for GIy; cyclohexylalanine (Cha) for VaI, and Leu and He; homoarginine (Har) for Arg and Lys; 2,3-diaminopropionic acid (Dpr) for Lys, Arg and His; N-ethylglycine (EtGIy) for GIy, Pro, and Ala; N-ethylglycine (EtGIy) for GIy, Pro, and Ala; N-ethylasparigine (EtAsn) for Asn, and GIn; Hydroxyllysine (HyI) for Lys; allohydroxyllysine (AHyI) for Lys; 3-(and 4)- hydoxyproline (3Hyp, 4Hyp) for Pro, Ser, and Thπ, allo-isoleucine (AIIe) for He, Leu, and VaI; p- amidinophenylalanine for Ala; N-methylglycine (MeGIy, sarcosine) for GIy, Pro, and Ala; N-methylisoleucine
(MeIIe) for He; Norvaline (Nva) for Met and other aliphatic amino acids; Norleucine (NIe) for Met and other aliphatic amino acids; Ornithine (Orn) for Lys, Arg and His; Citrulline (Cit) and methionine sulfoxide (MSO) for Thr, Asn and GIn; N-methylphenylalanine (MePhe), trimethylphenylalanine, halo (F, Cl, Br, and I) phenylalanine, trifluorylphenylalanine, for Phe. SABMs and TAs within the context of the present invention may be "engineered", i.e., can be non- native or non-naturally occurring TAs. By "non-native" or "non-naturally occurring" is meant that the amino acid sequence of the particular SABM is not found in nature. That is to say, amino acid sequences of non- native or non-naturally occurring TAs or SABMs need not correspond to an amino acid sequence of a naturally occurring protein or polypeptide. TAs or SABMs of this variety may be produced or selected using a variety of techniques, including those well known to the skilled artisan. For example, constrained or unconstrained peptide libraries may be randomly generated and displayed on phage utilizing art standard techniques, for example, Lowman et al, 1998, Biochemistry 37:8870-8878.
SABMs and TAs and cytotoxic agents, when used within the context of the present invention, can be "conjugated" to eachother. The term "conjugated" is used in its broadest sense to encompass all methods of covalent attachment or joining that are known in the art. For example, in a typical embodiment, the SABM is a protein and the TA is an amino acid extension C- or N-terminus to the SABM. In addition, a short amino acid linker sequence may lie between the protein therapeutic and the SABM. In this scenario, the SABM, optional linker and TA will be encoded by a nucleic acid comprising a sequence encoding SABM operably linked (in the sense that the DNA sequences are contiguous and in reading frame) to an optional linker sequence encoding a short polypeptide as described below, and a sequence encoding the TA. In this typical scenario, the
SABM is considered to be "conjugated" to the TA optionally via a linker sequence. In a related embodiment, the SABM amino acid sequence may interrupt or replace a section of the TA amino acid sequence, provided, of course, that the insertion of the SABM amino acid sequence does not interfere with the function of the protein therapeutic. In a further typical embodiment, the SABM will be linked, e.g., by chemical conjugation to the TA or other therapeutic optionally via a linker sequence. Typically, according to this embodiment, the SABM will be linked to the TA via a side chain of an amino acid somewhere in the middle of the TA that doesn't interfere with TA's ability to recognize the target activity. Here again, the SABM is considered to be "conjugated" to the TA. The term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies
(including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.
"Functional fragments", of the antibodies of the invention comprise a portion of an intact antibody, generally including the antigen binding or variable region of the intact antibody or the Fc region of an antibody which retains FcR binding capability. Examples of antibody fragments include linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that can be present in minor amounts. Monoclonal antibodies are highly specific, each being directed against one or two antigenic site(s), typically one site. Furthermore, in contrast to conventional (polyclonal) antibody preparations which are derived from animals against an antigen so that several different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized by the hybridoma culture, uncontaminated by other immunoglobulins. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567). The "monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in
Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. MoI. Biol., 222:581-597 (1991), for example.
The monoclonal antibodies herein specifically include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in' antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Methods of making chimeric antibodies are known in the art. "Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity-determining region (CDR) of the recipient are replaced by residues from a CDR of a non- human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence although the FR regions may include one or more amino acid substitutions that improve binding affinity. The number of these amino acid substitutions in the FR are typically no more than 6 in the H chain, and in the L chain, no more than 3. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol, 2:593-596 (1992). The humanized antibody includes a PRIMATIZED® antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by, e.g., immunizing macaque monkeys with the antigen of interest. Methods of making humanized antibodies are known in the art.
Human antibodies can also be produced using various techniques known in the art, including phage- display libraries. Hoogenboom and Winter, J. MoI. Biol., 227:381 (1991); Marks et al., J. MoI. Biol., 222:581 (1991). The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies. Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985);
Boerner et al., J. Immunol., 147(l):86-95 (1991).
As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is
"heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin can be obtained from any immunoglobulin, such as IgG-I, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-I and IgA-2), IgE, IgD or IgM.
A "fusion protein" and a "fusion polypeptide" refer to a polypeptide having at least two portions covalently linked together, where each of the portions is a polypeptide having a different property. The property may be a biological property, such as activity in vitro or in vivo. The property may also be a simple chemical or physical property, such as binding to a target molecule, catalysis of a reaction, etc. The portions may be linked directly by a single peptide bond or through a peptide linker containing one or more amino acid residues. Generally, the portions and the linker will be in reading frame with each other.
An "isolated" polypeptide or antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the polypeptide or antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes, in preferred embodiments, the antibody will be purified ( 1 ) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or. preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.
Humanized anti-ErbB2 (HER2) antibodies include huMAb4D5-l , huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 (HERCEPTIN7) as described in Table 3 of U.S. Pat. No. 5,821,337 expressly incorporated herein by reference; humanized 520C9 (WO93/21319) and humanized 2C4 antibodies as described in copending application Ser. No. 09/81 1115, and antibodies comprising the variable regions of anti-HER2 variants disclosed in WO 03/08713 land United States Patent Publication No. 2003/0228663, incorporated herein by reference. Throughout the disclosure, the terms "huMAb4D5-8" and "hu4D5-8" are used interchangeably.
The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents the function of cells and/or causes destruction of cells. The cytotoxic agent should be capable of being internalized and/or capable of inhibiting cell growth from outside the cell without necessarily binding to the cell surface. According to one preferred embodiment, the agent is a small molecule. According to another embodiment, the active portion of the cytotoxic agent is 110OkD or less. The term is intended to include radioactive isotopes
, . 211 T131 T125 „90 n 186 „ 188 c 153 „.212 - .213 „32 , ,. . . , -τ .
(e.g. At , 1 , 1 , Y , Re , Re , Sm , Bi , Bi , P and radioactive isotopes of Lu), chemotherapeutic agents e.g. methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin, or other intercalating agents, enzymes and fragments thereof such as nucleolytic enzymes, antibiotics, and toxins such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, (e.g., MMAE) including fragments and/or variants thereof, and the various antitumor or anticancer agents or grow inhibitory agents disclosed below. Other cytotoxic agents are described below. According to one preferred embodiment, the cytotoxic agent is not a radioisotope.
A "chemotherapeutic agent" is a chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and CYTOXAN® cyclosphosphamide; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethiylenethiophosphoramide and trimethylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins
(particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CBl-TMl); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chloro/.otocin, fotemustine, lomustine, nimustine, and ranimnustine; antibiotics such as the enediyne antibiotics (e. g., calicheamicin, especially calicheamicin gammall and calicheamicin omegall (see, e.g., Agnew, Chem Intl. Ed. Engl., 33: 183-186 (1994)); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6~diazo-5-oxo-L-norleucine, ADRIAMYCIN® doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfϊromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti- adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2- ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g., TAXOL® paclitaxel (Bristol- Myers Squibb Oncology,
Princeton, NJ.), AB RAXANETM Cremophor-free, albumin-engineered nanoparticle formulation of paclitaxel (American Pharmaceutical Partners, Schaumberg, Illinois), and TAXOTERE® doxetaxel (Rhone- Poulenc Rorer, Antony, France); chloranbucil; GEMZAR® gemcitabine; 6- thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE® vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; CPT-I l; topoisomerase inhibitor RFS 2000; difluorometlhylornithine (DMFO); retinoids such as retinoic acid; capecitabine; oxaliplatin, including the oxaliplatin treatment regimen (FOLFOX); inhibitors of PKC-alpha, Raf, H-Ras, and EGFR (e.g., erlotinib (TarcevaTM)) and pharmaceutically acceptable salts, acids or derivatives of any of the above. A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell in vitro and/or in vivo. Thus, the growth inhibitory agent may be one that significantly reduces the percentage of cells in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce GI arrest and M-phase arrest. Classical M-phase blockers include the vincas (vincristine and vinblastine), TAXOL® paclitaxel, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest Ul also spill over into S-phase arrest, for example, DNA alkylating agents such as tanoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C. Further information can be found in The Molecular Basis of Cancer, Mendelsohn and Israel, eds., Chapter 1 , entitled "Cell cycle regulation, oncogenes, and antieioplastic drugs" by Murakaini et al. (W B Saunders: Philadelphia, 1995), especially p. 13.
Examples of "growth inhibitory" agents include an epidermal growth factor receptor (EGFR) antagonist (e.g., a tyrosine kinase inhibitor), HERl /EGFR inhibitor (e.g., erlotinib (TarcevaTM), platelet derived growth factor inhibitors (e.g., GleevecTM (Imatinib Mesylate)), a COX-2 inhibitor (e.g., celecoxib), and other bioactive and organic chemical agents, etc. The term "therapeutically effective amount" refers to an amount of a conjugate molecule effective to
"alleviate" or "treat" a disease or disorder in a subject. To the extent the conjugate molecule may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
"Treatment" refers to amelioration or alleviation of a disease or disorder. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. A subject is successfully "treated" for a cancer or an autoimmune disease if, after receiving a therapeutic amount of a conjugate according to the methods of the present invention, the subject shows observable and/or measurable reduction in or absence of one or more signs and symptoms of the particular disease. For example, for cancer, reduction in the number of cancer cells or absence of the cancer cells; reduction in the tumor size; inhibition (i.e., slow to some extent and preferably stop) of tumor metastasis; inhibition, to some extent, of tumor growth; increase in length of remission, and/or relief to some extent, one or more of the symptoms associated with the specific cancer; reduced morbidity and mortality, and improvement in quality of life issues. Reduction of the signs or symptoms of a disease may also be felt by the patient. Treatment can achieve a complete response, defined as disappearance of all signs of cancer, or a partial response, wherein the size of the tumor is decreased, preferably by more than 50 percent, more preferably by 75%. A patient is also considered treated if the patient experiences stable disease. In a preferred embodiment, the cancer patients are still progression-free in the cancer after one year, preferably after 15 months. These parameters for assessing successful treatment and improvement in the disease are readily measurable by routine procedures familiar to a physician of appropriate skill in the art. In a preferred embodiment, the subject shows improvement from the illness while experiencing less side effects than a subject who may be treated received with the same conjugate molecule lacking the SABM.
The terms "cancer" and "cancerous" refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, cancer of the urinary tract, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, melanoma, multiple myeloma and B-cell lymphoma, brain, as well as head and neck cancer, and associated metastases.
The terms "cell proliferative disorder" and "proliferative disorder" refer to disorders that are associated with some degree -of abnormal cell proliferation. In one embodiment, the cell proliferative disorder is cancer.
"Tumor", as used herein, refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues.
B-cell regulated autoimmune diseases include arthritis (rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, psoriatic arthritis), psoriasis, dermatitis including atopic dermatitis; chronic autoimmune urticaria, polymyositis/dermatomyositis, toxic epidermal necrolysis, systemic scleroderma and sclerosis, responses associated with inflammatory bowel disease (IBD) (Crohn's disease, ulcerative colitis), respiratory distress syndrome, adult respiratory distress syndrome (ARDS), meningitis, allergic rhinitis, encephalitis, uveitis, colitis, glomerulonephritis, allergic conditions, eczema, asthma, conditions involving infiltration of T cells and chronic inflammatory responses, atherosclerosis, autoimmune myocarditis, leukocyte adhesion deficiency, systemic lupus erythematosus (SLE), lupus (including nephritis, non-renal, discoid, alopecia), juvenile onset diabetes, multiple sclerosis, allergic encephalomyelitis, immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T-lymphocytes, tuberculosis, sarcoidosis, granulomatosis including Wegener's granulomatosis, agranulocytosis, vasculitis (including ANCA), aplastic anemia, Coombs positive anemia, Diamond Blackfan anemia, immune hemolytic anemia including autoimmune hemolytic anemia (AIHA), pernicious anemia, pure red cell aplasia (PRCA), Factor VIII deficiency, hemophilia A, autoimmune neutropenia, pancytopenia, leukopenia, diseases involving leukocyte diapedesis, CNS inflammatory disorders, multiple organ injury syndrome, myasthenia gravis, antigen-antibody complex mediated diseases, anti-glomerular basement membrane disease, anti-phospholipid antibody syndrome, allergic neuritis, Bechet disease, Castleman's syndrome, Goodpasture's Syndrome, Lambert-Eaton Myasthenic Syndrome, Reynaud's syndrome, Sjorgen's syndrome, Stevens- Johnson syndrome, solid organ transplant rejection (including pretreatment for high panel reactive antibody titers, IgA deposit in tissues, etc), graft versus host disease (GVHD), pemphigoid bullous, pemphigus (all including vulgaris, foliaceus), autoimmune polyendocrinopathies, Reiter's disease, stiff-man syndrome, giant cell arteritis, immune complex nephritis, IgA nephropathy, IgM polyneuropathies or IgM mediated neuropathy, idiopathic thrombocytopenic purpura (ITP), thrombotic throbocytopenic purpura (TTP), autoimmune thrombocytopenia, autoimmune disease of the testis and ovary including autoimune orchitis and oophoritis, primary hypothyroidism; autoimmune endocrine diseases including autoimmune thyroiditis, chronic thyroiditis (Hashimoto's Thyroiditis), subacute thyroiditis, idiopathic hypothyroidism, Addison's disease, Grave's disease, autoimmune polyglandular syndromes (or polyglandular endocrinopathy syndromes), Type I diabetes also referred to as insulin-dependent diabetes mellitus (IDDM) and Sheehan's syndrome; autoimmune hepatitis, Lymphoid interstitial pneumonitis (HIV), bronchiolitis obliterans (non-transplant) vs NSIP, Guillain-Barre' Syndrome, Large Vessel Vasculitis (including Polymyalgia Rheumatica and Giant Cell (Takayasu's) Arteritis), Medium Vessel Vasculitis (including Kawasaki's Disease and Polyarteritis Nodosa), ankylosing spondylitis, Berger's Disease (IgA nephropathy), Rapidly Progressive Glomerulonephritis, Primary biliary cirrhosis. Celiac sprue (gluten enteropathy), Cryoglobulinemia, ALS, coronary artery disease.
B cell neoplasms include CD20-positive Hodgkin's disease including lymphocyte predominant Hodgkin's disease (LPHD); non-Hodgkin's lymphoma (NHL); follicular center cell (FCC) lymphomas; acute lymphocytic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hairy cell leukemia. The non-Hodgkins lymphoma include low grade/follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate grade/follicular NHL, intermediate grade diffuse NHL, high grade immunoblastic NHL, high grade lymphoblastic NHL, high grade small non-cleaved cell NHL, bulky disease NHL, plasmacytoid lymphocytic lymphoma, mantle cell lymphoma, AIDS- related lymphoma and Waldenstrom's macroglobulinemia. Treatment of relapses of these cancers are also contemplated. LPHD is a type of
Hodgkin's disease that tends to relapse frequently despite radiation or chemotherapy treatment and is characterized by CD20-positive malignant.cells. CLL is one of four major types of leukemia. A cancer of mature B-cells called lymphocytes, CLL is manifested by progressive accumulation of cells in blood, bone marrow and lymphatic tissues. Indolent lymphoma is a slow-growing, incurable disease in which the average patient survives between six and 10 years following numerous periods of remission and relapse.
"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cows, etc. Preferably, the mammal is human. The subject to be treated according to this invention is a mammal.
A "disorder" is any condition that would benefit from treatment with the compositions comprising the conjugate molecules of the invention. This includes chronic and acute disorders or diseases including those pathological conditions which predispose the mammal to the disorder in question.
"Elimination half-time" is used in its ordinary sense, as is described in Goodman and Gillman 's The Pharmaceutical Basis of Therapeutics, pp. 21-25 Alfred Goodman Gilman, Louis S. Goodman, and Alfred Gilman, eds., 6th ed. 1980. Briefly, the term is meant to encompass a quantitative measure of the time course of drug elimination. The elimination of most drugs is exponential (i.e., follows first-order kinetics), since drug concentrations usually do not approach those required for saturation of the elimination process. The rate of an exponential process may be expressed by its rate constant, k, which expresses the fractional change per unit of time, or by its half-time, ti/2, the time required for 50% completion of the process. The units of these two constants are time"1 and time, respectively. A first-order rate constant and the half-time of the reaction are simply related (k x t% = 0.693) and may be interchanged accordingly. Since first-order elimination kinetics dictates that a constant fraction of drug is lost per unit time, a plot of the log of drug concentration versus time is linear at all times following the initial distribution phase (i.e. after drug absorption and distribution are complete). The half-time for drug elimination can be accurately determined from such a graph. According to one preferred embodiment of this invention, the conjugate molecules of this invention have a longer half-life and lower toxicity than conjugate molecules that lack the SABM.
"Transfection" refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for. example, CaPO4 precipitation and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.
"Transformation" means introducing DNA into an organism so that the DNA is replicable, either as an-extrachromosomal element or by chromosomal integrant. Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in section 1.82 of Sambrook et ai, 1989, Molecular Cloning (2nd ed.), Cold Spring Harbor Laboratory, NY, is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. Infection with Agrobacterium tumefaciens is used for transformation of certain plant cells, as described by Shaw er a/., 1983 Gene, 23:315 and WO 89/05859, published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method described in sections 16.30-16.37 of
Sambrook et at, supra, is preferred. General aspects of mammalian cell host system transformations have been described by Axel in U.S. Patent No. 4,399,216, issued 16 August 1983. Transformations into yeast are typically carried out according to the method of Van Solingen et ai, 1977, 7. Bad., 130:946 and Hsiao et al, 1979, Proc. Natl. Acad. ScL (USA), 76:3829. However, other methods for introducing DNA into cells such as by nuclear injection, electroporation, or by protoplast fusion may also be used.
As used herein, the term "pulmonary administration" refers to administration of a formulation of the invention through the lungs by inhalation. As used herein, the term "inhalation" refers to intake of air to the alveoli. In specific examples, intake can occur by self-administration of a formulation of the invention while inhaling, or by administration via a respirator, e.g., to an patient on a respirator. The term "inhalation" used with respect to a formulation of the invention is synonymous with "pulmonary administration."
As used herein, the term "parenteral" refers to introduction of a compound of the invention into the body by other than the intestines, and in particular, intravenous (i.v.), intraarterial (La.), intraperitoneal (i.p.), intramuscular (i.m.), intraventricular, and subcutaneous (s.c.) routes.
As used herein, the term "aerosol" refers to suspension in the air. In particular, aerosol refers to the particlization of a formulation of the invention and its suspension in the air. According to the present invention, an aerosol formulation is a formulation comprising a compound of the present invention that is suitable for aerosolization, i.e., particlization and suspension in the air, for inhalation or pulmonary administration.
II. Modes for Carrying out the Invention A. SABM
SABMs within the context of the present invention bind albumin. Preferred SABMs that bind serum albumin include linear and cyclic peptides, preferably cyclic peptide compounds comprising the following formulae or are' peptides that compete for binding serum albumin of a particular mammalian species with peptides of the following formulae: Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa
Phe-Cys-Xaa-Asp-Trp-Pro-Xaa-Xaa-Xaa-Ser-Cys [SEQ ID NO: 1] Val-Cys-Tyr-Xaa-Xaa-Xaa-ne-Cys-Phe [SEQ ID NO: 2] Cys-Tyr-Xaai-Pro-Gly-Xaa-Cys [SEQ ID NO: 3] and Asp-Xaa-Cys-Leu-Pro-Xaa-Trp-Gly-Cys-Leu-Trp [SEQ ID NO: 4] Preferred are peptide compounds of the foregoing general formulae comprising additional amino acids at the N-terminus (Xaa)x and additional amino acids at the C-terminus (Xaa)z, wherein Xaa is an amino acid and x and z are a whole number greater or equal to 0 (zero), generally less than 100, preferably less than 10 and more preferably 0, 1 , 2, 3, 4 or 5 and more preferably 4 or 5 and wherein Xaai is selected from the group consisting of He, Phe, Tyr and VaI.
Further preferred SABMs that bind a serum albumin are identified as described herein in the context of the following general formulae:
Trp-Cys-Asp-Xaa-Xaa-Leu-Xaa-Ala-Xaa-Asp-Leu-Cys (SEQ ID NO: 5) and Asp-Leu- Val-Xaa-Leu-Gly-Leu- Glu-Cys-Trp [SEQ ID NO: 6] where additional amino acids may be present at the N-terminal end (Xaa)x and additional amino acids may be present at the C-terminal end (Xaa)z, and where Xaa is an amino acid and x and z are a whole number greater or equal to zero, generally less than 100, preferably less than 10 and more preferably 0, 1, 2, 3, 4 or 5 and more preferably 4 or 5. According to this aspect of the invention reference is made to the Examples below and particularly the
Tables contained therein showing especially exemplary peptides and appropriate amino acids for selecting peptides ligands that bind a mammalian serum albumin. In a preferred aspect, reference is made to Table 7 for selecting SABMs that bind across several species of serum albumin.
Preferred compounds according to this aspect of the invention include: DLCLRDWGCLW (SEQ ID NO:7)
DICLPRWGCLW (SEQ ID NO:8)
MEDICLPRWGCLWGD (SEQ ID NO:9)
QRLMEDICLPRWGCLWEDDE (SEQ ID NO: 10)
QGLIGDICLPRWGCLWGRSV (SEQ ID NO: 11) QGLIGDICLPRWGCLWGRSVK (SEQ ID NO: 12)
EDICLPRWGCLWEDD (SEQ ID NO: 13)
RLMEDICLPRWGCLWEDD (SEQ ID NO: 14)
MEDICLPRWGCLWEDD (SEQ ID NO: 15)
MEDICLPRWGCLWED (SEQ ID NO: 16) RLMEDICLARWGCLWEDD (SEQ ID NO: 17)
EVRSFCTRWPAEKSCKPLRG (SEQ ID NO: 18)
RAPESFVCYWETICFERSEQ (SEQ ID NO: 19)
EMCYFPGICWM (SEQ ID NO:20)
In a preferred embodiment, SABMs of the present invention bind human serum albumin and can be identified by their ability to compete for binding of human serum albumin in an in vitro assay with SABMs having the general formulae shown below, where additional amino acids may be present at the N-terminal end (Xaa)x and at the C-terminal end (Xaa)z:
D X C L P X W G C L W (SEQ ID NO:4) F C X D W P X X X S C (SEQ ID NO:1) V C Y X X X I C F (SEQ ID NO:2)
C Y X, P G X C X (SEQ ID NO:3) where Xaa is an amino acid, x and z are preferably 4 or 5, and Xaai is selected from the group consisting of Re, Phe, Tyr, and VaI.
In particular embodiments, the SABMs of the present invention will compete with any of the SABMs represented in SEQ ID NO: 7 - 20 described herein above and preferably will compete with SEQ ID NO: 10 for binding human serum albumin.
As will be appreciated from the foregoing, the term "compete" and "ability to compete" are relative terms. Thus the terms, when used to describe the SABMs of the present invention, refer to SABMs that produce a 50% inhibition of binding of, for example the peptide represented by SEQ ID NO: 10, when present at 50 μM, preferably when present at 1 μM, more preferably 100 nM, and preferably when present at 1 nM or less in a standard competition assay as described herein. However, SABMs having an affinity for a serum albumin of less than about 1 nM and preferably between about 1 pM and 1 nM are equally likely to be SABMs within the context of the present invention.
For in vitro assay systems to determine whether a peptide or other compound has the "ability" to compete with a SABM for binding to serum albumin as noted herein, the skilled artisan can employ any of a number of standard competition assays. Competitive binding assays rely on the ability of a labeled standard to compete with the test sample analyte for binding with a limited amount of ligand. The amount of analyte in the test sample is inversely proportional to the amount of standard that becomes bound to the ligand.
Thus, the skilled artisan may determine whether a peptide or other compound has the ability to compete with a SABM for binding to albumin employing procedures that include, but are not limited to, competitive assay systems using techniques such as radioimmunoassays (RIA), enzyme immunoassays (EIA), preferably the enzyme linked immunosorbent assay (ELISA), "sandwich" immunoassays, immunoradiometric assays, fluorescent immunoassays, and immunoelectrophoresis assays, to name but a few.
For these purposes, the selected SABM will be labeled with a detectable moiety (the detectably labeled SABM hereafter called the "tracer") and used in a competition assay with a candidate compound for binding albumin. Numerous detectable labels are available that can be preferably grouped into the following categories: ■ (a) Radioisotopes, such as S, C, I, H, and I. The SABM can be labeled with the radioisotope using techniques described in Coligen et al, 1991, eds., Current Protocols in Immunology, Volumes 1 and 2, Wiley-Interscience, New York, N. Y., for example. Radioactivity can be measured using scintillation counting.
(b) Fluorescent labels such as rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, lissamine, phycoerythrin, and Texas Red are available. The fluorescent labels can be conjugated to the peptide compounds using the techniques disclosed in Current Protocols in Immunology, supra, for example. Fluorescence can be quantified using a fluorimeter.
(c) Various enzyme-substrate labels are available and U.S. Patent No. 4,275,149 provides a review of some of these. The enzyme preferably catalyzes a chemical alteration of the chromogenic substrate that can be measured using various techniques. For example, the enzyme may catalyze a color change in a substrate, that can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light that can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRP), alkaline phosphatase, beta-galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like.
Examples of enzyme-substrate combinations include, for example:
(i) Horseradish peroxidase (HRP) with hydrogen peroxidase as a substrate, where the hydrogen peroxidase oxidizes a dye precursor (e.g. ABTS, orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB));
(ii) alkaline phosphatase (AP) with para-nitrophenyl phosphate as chromogenic substrate; and (iii) β-D-galactosidase (β -D-GaI) with a chromogenic substrate (e.g. p-nitrophenyl- β -D- galactosidase) or fluorogenic substrate 4-methylumbelliferyl- β -D-galactosidase.
According to a particular assay, the tracer is incubated with immobilized target in the presence of varying concentrations of unlabeled candidate compound. Increasing concentrations of successful candidate compound effectively compete with binding of the tracer to immobilized target. The concentration of unlabeled candidate compound at which 50% of the maximally-bound tracer is displaced is referred to as the "IC50" and reflects the IgG binding affinity of the candidate compound. Therefore a candidate compound with an IC50 of 1 HiM displays a substantially weaker interaction with the target than a candidate compound with an IC50 of 1 ΪM.
In some phage display ELISA assays, binding affinity of a mutated ("mut") sequence was directly compared of a control ("con") peptide using methods described in Cunningham et al., 1994, EMBO J. 13:2508, and characterized by the parameter EC50. Assays were performed under conditions where EC5o(con)/EC5o(mut) will approximate Kd(con)/Kd(mut). Accordingly, the invention provides compounds "having the ability to compete" for albumin such as human serum albumin binding in an in vitro assay as described. Preferably the compound has an IC50 for the target such as human serum albumin of less than 1 ΪM. Preferred among these compound are compounds having an IC50 of less than about 100 nM , and preferably less than about 10 nM or less than about 1 nM. In further preferred embodiments according to this aspect of the invention the compounds display an IC50 for the target molecule such as or human serum albumin of less than about 100 pM and more preferably less than about 10 pM.
A preferred in vitro assay for the determination of a candidate compound's ability to compete with a SABM described herein is as follows and is described more fully in the Examples. In preferred embodiments the candidate compound is a peptide. The ability of a candidate compound to compete with a labeled SABM tracer for binding to human serum albumin is monitored using an ELISA. Dilutions of a candidate compound in buffer are added to microtiter plates coated with human serum albumin (as described in the Example Sections) along with tracer for 1 hour. The microtiter plate is washed with wash buffer and the amount of tracer bound to human serum albumin measured.
B. SABM:TA:Cytotoxic Agent Combinations
The SABM is linked to a TAxytotoxic agent to form a conjugate molecule that comprises at least one of each component (i.e., at least three different components). Each component can be optionally joined to each other via a flexible linker domain. Depending on the type of linkage and its method of production, the SABM domain may be joined via its N- or C-terminus to the N- or C-terminus of the TA. For example, when preparing the conjugate molecules of the present invention via recombinant techniques, nucleic acid encoding a SABM will be operably linked to nucleic acid encoding the TA sequence, optionally via a linker domain. Typically the construct encodes a fusion protein wherein the C-terminus of the SABM is joined to the N-terminus of the TA. However, especially when synthetic techniques are employed, fusions where, for example, the N-terminus of the SABM is joined to the N- or C-terminus of the TA also are possible.
In some instances, the SABM domain may be inserted within the TAs molecule rather than being joined to the TAs at its N-or C-terminus. This configuration may be used to practice the invention so long as the functions of the SABM domain and the TAs are preserved. For example, a SABM may be inserted into a non-binding light chain CDR of an immunoglobulin without interfering with the ability of the immunoglobulin to bind to its target. Regions of TAs molecules that can accommodate SABM domain insertions may be identified empirically {i.e., by selecting an insertion site, randomly, and assaying the resulting conjugate for the function of the TAs ), or by sequence comparisons amongst a family of related TAs molecules {e.g., for TAs s that are proteins) to locate regions of low sequence homology. Low sequence homology regions are more likely to tolerate insertions of SABMs domains than are regions that are well-conserved. For TAs whose three- dimensional structures are known {e.g. from X-ray crystallographic or NMR studies), the three-dimensional structure may provide guidance as to SABM insertion sites. For example, loops or regions with high mobility (i.e., large temperature or "B" factors) are more likely to accommodate SABM domain insertions than are highly ordered regions of the structure, or regions involved in ligand binding or catalysis. C. Linker Domains
The SABM domain is optionally linked to the TAs via a linker. The linker component of the conjugate molecule of the invention does not necessarily participate, but may contribute to the function of the conjugate molecule. Therefore, the linker domain is defined as any group of molecules that provides a spatial bridge between the TAs and the SABM domain. The linker domain can be of variable length and makeup, however, it is the length of the linker domain and not its structure that is important for creating the spatial bridge. The linker domain preferably allows for the SABM of the conjugate molecule to bind, substantially free of steric and/or conformational restrictions to the target molecule. Therefore, the length of the linker domain is dependent upon the character of the two "functional" domains of the conjugate molecule, Le., the SABM and the TAs . One skilled in the art will recogni7x that various combinations of atoms provide for variable length molecules based upon known distances between various bonds. See, for example, Morrison and Boyd, 1997, Organic Chemistry, 3rd Ed., Allyn and Bacon, Inc., Boston, MA. The linker domain may be a polypeptide of variable length. The amino acid composition of the polypeptide determines the character and length of the linker. In a preferred embodiment, the linker molecule comprises a flexible, hydrophilic polypeptide chain.
Exemplary linker domains comprise one or more GIy and/or Ser residues, such as those described in the Example sections below.
D. Recombinant Synthesis
The present invention encompasses a composition of matter comprising an isolated nucleic acid, preferably DNA, encoding a SABM or a conjugate molecule comprising a SABM and a polypeptide TAs as described herein. DNAs encoding the peptides of the invention can be prepared by a variety of methods known in the art. These methods include, but are not limited to, chemical synthesis by any of the methods described in Engels et al. 1989, Agnew. Chem. Int. Ed. Engl. 28:716-734 (the entire disclosure of which is incorporated herein by reference) such as the triester, phosphite, phosphoramidite, and H-phosphonate chemical synthesis methods. In one embodiment, codons preferred by the expression host cell are used in the design of the encoding DNA. Alternatively, DNA encoding the peptides can be altered to encode one or more variants by using recombinant DNA techniques, such as site specific mutagenesis (Kunkel et ai, 1991 , Methods EnzymoL, 204:125-139; Carter et al. 1986, Nucl. Acids Res. 13:4331; ZoWeτ etal. 1982, Nucl. Acids Res. 10:6487), cassette mutagenesis (Wells et al. 1985, Gene 34:315), restriction selection mutagenesis (Carter, 1991 , In: Directed Mutagenesis: A Practical Approach, MJ. McPherson, ed., IRL Press, Oxford), and the like.
According to preferred aspects described above, the nucleic acid encodes a SABM capable of binding a target molecule. Target molecules include, for example, extracellular molecules such as various serum factors, including but not limited to, plasma proteins such as serum albumin, immunoglobulins, apolipoproteins or transferrin, or proteins found on the surface of erythrocytes or lymphocytes, provided, of course, that binding of the SABM to the cell surface protein does not substantially interfere with the normal function of the cell. Preferred for use in the present invention are SABMs that bind serum albumin with a desired affinity, for example, with high affinity, or with an affinity that facilitates useful tissue uptake and diffusion of a bioactive molecule that is fused to the SABM. According to another preferred aspect of the invention, the nucleic acid encodes a conjugate molecule comprising a SABM sequence and an TAs . In this aspect of the invention, the TAs may comprise any polypeptide compound useful as a therapeutic or diagnostic agent, e.g., enzymes, hormones, cytokines, antibodies, or antibody fragments. The nucleic acid molecule according to this aspect of the present invention encodes a conjugate molecule and the nucleic acid encoding the SABM sequence is operably linked to (in the sense that the DNA sequences are contiguous and in reading frame) the nucleic acid encoding the biologically active agent. Optionally these DNA sequences may be linked through a nucleic acid sequence encoding a linker domain amino acid sequence.
According to this aspect, the invention further comprises an expression control sequence operably linked to the DNA molecule encoding a peptide of the invention, an expression vector, such as a plasmid, comprising the DNA molecule, where the control sequence is recognized by a host cell transformed with the vector, and a host cell transformed with the vector. In general, plasmid vectors contain replication and control sequences derived from species compatible with the host cell. The vector ordinarily carries a replication site, as well as sequences that encode proteins capable of providing phenotypic selection in transformed cells. For expression in prokaryotic hosts, suitable vectors include pBR322 (ATCC No. 37,017), phGH107
(ATCC No. 40,01 1), pBO475, pS0132, pRIT5, any vector in the pRIT20 or pRIT30 series (Nilsson and Abrahmsen 1990, Meth. Enzymol 185:144-161), pRIT2T, pKK233-2, pDR540, and pPL-lambda. Prokaryotic host cells containing the expression vectors of the present invention include E, coli Kl 2 strain 294 (ATCC NO. 31,446), E. coli strain JMlOl (Messing et al. 1981 , Nucl. Acid Res. 9:309), E. coli strain B, E. coli Strain _1776 (ATCC No. 31537), E. coli c60Q, E. co// W3110 (F-, gamma-, prototrophic, ATCC No. 27,325), E. coli strain 27C7 (W3110, tonA, phoA El 5, (argF-lac)169, ptr3, degP41, ompT, kanr) (U.S. Patent No. 5,288,931, ATCC No. 55,244), Bacillus subtilis, Salmonella typhimurium, Serratia marcesans, and Pseudomonas species.
In addition to prokaryotes, eukaryotic organisms, such as yeasts, or cells derived from multicellular organisms can be used as host cells. For expression in yeast host cells, such as common baker's yeast or
Saccharomyces cerevisiae, suitable vectors include episomally-replicating vectors based on the 2-micron plasmid, integration vectors, and yeast artificial chromosome (YAC) vectors. For expression in insect host cells, such as Sf9 cells, suitable vectors include baculoviral vectors. For expression in plant host cells, particularly dicotyledonous plant hosts, such as tobacco, suitable expression vectors include vectors derived from the Ti plasmid of Agrobacterium tumefaciens.
Examples of useful mammalian host cells include monkey kidney CVl line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al 1977, J. Gen Virol 36:59); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin 1980, Proc. Natl. Acad. Sci. USA, 77:4216); mouse Sertoli cells (TM4, Mather 1980, Biol. Reprod. 23:243-251); monkey kidney cells (CVl
ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (Wl 38, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al 1982, Annals N. Y. Acad. ScL 383:44-68); MRC 5 cells; FS4 cells; and a human hepatoma cell line (Hep G2). For expression in mammalian host cells, useful vectors include vectors derived from SV40, vectors derived from cytomegalovirus such as the pRK vectors, including pRK5 and pRK7 (Suva et al. 1987, Science 237:893-896; EP 307,247 (3/15/89), EP 278,776 (8/17/88)) vectors derived from vaccinia viruses or other pox viruses, and retroviral vectors such as vectors derived from Moloney's murine leukemia virus (MoMLV). Optionally, DNA encoding the peptide of interest is operably linked to a secretory leader sequence resulting in secretion of the expression product by the host cell into the culture medium. Examples of secretory leader sequences include STII, ecotin, lamB, herpes GD, lpp, alkaline phosphatase, invertase, and alpha factor. Also suitable for use herein is the 36 amino acid leader sequence of protein A (Abrahmsen et al 1985, EMBO J. 4:3901). Host cells are transfected and preferably transformed with the above-described expression or cloning vectors of this invention and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.
Prokaryotic host cells used to produce the present peptides can be cultured as described generally in Sambrook et aL, supra.
The mammalian host cells used to produce peptides of the invention can be cultured in a variety of media. Commercially available media such as Ham's FlO (Sigma), Minimal Essential Medium ((MEM), Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in the art (for example, Ham and Wallace, 1979, Meth. Em. 58:44; Barnes and Sato 1980, Anal. Biochem. 102:255, U.S. Patent Nos. 4,767,704;
4,657,866; 4,927,762; or 4,560,655; WO 90/03430; WO 87/00195; U.S. Pat. Re. 30,985; or U.S. 5,122,469, the disclosure of each is incorporated herein by reference) may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleosides (such as adenosine and thymidine), antibiotics (such as
Gentamycin™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
The host cells referred to in this disclosure encompass cells in in vitro culture as well as cells that are within a host animal.
E. Chemical Synthesis
Another method of producing the SABMs of the invention involves chemical synthesis. This can be accomplished by using methodologies well known in the art (see Kelley and Winkler, 1990, In: Genetic
Engineering Principles and Methods, Setlow, J.K, ed., Plenum Press, N.Y., Vol. 12, pp 1-19; Stewart, et al., 1984, J.M. Young, J.D., Solid Phase Peptide Synthesis, Pierce Chemical Co., Rockford, IL. See also U.S. Pat. Nos. 4,105,603; 3,972,859; 3,842,067; and 3,862,925).
SABMs of the invention can be prepared conveniently using solid-phase peptide synthesis. Merrifield, 1964, J. Am. Chem. Soc. 85:2149; Houghten, 1985, Proc. Natl. Acad. ScL USA 82:5132. Solid- phase peptide synthesis also can be used to prepare the conjugate molecule compositions of the invention if the TAs is or comprises a polypeptide.
Solid-phase synthesis begins at the carboxy terminus of the nascent peptide by coupling a protected amino acid to an inert solid support. The inert solid support can be any macromolecule capable of serving as an anchor for the C-terminus of the initial amino acid. Typically, the macromolecular support is a cross-linked polymeric resin (e.g., a polyamide or polystyrene resin) as shown in Figures 1-1 and 1-2, on pages 2 and 4 of Stewart and Young, supra. In one embodiment, the C-terminal amino acid is coupled to a polystyrene resin to form a benzyl ester. A macromolecular support is selected such that the peptide anchor link is stable under the conditions used to deprotect the alpha-amino group of the blocked amino acids in peptide synthesis. If a base- labile alpha-protecting group is used, then it is desirable to use an acid-labile link between the peptide and the solid support. For example, an acid-labile ether resin is effective for base-labile Fmoc-amino acid peptide synthesis as described on page 16 of Stewart and Young, supra. Alternatively, a peptide anchor link and α- protecting group that are differentially labile to acidolysis can be used. For example, an aminomethyl resin such as the phenylacetamidomethyl (Pam) resin works well in conjunction with Boc-amino acid peptide synthesis as described on pages 1 1 - 12 of Stewart and Young, supra.
After the initial amino acid is coupled to an inert solid support, the alpha-amino protecting group of the initial amino acid is removed with, for example, trifluoroacetic acid (TFA) in methylene chloride and neutralized in, for example, triethylamine (TEA). Following deprotection of the initial amino acid's alpha- amino group, the next alpha-amino and side chain protected amino acid in the synthesis is added. The remaining alpha-amino and, if necessary, side chain protected amino acids are then coupled sequentially in the desired order by condensation to obtain an intermediate compound connected to the solid support. Alternatively, some amino acids may be coupled to one another to form a fragment of the desired peptide followed by addition of the peptide fragment to the growing solid phase peptide chain. The condensation reaction between two amino acids, or an amino acid and a peptide, or a peptide and a peptide can be carried out according to the usual condensation methods such as the axide method, mixed acid anhydride method, DCC (NjN'-dicyclohexylcarbodiimide) or DIC (N,N'-diisopropylcarbodiimide) methods, active ester method, p-nitrophenyl ester method, BOP (benzotriazole-1-yl-oxy-tris [dimethylamino] phosphonium hexafluorophosphate) method, N-hydroxysuccinic acid imido ester method, etc., and Woodward reagent K method.
It is common in the chemical synthesis of peptides to protect any reactive side chain groups of the amino acids with suitable protecting groups. Ultimately, these protecting groups are removed after the desired polypeptide chain has been sequentially assembled. Also common is the protection of the alpha-amino group on an amino acid or peptide fragment while the C-terminal carboxy group of the amino acid or peptide fragment reacts with the free N-terminal amino group of the growing solid phase polypeptide chain, followed by the selective removal of the alpha-amino group to permit the addition of the next amino acid or peptide fragment to the solid phase polypeptide chain. Accordingly, it is common in polypeptide synthesis that an intermediate compound is produced that contains each of the amino acid residues located in the desired sequence in the peptide chain wherein individual residues still carry side-chain protecting groups. These protecting groups can be removed substantially at the same time to produce the desired polypeptide product following removal from the solid phase.
Alpha- and epsilon-amino side chains can be protected with benzyloxycarbonyl (abbreviated Z), isonicotinyloxycarbonyl (iNOC), o-chlorobenzyloxycarbonyl [Z(2C1)], p-nitrobenzyloxycarbonyl [Z(NO2)], p- methoxybenzyloxycarbonyl [Z(OMe)], t-butoxycarbonyl (Boc), t-amyloxycarbonyl (Aoc), isobornyloxycarbonyl, adamantyloxycarbonyl, 2-(4-biphenyl)-2-propyloxycarbonyl (Bpoc), 9- fluorenylmethoxycarbonyl (Fmoc), methylsulfonyethoxycarbonyl (Msc), trifluoroacetyl, phthalyl, formyl, 2- nitrophenylsulphenyl (NPS), diphenylphosphinothioyl (Ppt), and dimethylphosphinothioyl (Mpt) groups, and the like. Protective groups for the carboxy functional group are exemplified by benzyl ester (OBzI), cyclohexyl ester (Chx), 4-nitrobenzyl ester (ONb), t-butyl ester (Obut), 4-pyridylmethyl ester (OPic), and the like. It is often desirable that specific amino acids such as arginine, cysteine, and serine possessing a functional group other than amino and carboxyl groups are protected by a suitable protective group. For example, the guanidino group of arginine may be protected with nitro, p-toluenesulfonyl, benzyloxycarbonyl, adamantyloxycarbonyl, p-methoxybenzesulfonyl, 4-methoxy-2,6-dimethylbenzenesulfonyl (Nds), 1 ,3,5-trimethylphenysulfonyl (Mts), and the like. The thiol group of cysteine can be protected with p-methoxybenzyl, trityl, and the like.
Many of the blocked amino acids described above can be obtained from commercial sources such as Novabiochem (San Diego, CA), Bachem CA (Torrence, CA) or Peninsula Labs (Belmont, CA). Stewart and Young, supra, provides detailed information regarding procedures for preparing peptides.
Protection of alpha-amino groups is described on pages 14-18, and side chain blockage is described on pages 18-28. A table of protecting groups for amine, hydroxyl, and sulfhydryl functions is provided on pages 149- 151.
After the desired amino acid sequence has been completed, the peptide can be cleaved away from the solid support, recovered, and purified. The peptide is removed from the solid support by a reagent capable of disrupting the peptide-solid phase link, and optionally deprotects blocked side chain functional groups on the peptide. In one embodiment, the peptide is cleaved away from the solid phase by acidolysis with liquid hydrofluoric acid (HF), which also removes any remaining side chain protective groups. Preferably, in order to avoid alkylation of residues in the peptide (for example, alkylation of methionine, cysteine, and tyrosine residues), the acidolysis reaction mixture contains thio-cresol and cresol scavengers. Following HF cleavage, the resin is washed with ether, and the free peptide is extracted from the solid phase with sequential washes of acetic acid solutions. The combined washes are lyophilized, and the peptide is purified.
F. Chemical Conjugation of Conjugate Molecules
In certain embodiments, the conjugate molecules may comprise TAs that are organic compounds having diagnostic or therapeutic utility, or alternatively, fusions between a SABM and a polypeptide TAs in configurations that cannot be encoded in a single nucleic acid. Examples of the latter embodiment include fusions between the amino terminus of a SABM and the amino terminus of the TAs , or fusions between the carboxy-terminus of a SABM and the carboxy-terminus of the TAs .
Chemical conjugation may be employed to prepare these embodiments of the conjugate molecule, using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate
(SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)- ethylenediamine), diisocyanates (such as toluene, 2,6-diisocyanate), and bis-active fluorine compounds (such as l,5-difluoro-2,4-dinitrobenzene). Methods useful for conjugating cytotoxic agentss to polypeptides such as antibodies are known.
G. Disulfide-Linked Peptides
As described above, some embodiments of the invention include cyclized SABMs. SABMs may be cyclized by formation of a disulfide bond between cysteine residues. Such peptides can be made by chemical synthesis as described above and then cyclized by any convenient method used in the formation of disulfide linkages. For example, peptides can be recovered from solid phase synthesis with sulfhydryls in reduced form, dissolved in a dilute solution wherein the intramolecular cysteine concentration exceeds the intermolecular cysteine concentration in order to optimize intramolecular disulfide bond formation, such as a peptide concentration of 25 mM to 1 uM, and preferably 500 uM to 1 uM, and more preferably 25 uM to 1 uM, and then oxidized by exposing the free sulfhydryl groups to a mild oxidizing agent that is sufficient to generate intramolecular disulfide bonds, e.g., molecular oxygen with or without catalysts such as metal cations, potassium ferricyanide, sodium tetrathionate, and the like. Alternatively, the peptides can be cyclized as described in Pelton et al, 1986, J. Med. Chem. 29:2370-2375. Cyclization can be achieved by the formation, for example, of a disulfide bond or a lactam bond between a first and a second residue capable of forming a disulfide bond, for example, Cys, Pen, Mpr, and Mpp and its 2-amino group-containing equivalents. Residues capable of forming a lactam bridge include, for example, Asp, GIu, Lys, Om, αβ-diaminobutyric acid, diaminoacetic acid, aminobenzoic acid, and mercaptobenzoic acid. The compounds herein can be cyclized for example via a lactam bond that can utilize the side chain group of a non-adjacent residue to form a covalent attachment to the N-terminus amino group of
Cys or other amino acid. Alternative bridge structures also can be used to cyclize the compounds of the invention, including for example, peptides and peptidomimetics, that can cyclize via S-S, CH2-S, CH2-O-CH2, lactam ester or other linkages.
H. Pharmaceutical Compositions Pharmaceutical compositions which comprising the conjugate molecules of the invention may be administered in any suitable manner, including parental, topical, oral, or local (such as aerosol or transdermal), or any combination thereof.
Other suitable compositions of the present invention comprise any of the conjugate molecules noted above with a pharmaceutically acceptable carrier. The nature of the carrier differs with the mode of administration. For example, for oral administration, a solid carrier is preferred; for i.v. administration, a liquid salt solution carrier is generally used.
The compositions of the present invention include pharmaceutically acceptable components that are compatible with the subject and the protein of the invention. These generally include suspensions, solutions, and elixirs, and most especially biological buffers, such as phosphate buffered saline, saline, Dulbecco's Media, and the like. Aerosols may also be used, or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like (in the case of oral solid preparations, such as powders, capsules, and tablets).
As used herein, the term "pharmaceutically acceptable" generally means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
The formulation of choice can be accomplished using a variety of the aforementioned buffers, or even excipients including, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin cellulose, magnesium carbonate, and the like. "PEGylation" of the compositions may be achieved using techniques known to the art (see for example International Patent Publication No WO92/16555, U S Patent No 5,122,614 to Enzon, and International Patent Publication No WO92/00748)
A preferred route of administration of the present invention is in the aerosol 01 inhaled form The compounds of the present invention, combined with a dispersing agent or dispersant, can be administered in an aerosol formulation as a dry powder or in a solution or suspension with a diluent
As used herein, the term "dispersant" refers to an agent that assists aerosohzation of the compound or absorption of the protein in lung tissue, or both Preferably the dispersant is pharmaceutically acceptable Suitable dispersing agents are well known in the art, and include but are not limited to surfactants and the like For example, surfactants that are generally used in the art to reduce surface induced aggregation of a compound, especially a peptide compound, caused by atomization of the solution forming the liquid aerosol, may be used Nonlimiting examples of such surfactants are surfactants such as polyoxyethylene fatty acid esters and alcohols, and polyoxyethylene sorbitan fatty acid esters Amounts of surfactants used will vary, being generally within the range of from about 0 001% to about 4% by weight of the formulation In a specific aspect, the surfactant is polyoxyethylene sorbitan monooleate or sorbitan trioleate Suitable surfactants are well known in the art, and can be selected on the basis of desired properties, depending on the specific formulation, concentration of the compound, diluent (in a liquid formulation) or form of powder (in a dry powder formulation), and the like
Moreover, depending on the choice of the conjugate molecule, the desired therapeutic effect, the quality of the lung tissue (e g , diseased or healthy lungs), and numerous other factors, the liquid or dry formulations can comprise additional components, as discussed further below
The liquid aerosol formulations generally contain the conjugate molecules and a dispersing agent in a physiologically acceptable diluent The dry powder aerosol formulations of the present invention consist of a finely divided solid form of the conjugate molecule and a dispersing agent With either the liquid or dry powder aerosol formulation, the formulation must be aerosolized That is, it must be broken down into liquid or solid particles in order to ensure that the aerosolized dose actually reaches the alveoli In general the mass median dynamic diameter will be 5 micrometers or less in order to ensure that the drug particles reach the lung alveoli (Wearley, 1991, Cut Rev in Ther Drug Came) Systems 8 333) The term "aerosol particle" is used herein to describe the liquid or solid particle suitable for pulmonary administration, i e , that will reach the alveoli Other considerations such as construction of the delivery device, additional components in the formulation and particle characteristics are important These aspects of pulmonary administration of a drug are well known in the art, and manipulation of formulations, aerosohzation means and construction of a delivery device require at most routine experimentation by one of ordinary skill in the art
With regard to construction of the delivery device, any form of aerosohzation known in the art, including but not limited to nebuhzation, atomization or pump aerosohzation of a liquid formulation, and aerosohzation of a dry powder formulation, can be used m the practice of the invention A delivery device that is uniquely designed for administration of solid formulations is envisioned Often, the aerosohzation of a liquid or a dry powder formulation will require a propellant The propellant may be any propellant generally used in the art Specific nonlimiting examples of such useful propellants are a chloroflourocarbon, a hydrofluorocarbon, a hydochlorofluorocarbon, or a hydrocarbon, including triflouromethane, dichlorodiflouromethane, dichlorotetrafuoroethanol, and 1 ,1,1 ,2-tetraflouroethane, or combinations thereof.
In a preferred aspect of the invention, the device for aerosolization is a metered dose inhaler. A metered dose inhaler provides a specific dosage when administered, rather than a variable dose depending on administration. Such a metered dose inhaler can be used with either a liquid or a dry powder aerosol formulation. Metered dose inhalers are well known in the art.
Once the conjugate molecule reaches the lung, a number of formulation-dependent factors affect the drug absorption. It will be appreciated that in treating a disease or disorder that requires circulatory levels of the compound, such factors as aerosol particle size, aerosol particle shape, the presence or absence of infection, lung disease or emboli may affect the absorption of the compounds. For each of the formulations described herein, certain lubricators, absorption enhancers, protein stabilizers or suspending agents may be appropriate. The choice of these additional agents will vary depending on the goal. It will be appreciated that in instances where local delivery of the compounds is desired or sought, such variables as absorption enhancement will be less critical. I. Liquid Aerosol Formulations
The liquid aerosol formulations of the present invention will typically be used with a nebulizer. The nebulizer can be either compressed air driven or ultrasonic. Any nebulizer known in the art can be used in conjunction with the present invention such as but not limited to: Ultravent, Mallinckrodt, Inc. (St. Louis, MO); the Acorn II nebulizer (Marquest Medical Products, Englewood CO). Other nebulizers useful in conjunction with the present invention are described in U.S. Patent Nos. 4,624,251 issued November 25, 1986;
3,703,173 issued November 21, 1972; 3,561,444 issued February 9, 1971 and 4,635,627 issued January 13, 1971.
The formulation may include a carrier. The carrier is a macromolecule which is soluble in the circulatory system and which is physiologically acceptable where physiological acceptance means that those of skill in the art would accept injection of said carrier into a patient as part of a therapeutic regime. The carrier preferably is relatively stable in the circulatory system with an acceptable elimination half-time. Such macromolecules include but are not limited to soya lecithin, oleic acid, and sorbetan trioleate, with sorbitan trioleate preferred.
The formulations of the present embodiment may also include other agents useful for protein stabilization or for the regulation of osmotic pressure. Examples of the agents include but are not limited to salts, such as sodium chloride, or potassium chloride, and carbohydrates, such as glucose, galactose, or mannose, and the like.
J. Aerosol Dry Powder Formulations
It is also contemplated that the present pharmaceutical formulation will be used as a dry powder inhaler formulation comprising a finely divided powder form of the SABM and a dispersant. The form of the compound will generally be a lyophilized powder. Lyophilized forms of conjugate molecule can be obtained through standard techniques.
In another embodiment, the dry powder formulation will comprise a finely divided dry powder containing one or more compounds of the present invention, a dispersing agent and also a bulking agent. Bulking agents useful in conjunction with the present formulation include such agents as lactose, sorbitol, sucrose, or mannitol, in amounts that facilitate the dispersal of the powder from the device.
All publications (including patents and patent applications) cited herein are hereby incorporated in their entirety by reference. Throughout this specification and claims, the word "comprise," or variations such as "comprises" or
"comprising," will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.
The following examples are offered by way of illustration and not by way of limitation. The disclosures of all citations in the specification are expressly incorporated herein by reference.
EXAMPLES
Example 1 - Materials For these studies, a Fab of a humanized antibody that binds to the extracellular domain of pi 85HER2 (HER2) was recombinantly engineered to include an albumin binding peptide (AB). The sequence of the variable region of the antibody used in this study, humAb4D5-8, can be found in Carter et al., (1992) PNAS 89:4285-4289. Previously,the humanized Fab had been derived from the murine monoclonal antibody muMAb4D5 (herein 4D5), which monoclonal antibody was produced by a hybridoma deposited with the American Type Culture Collection in Manassas, Virginia, and has ATCC accession number CRL 10463. Methods of making humanized anti-Her-2 antibodies and the identity of example variable domain sequences are provided in, e.g., U.S. Pat. Nos. 5,821,337 and 6,054,297 and in Carter et al., (1992) PNAS 89:4285-4289.
The nucleic acid sequence encoding the albumin binding peptide ("AB"),
QRLMEDICLPRWGCLWEDDF (SEQ ID NO: 1), was joined via a nucleic acid sequence encoding a linker sequence, GGGS (SEQ ID NO:422), to a nucleic acid sequence encoding the Fab. The nucleic acid sequence encoding the linker was joined to the heavy chain C-terminal KTHT residues of the Fab. As a control, an anti- tissue factor Fab containing the variable region of the D3H44 antibody fused to an AB through its light chain was constructed by recombinant DNA engineering. See Presta, L., et al., (2001) Thromb. Haemost. 85:379- 389 for D3H44 amino acid sequence.
The resulting construct was expressed and secreted from E. coli as a fusion protein ("AB.Fab4D5-H" or "rhuABFabATFL"), then isolated and purified. Next, the fusion proteins were conjugated to monomethylauristatin (MMAE). For the tumor efficacy study, the fusion proteins were attached to MMAE via a valine-citrulline (val-cit or vc) dipeptide Linker reagent having a maleimide moiety and a para- aminobenzylcarbamoyl (PAB) spacer. See Klussman, K et al., (2004) Bioconjugate Chem. 15:765-773 for an example of methods for attaching MMAE to antibodies. For the toxicity study, the fusion proteins were attached to MMAE via, for example, conjugation with an MMAE modified with an activated derivative of maleimidocaproyl through their lysines using succinimidyl acetylthioacetate (Sata) to generate free thiols followed by conjugation to valine-citrulline-MMAE ("vc-MMAE"). The ratio of MMAE on the resulting AB.Fab4D5-H was generally an average around 1:1 with ratios as high as 4:1 and as low as 0:1 such that between 0-4 MMAE moieties were randomly distributed on exposed lysines, the overall average being about 1 MMAE per AB.Fab4D5-H.
Example 2 - Efficacy Studies with MMAE Conjugates AB.Fab-4D5-H-MMAE conjugates were tested against established MMTV-HER2 transgenic mammary tumors (Fo5). This tumor line is non-responsive to Herceptin® but responds well to a Herceptin®-
MC-vc-PAB-MMAE conjugate.
2 A single intravenous dose of 1650 μg MMAE /m rhuAB.Fab-4D5-H-vc-MMAE (i.e., with AB), rhuFab4D5vcMMAE (i.e., without AB), or rhuABFabATFL-vc-MMAE (negative control) was given to mMMTV-HER2 Fo5 tumor bearing mice. Each treated mouse had a mean tumor volume between 100 and
200 mm3. The MMAE-conjugated molecules or a phosphate buffer saline ("vehicle") were administered on day 0 of the study and tumor measurements were performed twice weekly for 17 days. A known efficacious MMAE conjugate, Herceptin®-MC-vc-PAB-MMAE was run for comparison at a dose of 1245 μg/m2 MMAE. Log Cell Kill analyses based on tumor doubling times were conducted. The Log Cell Kill analysis uses a mathematical computation of tumor growth delay based on the time it takes for tumors to double in size after treatment begins compared to controls. The mathematical equation is:
Tumor Doubling Time - Mean Doubling Time for Control
3.32 X Mean Doubling Time for Control
Figure 1 shows no significant difference between rhuAB.Fab4D5-H-vc-MMAE and the Herceptin®- MC-vc-PAB-MMAE group (p=0.0001 ) whereas the negative MMAE control Fab, rhuABFabATFL-vc-
MMAE, was not significantly different from Vehicle control (p=0.6) by Fisher's PSLD.
Example 3 - Toxicity of IgG-MMAE, Ffab'VMMAE conjugates and free MMAE Female Spraque-Dawley (SD) rats weighing between 75-80 grams (Charles River Laboratories, Hollister, CA) were used in the following studies to compare the toxicity of free MMAE, Fab-MMAE and
F(ab')2-MMAE conjugates. Dosin Grou s:
Figure imgf000033_0001
Dosing Groups:
For the Herceptin®- val-cit-MMAE, the μg MMAE/m2 was calculated using 718 as the MW of MMAE and
145167 as the MW of Herceptin®. For the Herceptin® F(ab')2- val-cit-MMAE, the μg MMAE/m2 was calculated using 718 as the MW of MMAE and 100000 as the MW of Herceptin® F(ab')2. The body surface area was calculated as follows: [{ (body weight in grams to 0.667 power) x 1 ] .8 J/10000]. (Guidance for Industry and Reviewers. Estimating the Safety Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. U. S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologies Evaluation and research (CBER), December
2002).
The dose solutions were administered by a single intravenous bolus tail-vein injection on Study Day 1 at a dose volume of 10 mL/kg (diluted in PBS). General clinical observations were performed daily. Morbidity and mortality checks were performed twice daily (AM and PM). The body weights of the animals were measured pre-dose on Study Day 1 and daily thereafter. Whole blood was collected into EDTA containing tubes for hematology parameters (e.g., mean serum AST levels, ALT levels, GGT levels and billirubin levels) and differential cell counts (e.g., mean white blood cell counts and platlet counts). Whole blood was collected into serum separator tubes for clinical chemistry parameters. Blood samples were collected pre-dose on Study Day -4, on Study Day 3 and on Day 5 at necropsy. Whole blood was also collected into lithium heparin containing tubes at necropsy and the plasma was frozen at — 70oC for later analysis. The following tissues were collected at necropsy: liver, kidneys, heart, thymus, spleen, brain, sternum and sections of the GI tract, including stomach, large and small intestine. At necropsy, only spleen and thymus were weighed. All statistical analyses were done on Day 5 body weights using a One Way ANOVA, Tukey's test, (SigmaStat 2.03 Software). On Study Day 3 animals on dose groups 4 and 5 (27.14 mg/kg Herceptin® F(ab')2-val-cit-MMAE and 516 ug/kg free MMAE, respectively) were moribund. All group 4 and 5 animals were severely lethargic and most had a yellow discharge in the urogenital area. The animals in these dose groups were necropsied on Day 3. On study day 5 animals in dose group 3 (10.83 mg/kg Herceptin® F(ab')2-val-cit-MMAE) also had yellow discharges in the urogenital area. A complete set (baseline, days 3 & 5) of clinical chemistry and hematology data is only available for groups 1-3; day 5 data are not available for groups 4 & 5 as these animals were necropsied on day 3 due to significant morbidity or weight loss. This should also be considered in the interpretation of the histologic changes of these animals when comparing findings with those observed in animals terminated on day 5. On day 3 animals of group 4 (high dose of the Herceptin® F(ab')2 )and group 5 (free MMAE) showed the highest elevations in liver associated serum enzymes ALT, AST and GGT and the lowest platelet and white blood cell counts. The elevations in AST and ALT were similar in the two groups, however, group
4 showed significantly higher elevations in GGT and total bilirubin than group 5. Elevations in GGT and total bilirubin may indicate problems with the excretory liver function or the biliary system. The histologic evaluation did not show a morphologic correlate for this observation and it is unclear, whether differences in the PK characteristics of free MMAE vs immunoconjugate can account for this finding. The low dose
Herceptin® F(ab')2 -vc-MMAE group 3 showed transient elevations of liver function tests on day 3, which returned to baseline levels by day 5. However, platelet and white blood cell counts remained decreased on day
5 without sign of recovery. Animals treated with the full length immunoconjugate Herceptin®- vc-MMAE (dose of MMAE matches groups 4 & 5) showed the typical toxicology profile of increased liver function tests and leuko- and thrombocytopenia. With the exception of bilirubin, all parameters showed progression over the five-day period; however, on day 3 changes were less severe in group 2 than in groups 4 and 5. Morphologically, the pattern of toxicity observed in groups 2-5 was identical and matched that seen in previous studies. Although only a limited number of organs was evaluated, clinical pathology data does not suggest significant organ-specific damage at other sites. The morphologic changes were least severe in group 3 (low dose Herceptin® F(ab')2) and most severe in groups 4 and 5 (high dose Herceptin® F(ab')2 and free MMAE). The changes included bone marrow hypocellularity, thymic atrophy with marked apoptotic activity, increased numbers of mitotic and apoptotic cells in intestinal mucosa with variable extent of mucosal degeneration and atrophy and increased numbers of mitotic and apoptotic cells among hepatocytes and biliary epithelium. Animals of groups 2, 4 and 5 also showed evidence of hepatocyte dropout and occasional areas of hepatic necrosis.
Animals in dose groups 4 and 5 (27.14 mg/kg Herceptin® F(ab')2-val-cit-MMAE and 516 ug/kg free MMAE, respectively) lost 14.5 and 12 grams body weight, respectively, by Day 3 compared with Day 1 weights. The decrease in body weight in Group 2 animals administered a comparable amount of MMAE (2105 ug MMAE/m2) was not as severe as in group 4 and 5 animals. As shown in Figure 2, the regimen of free MMAE resulted in a similar weight loss profile as the Fa(b')2 regimen (without a serum albumn binding protein). Weight loss is an indicator of toxicity.
In sum, Herceptin® F(ab')2-val-cit-MMAE (lysine) caused acute toxicity in a dose-dependent fashion.. Animals in the high dose Herceptin® F(ab')2-val-cit-MMAE showed a significantly greater weight loss compared with animals receiving the same amount of drug as Herceptin®- val-cit-MMAE. Animals administered free MMAE at a comparable dose (2150 ug/m2) to the high dose of Herceptin® F(ab')2- val-cit- MMAE had comparable weight loss and changes in liver associated serum enzyme levels and white blood cell and platelet counts. The findings are consistent with the administration of agents that inhibit tubulin formation (Wood KW, Cornwell WD, and Jackson JR. Past and future of the mitotic spindle as an oncology target.
Current Opinion in Pharmacology, 1:370-377. 2001).
Example 4 - Toxicity Studies with MMAE-Fab conjugates
The toxicity of Herceptin®-monomethylauristatin (MMAE) immunoconjugates, Fab4D5-MMAE and AB.Fab4D5-H-MMAE immunoconjugates were compared in female Sprague-Dawley rats (80-100 grams).
Female rats were administered equivalent doses (2105ug MMAE/m2) via tail-vein injections at a dose volume of 10 ml/kg (diluted in PBS). All dose solutions were administered as a single bolus injection.
Dosing groups: 1 = PBS, 6 females 2 = 20.2 mg/kg Herceptin®-val-cit-MMAE, 6 females
3 = 5.7 mg/kg Fab4D5-vc-MMAE
4 = 14.24 mg/kg Fab4D5-vc-MMAE, 6 females
5 = 7.85 mg/kg AB.Fab4D5-H-vc-MMAE
6 = 19.62 mg/kg AB.Fab4D5-H-vc-MMAE, 6 females In a previous study, the 2105 ug MMAE/rrf dose of Herceptin@-val-cit-MMAE resulted in changes in liver associated serum enzyme levels and hematology parameters that were moderately severe. Doses of 5.7 mg/kg rhuFab4D5-val-cit-MMAE and 7.85 mg/kg rhuFab4D5-H-val-cit-MMAE were also administered in the present study to give an MMAE exposure of approximately 840ug MMAE/m . In these assays, blood samples (approximately 500 ul) were generally collected via the retro-orbital sinus under isofluorane anesthesia on Study Days -3 (pre-dose) and Day 3 for clinical chemistry and hematology. Blood was also collected on Day 5 at necropsy via the inferior vena cava under ketamine anesthesia. Clinical observations and body weight recordings were performed once daily and cageside mortality checks were conducted twice daily (am/pm). Animals which were moribund were euthanized. During necropsy on Study Day 5, the blood of the rats were collected via the abdominal aorta for clinical chemistry and hematology. The following tissues were collected: heart, lung, trachea, liver, kidney, thymus, spleen, brain, axillary lymph nodes, entire gastrointestinal tract, skin, urinary bladder, and bone marrow. Additionally, organ weights will be recorded for liver, thymus, spleen, and brain. At necropsy, the liver, spleen and thymus were weighed. The tests included the test for group mean change in animal body weight, white blood cell count, platelet counts, AST levels, ALT levels, GGT levels, and serum Billirubin levels.
On Study Day 4 animals in dose groups 3 and 4 (5.7 and 14.25 mg/kg rhuFab4D5-val-cit-MMAE) had moderate pilo-erection and many of the animals were lethargic. Two animals in the 14.25 mg/kg rhuFab4D5-val-cit-MMAE dose group were moribund on day 4 and were necropsied. The auristatin E conjugated full length antibody (Herceptin®-MC-val-cit-P AB-MMAE, group 2) showed the same toxicity profile as seen in previous studies: Liver function tests were elevated on days 3 and 5 and showed, with the exception of GGT, evidence of recovery by day 5. The same animals showed progressive neutro- and thrombocytopenia during the 5-day study. Animals treated with the two types of antibody fragments (rhuFab4D5 and rhuFab 4D5-H ) showed dose-dependent toxicity. The liver associated serum enzyme levels on days 3 and 5 are essentially identical to vehicle-treated animals for groups 3 and 5
(low doses of rhuFab 4D5 and rhuFab 4D5-H, respectively). There was a very mild elevation of AST and ALT in animals of group 5 (rhuFab4D5-H-val-cit-MMAE), however, whether this change is statistically significant and whether it actually represents hepatotoxicity is unclear. Animals in group 3 (low dose rhuFab4D5-val-cit-MMAE ), showed a very mild thrombocytopenia and a 50% decrease of leukocytes on day 5, whereas animals in group 5 showed normal leukocyte counts on day 5 (after a mild transitory decline on day
3) and a mild thrombocytosis on day 5. Animals in groups 4 and 6 (high doses of rhuFab 4D5 and rhuFab 4D5-H, respectively) showed clear signs of toxicity on days 3 and 5. Toxicity appeared more severe in group 4, two animals were euthanized on day 4 based on signs of morbidity. Levels of AST, ALT and GGT are higher in animals of group 4 than group 2 or 6 (comparable drug doses of Herceptin®-val-cit-MMAE and rhuFab4D5-H-val-cit-MMAE), at both time points. The levels are slightly lower in animals of group 6 than group 2. Animals in group 4 and 6 showed profound thrombo- and leukocytopenia on day 5. The levels are lower than those seen in animals of group 2 and animals in group 6 seem to do slightly better than animals in group 4. The results of the histopathological evaluation correlate very well with the clinical observations (body weight measurements) and the clinical pathology data. Animals in groups 2, 3, 4 and 6 show a markedly hypocellular bone marrow; signs of regeneration are only present in animals of group 3. In contrast, animals in group 5 show bone marrows of near normal cellularity. Similar findings are observed in the thymus: Animals of groups 2, 4 and 6 show marked atrophy and apoptotic activity, whereas animals of groups 3 and 5 show mild atrophy without significant apoptotic activity. The changes in liver, small and large intestine are more difficult to quantify, however, the number of mitotic and/or apoptotic cells in these organs appears greater in animals of groups 2, 4 and 6 than those in groups 3 and 5. Small areas of necrosis are only observed in two animals of group 4. Interestingly, only animals in group 5 (in addition to vehicle-treated animals) retain small foci of extramedullary hematopoiesis in the liver suggesting lower levels of free drug in these animals. Clinical pathology or histopathology data do not show any evidence of a different pattern of toxicity in animals treated with Fab immunoconjugates compared with animals treated with full length antibody conjugate.
Animals treated with the two types of antibody fragments showed dose-dependent toxicity. Animals administered high doses of rhuFab 4D5-val-cit-MMAE and rhuFab 4D5-H-val-cit-MMAE (containing albumin binding peptide) showed clear signs of toxicity on days 3 and 5. Toxicity appeared more severe in the rhuFab
4D5 group, two animals were euthanized on day 4 because they were moribund. The results of the histopathological evaluation correlate very well with the clinical observations (body weight measurements) and the clinical pathology data. Clinical pathology or histopathology data did not show any evidence of a different pattern of toxicity in animals treated with Fab immunoconjugates compared with animals treated with full length antibody conjugate. The findings are consistent with the administration of agents that inhibit tubulin formation (Wood et al, 2001).
Figure 3 indicates that the albumin binding peptide can alter the toxicity of a drug conjugate. Ab.Fab4D5-H-vc-MMAE (containing the albumin binding peptide) was significantly less toxic in rats than Fab4D5-vc-MMAE at Study Day 5. The group average change in body weight in animals administered 5.7 mg/kg rhuFab4D5-val-cit-MMAE and 7.85 mg/kg rhuFab4D5-H-val-cit-MMAE (Groups 3 and 5) were not significantly different from each other. Dose groups 2, 4, and 6 (20.2 mg/kg Herceptin®-val-cit-MMAE, 14.24 mg/kg rhuFab4D5-val-cit-MMAE, and 19.62 mg/kg rhuFab4D5-H-val-cit-MMAE, respectively) all received 2105 ug/M2 MMAE. The group average decrease in body weight in Group 2 and 4 animals was more severe than group 6 animals.
Example 5 - Affinity measurements by Surface Plasmon Resonance
Binding affinities between SA peptides and album were obtained using a BIAcore 3000 (BIAcore, Inc., Piscataway, NJ). Albumin was captured in a CM5 chip using amine coupling at approximately 5000 resonance units (RU). SA peptides (0, 0.625, 1.25, 2.5, 5, and lOμM were injected at a flow rate of 20 μl/minute for 30 seconds. The bound peptides were allowed to disassociate for 5 minutes before matrix regeneration using 1OmM glycine, pH 3.
The signal from an injection passing over an uncoupled cell was subtracted from that of an immobilized cell to generate sensongrams corresponding to the amount of peptide bound as a function of time. The running buffer, PBS containing 0.05% TWEEN-20T, was used for all sample dilutions. BIAcore kinetic evaluation software (v 3.1 ) was used to determine the dissociation constant (Kj) from the association and dissociation rates, using a one to one binding model.
The affinity of selected peptides for binding human (HAS), rabbit (BuSA), rat (RSA), and mouse
(MSA) albumin was assessed by the BIAcore assay as well as SA08 peptide competition assay. The data, shown below in Table 8, demonstrate that the IC50 values obtained in the competition assay compared favorably with the Ka values obtained in the BIAcore assay. Peptide SAl 5, representing the consensus peptide for binding rabbit albumin, had the lowest IC50 value in the competition assay and the highest affinity by surface plasmon resonance for rabbit albumin. A linear peptide, identical to SA06, but having both Cys residues altered to Ala, had an IC50 that was greater than 50 μM, demonstrating the importance of the disulfide.
Example 6 - Determination of relative Kd
Introduction:
In assessing the binding capacity between proteins, ELISA has been the method of choice. The ease of developing a highly specific and quantitative assay has resulted in ELISA wide application. However, in the format where protein is immobilized directly on the solid surface, the potential artifact due to denaturing or obscuring binding epitope can occur.
To determine the affinity of albumin binding peptide conjugated to Fab molecules (Fab-H) to
Albumin, we developed two types of ELISA. The first format involved the adsorption of albumin to the well surface and the bound Fab is detected with goat-anti-huFab-HRP. The second format involves the binding of Fab-H with albumin in solution and determines the dissociation constant (Kd). The basic principle of the second assay is to allow the binding, of a constant concentration of Fab-H to varying amount of albumin, to reach equilibrium in solution, and determine the un-bound Fab-H in ELISA well coated with albumin. The Kd value can be determined by analyzing the data using Scatchard Analysis (Munson et al, 1980, Anal. Biochem.,
107: 220) Materials & Methods:
Material:
Mouse Albumin -Lyophilized form, Cat. No. A3139
Rat Albumin - Lyophilized form, Cat. No. A6414
Rabbit Albumin- Lyophilized form, Cat. No. A0639 lmg/ml Albumin solution was prepared by dissolving 10 mg in 10ml of PBS. The solution is stored at 4°C.
Assay Buffer: PBS + 0.5%Chicken Egg Albumin (Sigma #A5503)+).5% Tween 20, PH 7.4)
Direct Binding ELISA Assay
Mouse, Rat, or Rabbit albumin (Sigma) was immobilized onto NUNC Maxisorp 96-well plates at 2μg/ml overnight at 40C. After removal of the coating solution, the plates were blocked with binding buffer
(PBS, 0.5% ovalbumin and 0.05% Tween 20) for 1 hour at 25°C. Serially diluted Fab-Hx in binding buffer, were added at 100 ul per well and allowed to bind to coated albumin for 30 minutes at 250C. The unbound
Fab-Hx was removed by washing the well with 0.05% PBS/Tween20 and the bound Fab-Hx molecules were detected by I hour incubation with Goat anti-human Fab'2-HRP for at 25°C. Bound HRP was then measured with a solution of tetramethylbenzidine (TMB VH2OT . After 15 minutes incubation, the reaction was quenched by the addition of 1 M phosphoric acid. The absorbance at 450 nm was read with a reference wavelength of 650 nm. Kd (Solution Binding with Preincubation) ELISA Assay
A fixed concentration of Fab-H (determined in above binding ELISA) was first incubated in solution with varying concentrations of albumin in Assay Buffer. After >2 hours of incubation at room temperature, 100 μl of the mixture was transferred to Albumin coated ELISA plates. The concentration of free Fab-Hx was then determined by the direct binding ELISA as described above.
The fixed concentration of Fab-H and the starting concentration of albumin are listed in the following table. Albumin were 1 :3 serially diluted for 8 points.
Figure imgf000039_0001
Results: The affinity measurement using ELISA was first published by Friguet et. al. in 1985. We have used this methodology in determining the Kd and selecting humanized antibody to HER2 ECD. (Carter et. AL,
Proc. Natl. Acad. ScL 89, 4285, 1992 ).
In general, binding equilibrium studies require that the concentration of antibody should be close to, or lower than, the value of the dissociation constant. Since the dissociation constant is a priori unknown, it is therefore best to choose total Fab-H concentration that will give sufficient absorbance in the binding ELISA used to measure the free Fab-Hx. This concentration was determined by titrating Fab-Hx in the direct binding
ELISA.
To verify that the antibody-albumin had reached equilibrium, Fab-H was incubated with rabbit albumin at 1 hr., 2 hr. and overnight, and then the reaction mixtures were assayed in the binding ELISA. Equilibrium was reached after 2 hours incubation.
To determine the optimal time needed for free Fab-H to bind to coated albumin in the well, the Ab- albumin mixture was incubated with coated albumin in the well for 15, 30, 45, 60 and 120 minute. Based on this assay, it was determined that 30 minutes was the minimum amount of time required to bind all the free
Fab-H. The results of the Kd (solution binding with preincubation) ELISA assay as shown in Table 10. LISTING OF SEQUENCES
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Table 1 Species Specificity of Albumin-Binding Phage Peptides
SEQ ID NO: Library Phage Binding
Selected on Rabbit SA Rabbit Human Rat
27 BA GENWCDS T L M A Y D LC GQVNM +++ 28 BB IDE LAF YCG I W E C L M HQE QK +++ 29 BC D LCD V D F CW F 30 BD KSCS E LHW L L V E E C L F Selected on Human SA
31 HA EVRS FCT DW P A E K SC K P LRG - +++
19 HB RAPESFVCYW E T I C F E RS EQ - ++ (+)
20 HC EMCY F P G I CWM - +++ ++
32 HE CEVALDACRGGESG C C R H I C E L I RQLC - (+)
Selected on Rat SA
33 RA RNED PCVV L L E M G L ECWEGV +++ 34 RD DTCV D L V R L G L ECWG 35 RB QRQMVD FCL P QWG C LWGD G F ++ + +++ 7 RC D LCL R DWG C LW 36 RE CGCVDVSDWD CWS E C LWSHGA +++
Table 2
Binds
Sequences Selected on Rabbit Albumin SEQ ID Human Rabbit Rat
Library BA G E N WC D S T L M A Y D L C G Q V N M 27 BA-B44 G E DW C D S T L L A F D L C G E G A R 37 +++ BA-B37 G E NW C DW V L L A Y D L C G E D N T 38 +++ BA-B39 M E LWC D S T L M A Y D L C G D F N M 39 +++
Sequences Selected on Human Albumin
Library HA E V R S F C T D WP A E K S C K P L R G 31
HA-H74 E V R S F C T D W P A H Y S C T S L Q G 40 +++
HA-H83 G - R S F C M DW P A H K S C T P L M L 41 +++
HA-H73 G V R T F C Q D W P A H N S C K L L R G 42 +++
HA-H76 Q T R S F C A D W P R H E S C K P L R G 43 +++
HA-H84 R - R T - C - D W P - H N S C K - L R G 44 +++
Library HB R A P E S F V C Y WE T I C F E R S E Q 19
HB-H2 R A A E S S V C Y W P G I C F D R T E Q 45 +++
HB-H8 M E P S R S V C Y A E G I C F D R G E Q 46 +++
HB-H3 R E P A S L V C Y F E D I C F V R A E A 47 + - -
HB-H6 R G P D - V - C Y W P S I C F E R S M P 48 + - -
HB-H4 L V P E R I V C Y F E S I C Y E R S E L 49 +
HB-H16 R M P A S L P C Y W E T I C Y E S S E Q 50 +
HB-H18 R T A E S L V C YW P G I C F A Q S E R 51 + - -
HB-H1 R A P E R W V C Y W E G I C F D R Y E Q 52 (+)
Library HC E M C Y F P G I C WM 20
HB-H12 E I C Y F P G I C W I 53 ++ - -
HB-H13 E L C Y F P G I C W T 54 ++
HC-H6 D I C Y I P G I C W M 55 ++
HC-H2 K L C Y F P G I C W S 56 ++
HC-H3 D L C Y F P G I C W M 57 ++
HC-H4 G M C Y F P G I C W A 58 ++
HC-H7 E M C Y F P G I C W S 59 ++
HC-H9 E M C Y F P G I C W T 60 ++
HC-H10 K T C Y F P G I C W M 61 ++
Human Rabbit Rat
HC-H5 K VCY FPG I CWM 62 HC-H8 D V C Y F P G I CWM 63 ++ HC-H17 E I C Y F PG I CWM 64 ++ HC-H14 A L C Y F P G I CWM 65 ++ HC-H15 E L C Y F PG I CWP 66 ++ HC-H20 E L C Y F PG I CWM 67 ++ HC-H13 D M C Y F PG I CWL 68 ++ HC-H18 D M C Y F PG I CFN 69 ++ HC-H12 E T C Y F PG I CW L 70 ++ HC-H11 E V C Y F P G I CWF 71 ++ HC-H16 E V C Y F PG I CWE 72 ++ HC-H19 E V C Y F P G I CWM 73 ++
Library HBC X X E M C V ' F P G / CW M X X 426
HBC-H7 L A E M C Y F P G I CW M S A 74 +++
HBC-H4 G G E I C Y F P G I C R V L P 75 +++
HBC-H6 E H D M C Y F P G I CW I A D 76 +++
HBC-H10 V Q E V C Y F P G I CWM Q E 77 +++
HBC-H2 S R E V C Y Y P G I CW N G A 78 +++
HBC-H1 D S E V C Y F P G I CWS G T 79 +++
HBC-H3 G T E V C Y F P G I CWG G G 80 +++
HBC-H8 S Y A P C Y F P G I CWM G N 81 +++
HBC-H17 H A E I C Y F P G I CWT E R 82 +++
HBC-H11 N D E I C Y F P G V CW K S G 83 +++
HBC-H18 R D T V C Y F P G I CWM A S 84 +++
HBC-H19 V R D M C Y F P G I CWK S E 85 +++
HBC-H12 A S E I C Y F P G I CWM V E 86 +++
HBC-H13 Q T E L C Y F P G I CWN E S 87 +++
HBC-H14 T T E M C Y F P G I CW K T E 88 +++
HBC-H15 K T E I C Y F P G I CWM S G 89 +++
HBC-H16 Q - - - C - F P G - - W V - K 90 +++
HB-H10 I V E M C Y Y P G I CW I S P 91 +++
HB-H7 S G A I C Y V P G I CWT H A 92 +++ Sequences Selected on Rat Albumin SEQIDNO:
Library RB Q R QM V DFCL PQ WGCL WGDGF 35 Human Rabbit Rat
RB-H1 Q R H P E D I CL P RWGCLWGD DD 93 ++ +++ +++
RB-H6 N R Q M E D I C L PQWGCLWG D D F 94 ++ +++ +++
RB-B2 Q R L M E D I C L P R W GCLW G D R F 95 ++ +++ +++
RB-B5 QW H M E D I C L PQWGCLWG D V L 96 ++ +++ +++
RB-B6 QWQ M E NVC L P KWGCLW E E L D 97 ++ +++ +++
RB-B4 L W A M E D I C L P KWGCLW E D D F 98 ++ +++ +++
RB-B7 L R L M D N I C L P R WGCLW D DG F 99 ++ +++ +++
RB-B8 H S Q M E D I C L P RWGCLWG D E L 100 ++ +++ +++
RB-B11 QWQ V M D I C L P RWGCLW A D E Y 101 ++ +++ +++
RB-B12 Q G L I G D I C L P RWGCLWG D S V 11 ++ +++ +++
RB-B16 H R L V E D I C L P RWGCLWG N D F 102 ++ +++ +++
RB-B9 Q M H M M D I C L P KWGCLWG DT S 103 (+) +++ +++
RB-B14 L R I F E D I C L P KWGCLWG E G F 104 (+) +++ +++
RB-B3 Q S Y M E D I C L P RWGCL S D D AS 105 (+) +++ +++
RB-B10 Q G D F W D I C L P RWGCL S G EGY 106 - +++ +++
RB-B1 RWQ T E DVC L P KWGCL F G DGV 107 - +++ +++
RB-R8 Q G L I G D I C L P RWGCLWG D SV 11 ++ +++ +++
RB-R16 L I F M E DVC L PQWGCLW E DGV 108 ++ +++ +++
HC-R10 Q R D M G D I C L P RWGCLW E DGV 109 ++ +++ +++
RB-R4 Q R H M M DFCLP KWGCLWG DGY 110 - (+) +++
RB-R7 Q R P I M DFC L P KWGCLW E DG F 111 - (+) +++
RB-R11 E R Q M V DFC L P KWGCLWGDG F 112 - (+) +++
RB-R12 Q G Y M V DFC L P RWGCLWG DAN 113 - (+) +++
RB-R13 K M G R V DFCLP KWGCLWG D E L 114 - (+) +++
RB-R15 Q S Q L E DFC L P KWGCLWG DG F 115 - (+) +++
RB-R17 Q G G M G DFC L PQWGCLWG E D L 116 - (+) +++
RB-R5 Q R L M W E I C L P L WGCLWG DG L 117 - - +++
RB-R10 Q R Q I M DFCLPHWGCLWG DG F 118 - - +++
RB-R2 G R Q V V DFC L P KWGCLW E E G L 119 - - +++
RB-R3 Q M Q M S DFCL PQWGCLWGDGY 120 - - +++
RB-R9 K S R M G DFC L P EWGCLWG D E L 121 - - +++
RB-R1 E R Q M E DFCLPQWGCLWGDGV 122 - - +++
RB-R14 Q R Q V V DFC L PQWGCLWG DGS 123 +++ SEQ ID human rabbit rat
Library RC DLCL RD WG CLW 7 RC-R6 D I CL P EWG CLW 124 RC-R8 D I CL P EW G CLW 124 ++ RC-R15 D ICL P EWGCLW 124 ++ RC-R1 D I CL P VW G CLW 125 ++ RC-R2 D I CL P VWG CLW 125 ++ RC-R3 D I CL P VWG CLW 125 ++ RC-R10 D I CL P VWG CLW 125 ++ RC-R12 D I CL P VWG CLW 125 ++ RC-R18 D I CL P VWGCLW 125 ++ RC-R9 DLCL P EWG CLW 126 (+) RC-R4 DLCL P KWGCLW 127 ++ RC-R5 DLCL PVWGCLW 128 (+) RC-R20 D I CL P AWG CLW 129 ++ RC-R17 D I CL P DWG CLW 130 ++ RC-R13 D I CL P RWG CLW 8 RC-R16 D I CL E RWG CLW 131 ++
Library RBC X X D L CL RD WG CL WXX 427
RBC-R16 E W DVC L PHWG CLW D G 132 (+) +++
RBC-R7 W D D I CF RDWG CLWG S 133
RBC-R1 M D D I C L HHWG CLW D E 134 +++
RBC-R2 M D D LC L PNWG CLWG D 135 +++
RBC-R4 F E DFCL PNWG CLWG S 136
RBC-R6 F E D LCV VRWG CLWG D 137 +++
RBC-R5 W E D LC L PDWG CLW E D 138
RBC-R9 S E D FC L PVWG CLW E D 139 +++
RBC-R10 D F D LC L PDWG CLW D D 140 +++
RBC-R8 N WD LCF P DWG CLW D D 141 +++
RBC-R14 E E D LC L PVWG CLWG A 142 +++
RBC-R20 E E DVC L PVWG CLW E G 143 +++
RBC-R12 M F D LC L P KWG CLWG N 144 +++
RBC-R13 E F D LCL PTWG CLW E D 145
RBC-R15 M WDVCF PDWG CLW D V 146 +++
RBC-R18 E WDVCF PAWG CLW DQ 147 +++
RBC-R11 V WD LC L PQWG CLW D E 148 +++ SEQ
ID Human Rabbit Rat
Library RD D T C V D L V R L G L E C WG 34 RD-R2 D T C A D L V R L G L E C W A 149 +++ RD-R7 N T C A D L V R L G L E C W A 150 +++ RD-R11 D T C D D L V Q L G L E C W A 151 +++ RD-R5 D T C E D L V R L G L E C W A 152 +++ RD-R6 D S C G D L L R L G L E C W A 153 +++ RD-R1 D T C S D L V G L G L E C W A 154 +++
Table 3
Multi Species Binders
Phage Binds
SEQID
NO: Human Rabbit Rat
RB QRQMV D F C L P Q W G C L W G D G F 35 + ++ +++
RB-H1 QRHPE D I C L P R W G C L W G D D D 93 ++ +++ +++
RB-H6 NRQME D I C L P Q W G C L W G D D F 94 ++ +++ +++
RB-B12 QG L I G D I C L P R W G C L W G D S V 11 ++ +++ +++
RB-B8 HSQME D I C L P R W G C L W G D E L 100 ++ +++ +++
RB-B7 L R LMD N I C L P R W G C L W D D G F 99 ++ +++ +++
RB-B5 QWHME D I C L P Q W G C L W G D V L 96 ++ +++ +++
RB-B6 QWQME N V C L P K W G C L W E E L D 97 ++ +++ +++
RB-B4 LWAME D I C L P K W G C L W E D D F 98 ++ +++ +++
RB-B11 QWQVM D I C L P R W G C L W A D E Y 101 ++ +++ +++
RB-B16 HR LVE D I C L P R W G C L W G N D F 102 ++ +++ +++
RB-B2 QR LME D I C L P R W G C L W G D R F 95 ++ +++ +++
RB-R8 QG L I G D I C L P R W G C L W G D S V 11 ++ +++ +++
RB-R16 L I FME D V C L P Q W G C L W E D G V 108 ++ +++ +++
HC-R10 QRDMG D I C L P R W G C L W E D G V 109 ++ +++ +++ Table 4 Sequences Selected on Rat Albumin
SEQ ID NO: Hard Randomization Library
155 X X X X X D X C L P X W G C L W X X X X
157 A A Q V G D I C L P R W G C L W S E Y A
8 A G W A A D V C L P R W G C L W E E D V
9 A S V V D D I C L P V W G C L W G E D I
160 A T M E D D I C L P R W G C L W G A E E
161 D E D F E D Y C L P P W G C L W G S S M
162 E G T W D D F C L P R W G C L W L G E R
163 E R W E G D V C L P R W G C L W G E S G
164 G D W M H D I C L P K W G C L W D E K A
165 G I E W G D T C L P K W G C L W R V E G
166 G Q Q G E D V C L P V W G C L W D T S S
167 G R Y P M D L C L P R W G C L W E D S A
168 G S A G D D L C L P R W G C L W E R G A
169 H A S D W D V C L P G W G C L W E E D D
170 L G V T H D T C L P R W G C L W D E V G
171 L V W E E D F C L P K W G C L W G A E D
172 N V G W N D I C L P R W G C L W A Q E S
173 Q G V E W D V C L P Q W G C L W T R E V
174 R L D A W D I C L P Q W G C L W E E P S
175 S E A P G D Y C L P R W G C L W A Q E K
176 T A M D E D V C L P R W G C L W G S G S
177 T E I G Q D F C L P R W G C L W V P G T
178 T L G W P D F C L P K W G C L W R E S D
179 T L S N Q D I C L P G W G C L W G G I N
180 T S T G G D L C L P R W G C L W D S S E
181 V S E M D D I C L P L W G C L W A D A P
182 V S E W E D I C L P S W G C L W E T Q D
183 V V G D G D F C L P K W G C L W D Q A R
184 V V W D D D V C L P R W G C L W E E Y G
185 W S D S D D V C L P R W G C L W G N V A
186 W V E E G D I C L P R W G C L W E S V E
187 A Q A M G D I C L P R W G C L W E A E I
188 A S D R G D L C L P Y W G C L W G P D G SEQ ID Table 4 (continued) NO: Hard Randomization Library
155 X X X X X D X C L P X W G C L W X X X X
189 A S D P G D V C L P R W G C L W G E S F
190 A S N W E D V C L P R W G C L W G E R N
191 A S T P R D I C L P R W G C L W S E D A
192 D G E E G D L C L P R W G C L W A L E H
193 E G E E V D I C L P Q W G C L W G Y P V
194 E V G D L D L C L P R W G C L W G N D K
195 F R D G E D F C L P Q W G C L W A D T S
196 G D M V N D F C L P R W G C L W G S E N
197 G R M G T D L C L P R W G C L W G E V E
198 H E W E R D I C L P R W G C L W R D G D
199 K K V S G D I C L P I W G C L W D N D Y
200 L L E S D D I C L P R W G C L W H E D G
201 M Q A E S D F C L P H W G C L W D E G T
202 M Q G P L D I C L P R W G C L W G G V D
203 Q M P L E D I C L P R W G C L W E G R E
204 R E E W G D L C L P T W G C L W E T K K
205 R V W T E D V- C L P R W G C L W S E G N
206 S I R E Y D V C L P K W G C L W E P S A
207 S P T E W D M C L P K W G C L W G D A L
208 S S G L E D I C L P N W G C L W A D G S
209 S V G W G D I C L P V W G C L W G E G G
210 T E E N W D L C L P R W G C L W G D D W
211 T S G S D D I C L P V W G C L W G E D S
212 T W P - G D L C L P R W G C L W E A E S
213 W D H E L D F C L P V W G C L W A E D V
214 W T E S E D I C L P G W G C L W G P E V
215 W V P F E D V C L P R W G C L W S S Y Q SEQ ID Table 4 (continued) NO: Hard Randomization Library
156 X X X X D X C L P X W G C L W X X X
216 E E D S D I C L P R W G C L W N T S
217 E G Y W D L C L P R W G C L W E L E
218 E L G E D L C L P R W G C L W G S E
219 E T W S D V C L P R W G C L W G A S
220 G D Y V D L C L P G W G C L W E D G
221 G V L D D I C L P R W G C L W G P K
222 H M M D D V C L P G W G C L W A S E
223 I D Y T D L C L P A W G C L W E L E
224 I E H E D L C L P R W G C L W A V D
225 I S E W D L C L P R W G C L W D R S
226 I S W A D V C L P K W G C L W G K D
227 I S W G D L C L P R W G C L W E G S
228 K L W D D I C L P R W G C L W S P L
229 L A W P D V C L P R W G C L W G G M
230 L N E S D I C L P T W G C L W G V D
231 L P E Q D V C L P V W G C L W D A N
232 M A W G D V C L P R W G C L W A G G
233 N E E W D V C L P R W G C L W G G V
234 Q E L Q D F C L P R W G C L W G V G
235 Q R E W D V C L P R W G C L W S D V
236 Q R F W D T C L P R W G C L W G G D
237 R V F T D V C L P R W G C L W D L G
238 S G W D D V C L P V W G C L W G P S
239 S S A S D Y C L P R W G C L W G D L
240 S W Q G D I C L P R W G C L W G V D
241 S Y E T D V C L P Y W G C L W E D A
242 S Y W G D V C L P R W G C L W S E A
243 T L E W D M C L P R W G C L W T E Q
244 V G E F D I C L P R W G C L W D A E
245 V T S W D V C L P R W G C L W E E D
246 W L W E D L C L P K W G C L W E E D
247 A L F E D V C L P V W G C L W G G E
248 A S E W D V C L P T W G C L W M E G
249 A Y S A D I C L P R W G C L W M S E SEQ ID Table 4 (continued) NO: Hard Randomization Library
156 X X X X D X C L P X W G C L W X X X
250 E D W E D I C L P Q W G C L W E G M
251 E D W T D L C L P A W G C L W D T E
252 E E W E D L C L P R W G C L W S A E
253 E F W Q D I C L P N W G C L W A E S
254 E G F S D I C L P R W G C L W S Q E
255 E T W E D L C L P N W G C L W D L E
256 G E V N D F C L P R W G C L W E G D
257 G G E W D V C L P A W G C L W G E E
258 K D W Y D I C L P R W G C L W G G E
259 K L G Q D I C L P R W G C L W D F A
260 L E E W D I C L P Q W G C L W R E G
261 L V L P D I C L P K W G C L W G D T
262 M D L A D I C L P K W G C L W E S D
263 M V L D D I C L P R W G C L W S E K
264 M W S G D L C L P R W G C L W G E T
265 N R M G D I C L P R W G C L W D G H
266 R D W E D L C L P N W G C L W E L S
267 R G D W D L C L P K W G C L W E G V
268 R Q W E D I C L P R W G C L W G V G
269 R V E Y D L C L P R W G C L W E P P
270 S I W S D I C L P R W G C L W E S D
271 T D E W D I C L P N W G C L W E A G
272 T E D V D F C L P L W G C L W E E P
273 V K E E D F C L P R W G C L W E A G
274 W D F E D I C L P R W G C L W A D M
275 W E D W D V C L P R W G C L W G G G
276 Y E D I D I C L P R W G C L W D L S
Table 5 Sequences Selected on Rabbit Albumin
SEQ ID NO: Hard Randomization Library
155 X X X X X D X C L P X W G C L W X X X X
277 A G L D E D I C L P R W G C L W G K E A
278 A G M M G D I C L P R W G C L W Q G E P
279 A P G D W D F C L P K W G C L W D D D A
280 A Q L F D D I C L P R W G C L W S D G Y
281 A R T M G D I C L P R W G C L W G A S D
282 A W Q D F D V C L P R W G C L W E P E S
283 D T T W G D I C L P R W G C L W S E E A
284 E G F L G D I C L P R W G C L W G H Q A
285 E Q W L H D I C L P K W G C L W D D T D
286 E T G W P D I C L P R W G C L W E E G E
287 F E L G E D I C L P R W G C L W E E H N
288 G A S L G D I C L P R W G C L W G P E D
289 G E W W E D I C L P R W G C L W G S S S
290 G S L E S D I C L P R W G C L W G I D E
291 G W L E E D I C L P K W G C L W G A D N
292 H E Q W D D I C L P R W G C L W G G S Y
293 Q R V D D D I C L P R W G C L W G E N S
294 S V G W G D I C L P K W G C L W A E S D
295 T L M S N D I C L P R W G C L W D E P K
296 T L V L D D I C L P R W G C L W D M T D
297 T W Q G E D I C L P R W G C L W D T E V
298 V G V F D D I C L P R W G C L W E Q P V
299 V P A M G D I C L P R W G C L W E A R N
300 V S L G D D I C L P K W G C L W E P E A
301 V W I D R D I C L P R W G C L W D T E N
302 W R W N E D I C L P R W G C L W E E E A
303 A V S W A D I C L P R W G C L W E R A D
304 A W L D E D I C L P K W G C L W N T G V
305 F S L D E D I C L P K W G C L W G A E K
306 G D L G D D I C L P R W G C L W D E Y P
307 G E G W S D I C L P R W G C L W A E D E
308 G L M G E D I C L P R W G C L W K G D I 155 X X X X X D X C L P X W G C L W X X X X
309 G W H D R D I C L P R W G C ' L W E Q N D
310 L L G G H D I C L P R W G C L W G G D V
311 M R W S S D I C L P K W G C L W G D E E
312 Q F E W D D I C L P R W G C L W E V E V
313 Q G W W H D I C L P R W G C L W E E G E
314 R E G W P D I C L P R W G C L W S E T G
315 R E L W G D I C L P R W G C L W E H A T
316 R L E L M D I C L P R W G C L W D P Q D
317 S G V L G D I C L P R W G C L W E E A G
318 S L G L T D L C L P R W G C L W E E E Q
319 S S L E Q D I C L P R W G C L W G Q D A
320 S V L S D D I C L P R W G C L W W D F S
321 T S L L D D I C L P R W G C L W Y E E G
322 T S L A D D I C L P R W G C L W S E D G
323 V E M W H D I C L P R W G C L W D S N A
324 W D L A S D I C L P R W G C L W E E E A
325 F I T Q D I C L P R W G C L W G E N
326 F L W R D I C L P R W G C L W S E G
327 F V H E D I C L P R W G C L W G E G
328 G L G D D I C L P R W G C L W G R D
329 G M F D D I C L P K W G C L W G L G
330 G P G W D I C L P R W G C L W G E E
331 G P W Y D I C L P R W G C L W D G V
332 G W D D D I C L P R W G C L W G D G
333 L E Y E D I C L P K W G C L W G G E
334 L L D E D I C L P R W G C L W G V R
335 L M S P D I C L P K W G C L W E G D
336 L V L G D I C L P R W G C L W E S D
337 M L S R D I C L P R W G C L W E E E
338 M P W T D I C L P R W G C L W S E S
339 R L G S D I C L P R W G C L W G A G
340 R L G S D I C L P R W G C L W D Y Q
341 S P W M D I C L P R W G C L W E S G
342 S T F T D I C L P R W G C L W E L E
343 S V L S D I C L P R W G C L W E E S
344 T W F S D I C L P R W G C L W E P G
345 V H Q A D I C L P R W G C L W G D T 155 X X X X X D X C L P X W G C L W X X X X
346 V L L G D I C L P L W G C L W G E D
347 V N W G D I C L P R W G C L W G E S
348 V V W S D I C L P R W G C L W D K E
349 V W Y K D I C L P R W G C L W E A E
350 W D Y G D I C L P R W G C L W E E G
351 W E V Q D I C L P R W G C L W G D D
352 Y I W R D I C L P R W G C L W E G E
353 Y R D Y D I C L P R W G C L W D E R
354 A F W S D I C L P R W G C L W E E D
355 D W G R D I C L P R W G C L W D E E
356 E A W G D I C L P R W G C L W E L E
357 L I L S D I C L P R W G C L W D D T
358 L K L E D I C L P R W G C L W G E S
359 L L T R D I C L P K W G C L W G S D
360 L R W S D I C L P R W G C L W E E T
361 L Y L R D I C L P K W G C L W E A D
362 N W Y D D I C L P R W G C L W D V E
363 Q D W E D I C L P R W G C L W G D -
364 Q S W P D I C L P K W G C L W G E G
365 T L L Q D I C L P R W G C L W E S D
366 V R L M D I C L P R W G C L W G E E
367 V R W E D I C L P R W G C L W G E E
368 W D V A D I C L P R W G C L W A E D
369 W H M G D I C L P R W G C L W S E V
370 W K D F D I C L P R W G C L W D D H
371 W L S E D I C L P Q W G C L W E E S
372 W L S E D I C L P R W G C L W A A D
373 W L S D D I C L P R W G C L W D D L
Table 6
Sequences Selected on Human Albumin
SEQ ID NO: Hard Randomization Library
155 X X X X X D X C L P X W G C L W X X X X
374 E V R E W D I C L P R W G C L W E N W R
375 F G Q E W D I C L P R W G C L W G N E Q
376 I W Q L E D I C L P R W G C L W E D G L
377 N T P T Y D I C L P R W G C L W G D V P
378 Q P V W S D I C L P R W G C L W G E D H
379 S W Y G G D I C L P - W G C L W S E E S
380 W G M A R D W C L P M W G C L W R G G G
381 W H L T D D I C L P R W G C L W G D E Q
382 N W A E N D I C L P R W G C L W G D E N
383 S A R E W D I C L P T W G C L W E K D I
156 X X X X D X C L P X W G C L W X X X
384 A G E W D I C L P R W G C L W D V E
385 E I R W D F C L P R W G C L W D E D
386 E S L G D I C L P R W G C L W G S G
387 E Y W G D I C L P R W G C L W D W Q
388 K M W S D I C L P R W G C L W E E E
389 M G T K D I C L P R W G C L W A E A
390 M H E W D I C L P R W G C L W E S S
391 R G L H D A C L P W W G C L W A G S
392 R L F G D I C L P R W G C L W Q G E
393 S G E W D I C L P R W G C L W G E G
394 S M F F D H C L P M W G C L W A E Q
395 V G E W D I C L P N W G C L W E R E
396 W W M A D R C L P L W G C L W R G D
397 W W V R D L C L P T W G C L W S G K
398 Y F D G D I C L P R W G C L W G S D
399 T L F Q D I C L P R W G C L W E E S
400 W F P K D R C L P V W G C L W E R H Table 7 Peptides Binding Multiple Species Albumin
SEO IDNO: IC50 (nM) Rabbit Rat Mouse
SA02 7 D L C L R D W G C LW -n
SA04 8 D I C L P R W G C LW -n 8543 787 40
SA05 16 M E D I C L P R W G C LW E D -n 804 161 6
SA06 401 Q R L M E D I C L P R W G C LW E D D F -n 128 68 8
SA07 11 Q G L I G D I C L P R W G C LW G D S V -n 30 35 6
SA08 12 ; Ac Q G L I G D I C L P R W G C LW G D S V K -n 63 68 10
SA09 13 Ac E D I C L P R W G C LW E D D -n 1687 258 6
SA10 14 Ac R L M E D I C L P R W G C LW E D D -n 86 77 4
SA11 15 Ac M E D I C L P R W G C LW E D D -n 1213 232 17
SA12 16 Ac M E D I C L P R W G C LW E D -n 1765 205 13
SA13 17 Ac R L M E D I C L A R W G C LW E D D -n 3200 2480 188
D3H44- 401
L Q R L E D I C L P R W G C LW E D D F -n 241 D3H44- 401
Ls Q R L M E D I C L P R W G C LW E D D F -n 75
TABLE 8 Surface Plasmon Resonance Peptide Competition
Kd (nM) IC50 (nM)
Figure imgf000066_0001
TABLE 9
Figure imgf000067_0001
Table 10 Kd (Solution Binding with Preincubation) ELISA Assay
Figure imgf000068_0001

Claims

CLAIMSWe claim:
1. A conjugate molecule comprising at least one serum albumin-binding domain (SABM), at least one targeting agent (TA) and at least one cytotoxic agent (CA).
2. The conjugate molecule according to claim 1 , wherein the SABM comprises an amino acid sequence that is at least 50% identical to the sequence of DICLPRWGCLW (SEQ ID NO:8) and wherein the amino acid sequence has two Cys residues with five amino acid residues in between the Cys residues.
3. The conjugate molecule according to claim 1, wherein the SABM comprises a variant of the amino acid sequence of DICLPRWGCLW (SEQ ID NO:8), wherein between 1-5 residues of any of one of the residues of SEQ ID NO:8, except for the Cys residues is substituted with a different amino acid residue.
4. The conjugate molecule according to claim 1, wherein the SABM comprises a linear or cyclic amino acid sequence selected from the group consisting of :
Xaa-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa-Cys-Xaa-Xaa
Phe-Cys-Xaa-Asp-Trp-Pro-Xaa-Xaa-Xaa-Ser-Cys [SEQ ID NO: 1]
Val-Cys-Tyr-Xaa-Xaa-Xaa-Ile-Cys-Phe [SEQ ID NO: 2]
Cys-Tyr-Xaal-Pro-Gly-Xaa-Cys [SEQ ID NO: 3] Asp-Xaa-Cys-Leu-Pro-Xaa-Trp-Gly-Cys-Leu-Trp [SEQ ID NO: 4]
Trp-Cys-Asp-Xaa-Xaa-Leu-Xaa-Ala-Xaa-Asp-Leu-Cys [SEQ ID NO: 5];
Asp-Leu-Val-Xaa-Leu-Gly-Leu-Glu-Cys-Trp [SEQ ID NO: 6];
CXXGPXXXXC [SEQ ID NO:21]
XXXXCXXGPXXXXCXXXX [SEQ ID NO:22] CXXXXXXCXXXXXXCCXXXCXXXXXXC [SEQ ID NO:23]
CCXXXCXXXXXXC [SEQ ID NO:24]
CCXXXXXCXXXXCXXXXCC [SEQ ID NO:25]
CXCXXXXXXXCXXXCXXXXXX [SEQ ID NO:26]
XXXXXDXCLPXWGCLWXXXX [SEQ ID NO: 155] XXXXDXCLPXWGCLWXXX [SEQ ID NO: 156]
DXCLPXWGCLW [SEQ ID NO:423]
XXXXDICLPRWGCLWXXX [SEQ ID NO:424],
XXXXXDICLPRWGCLWXXXXISEQIDNO^]
XXEMCYFPGICWMXX [SEQ ID NO:426] XXDLCLRDWGCLWXX[SEQIDNO:427] wherein X is any amino acid residue.
5. The conjugate molecule according to claim 1, wherein the SABM comprises any one of the amino acid sequences selected from the group consisting of SEQ ID NOs: 7-20, 27-154 and 157-421.
6. The conjugate molecule according to claim 1 , wherein, the SABM comprises the amino acid sequence selected from the group consisting of: SEQ ID NOs: 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19 and 20.
7. The conjugate molecule according to claim 1, wherein the SABM comprises any one of the peptides sequences described in Tables 1 -9.
8. The conjugate molecule according to claim, 1 , wherein the SABM binds to serum albumin with a Kd that is about 100 μM or less.
9. The conjugate molecule according to claim 1, wherein the TA is an antibody.
10. The conjugate molecule according to claim 9, wherein the antibody is a Fab, F(ab)2, scFv or a diabody.
11. The conjugate molecule according to claim 1 , wherein the TA binds to a cell surface protein that is elevated in a cancer.
12. The conjugate molecule according to claim 11 , wherein the cell surface protein is HER2, PSMA, PCMA, KDR and FIt-I.
13. The conjugate molecule according to claim 1 1, wherein the cell surface protein is a B cell surface marker.
14. The conjugate molecule according to claim 11 , wherein the cell surface protein is a B cell surface marker is CD20 or BR3.
15. The conjugate molecule according to claim 1 wherein the TA is an anti-HER2 antibody.
16. The conjugate molecule according to claim 15, wherein the TA is an antibody having a VH and
VL sequence of SEQ ID NO:428 and 429.
17. The conjugate molecule according to claiml5, wherein the TA comprises a variant sequence of the anti-HER2 antibody that comprises SEQ ID NO:428 and SEQ ID NO:429.
18. The conjugate molecule according to claim 1, wherein the cytotoxic agent is monomethylauristatin (MMAE).
19. The conjugate molecule according to claim 1, wherein a linker moiety located between said SABM and targeting agent or cytotoxic agent is GGGS.
20. The conjugate molecule according to claim 1, wherein the SABM binds to human albumin.
21. A composition comprising the conjugate molecule according to claim 1 admixed with a pharmaceutical carrier for therapeutic use.
22. A method for reducing the toxicity of a therapeutic agent comprising the step of producing a therapeutic agent with a serum albumin binding moiety (SABM) conjugated to the therapeutic agent.
23. A method for reducing the toxicity of a therapeutic agent in a mammal comprising administering to the mammal a therapeutically effective amount of the conjugate molecule according to claim 1.
24. The method according to claim 22 or 23, further comprising the step of measuring the toxicity of the therapeutic agent:SABM conjugate in vivo.
25. A method of treating a cancer in a mammal comprising the step of treating a mammal having the cancer with a therapeutically effective amount of a conjugate molecule according to claim 1.
26. A method of treating an autoimmune disorder in a mammal comprising the step of treating a mammal having the autoimmune disorder with a therapeutically effective amount of a conjugate molecule according to claim 1 that binds to B-cells that contribute to or cause the autoimmune disorder.
27. An article of manufacture comprising a container, a composition within the container comprising a conjugate molecule according to claim 1 , a package insert containing instructions to administer a therapeutically effective dose.
PCT/US2005/033952 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity WO2006041641A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MX2007003907A MX2007003907A (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity.
EP05810079A EP1796718A2 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity
JP2007535700A JP2008515889A (en) 2004-10-05 2005-09-22 A therapeutic agent with reduced toxicity
AU2005294723A AU2005294723A1 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity
CA002583137A CA2583137A1 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity
BRPI0516577-6A BRPI0516577A (en) 2004-10-05 2005-09-22 therapeutic agents with reduced toxicity
IL182261A IL182261A0 (en) 2004-10-05 2007-03-28 Therapeutic agents with decreased toxicity

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61650704P 2004-10-05 2004-10-05
US60/616,507 2004-10-05
US64153405P 2005-01-05 2005-01-05
US60/641,534 2005-01-05

Publications (2)

Publication Number Publication Date
WO2006041641A2 true WO2006041641A2 (en) 2006-04-20
WO2006041641A3 WO2006041641A3 (en) 2006-06-29

Family

ID=36051453

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/033952 WO2006041641A2 (en) 2004-10-05 2005-09-22 Therapeutic agents with decreased toxicity

Country Status (11)

Country Link
US (2) US20060073152A1 (en)
EP (1) EP1796718A2 (en)
JP (1) JP2008515889A (en)
KR (1) KR20070073886A (en)
AU (1) AU2005294723A1 (en)
BR (1) BRPI0516577A (en)
CA (1) CA2583137A1 (en)
IL (1) IL182261A0 (en)
MX (1) MX2007003907A (en)
RU (1) RU2007116973A (en)
WO (1) WO2006041641A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012143495A3 (en) * 2011-04-21 2012-12-13 Bayer Intellectual Property Gmbh Novel binder-drug conjugates (adcs) and their use
WO2014210029A1 (en) * 2013-06-24 2014-12-31 Riogin Corporation Double binding constructs
US8937159B2 (en) 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2494105C (en) * 2002-07-31 2013-04-02 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
ZA200603619B (en) * 2003-11-06 2008-10-29 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1817336B1 (en) * 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
AU2006269422B2 (en) 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
AR067543A1 (en) 2007-07-16 2009-10-14 Genentech Inc ANTI-CD79B ANTIBODIES AND HUMANIZED IMMUNOCATE PLAYERS AND METHODS OF USE
JP5469600B2 (en) 2007-07-16 2014-04-16 ジェネンテック， インコーポレイテッド Anti-CD79b antibody and immunoconjugate and method of use thereof
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
PE20091318A1 (en) 2008-01-31 2009-09-16 Genentech Inc ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE OF THE SAME
EP2842575B1 (en) * 2008-03-18 2017-09-27 Seattle Genetics, Inc. Auristatin drug linker conjugates
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
EP2726881A1 (en) 2011-06-28 2014-05-07 Koninklijke Philips N.V. Means for the examination of body fluids
US20130165628A1 (en) * 2011-12-23 2013-06-27 Sri International Double Binding Constructs
CA2922618C (en) 2013-08-30 2020-04-28 Aprilbio Co., Ltd An anti serum albumin fab-effector moiety fusion construct, and the preparing method thereof
ES2796903T3 (en) 2014-09-23 2020-11-30 Hoffmann La Roche Procedure for the use of anti-CD79b immunoconjugates
EP3665202A1 (en) 2017-08-09 2020-06-17 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
WO2023092733A1 (en) * 2021-11-25 2023-06-01 苏州慧疗生物医药科技有限公司 Cyclic polypeptide carrier for efficient delivery of nucleic acid, and variant thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001743A1 (en) * 1989-08-01 1991-02-21 Cemu Bioteknik Ab Stabilized protein or peptide conjugates
US6387371B1 (en) * 1988-01-12 2002-05-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
WO2003031464A2 (en) * 2001-10-10 2003-04-17 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
WO2004032828A2 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3862925A (en) * 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) * 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (en) * 1974-03-08 1982-06-04
US4105603A (en) * 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4970198A (en) * 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5079233A (en) * 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) * 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1992022653A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1993008842A1 (en) * 1991-11-08 1993-05-13 Somatogen, Inc. Hemoglobins as drug delivery agents
CA2173150C (en) * 1993-10-01 2004-11-30 Kyoichi Sakakibara Novel peptide derivatives
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20030009395A1 (en) * 2001-07-06 2003-01-09 Yu Philip Shi-Lung Method and apparatus for providing information regarding a product
WO2003087131A2 (en) * 2002-04-10 2003-10-23 Genentech, Inc Anti-her2 antibody variants
US20040032828A1 (en) * 2002-08-16 2004-02-19 Cellglide Technologies Corp. Service management in cellular networks
ZA200603619B (en) * 2003-11-06 2008-10-29 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387371B1 (en) * 1988-01-12 2002-05-14 Genentech, Inc. Monoclonal antibodies directed to the HER2 receptor
WO1991001743A1 (en) * 1989-08-01 1991-02-21 Cemu Bioteknik Ab Stabilized protein or peptide conjugates
WO2003031464A2 (en) * 2001-10-10 2003-04-17 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
WO2004032828A2 (en) * 2002-07-31 2004-04-22 Seattle Genetics, Inc. Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DENNIS M S ET AL: "Albumin binding as a general strategy for improving the pharmacokinetics of proteins" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 277, no. 38, 20 September 2002 (2002-09-20), pages 35035-35043, XP002285300 ISSN: 0021-9258 cited in the application *
FRANCISCO J A ET AL: "cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity" BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 102, no. 4, 15 August 2003 (2003-08-15), pages 1458-1465, XP002280965 ISSN: 0006-4971 *
MAO WEIGUANG ET AL: "EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 64, no. 3, 1 February 2004 (2004-02-01), pages 781-788, XP002343724 ISSN: 0008-5472 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937159B2 (en) 2009-12-16 2015-01-20 Abbvie Biotherapeutics Inc. Anti-HER2 antibodies and their uses
WO2012143495A3 (en) * 2011-04-21 2012-12-13 Bayer Intellectual Property Gmbh Novel binder-drug conjugates (adcs) and their use
US8992932B2 (en) 2011-04-21 2015-03-31 Seattle Genetics, Inc. Binder-drug conjugates (ADCs) and use thereof
WO2014210029A1 (en) * 2013-06-24 2014-12-31 Riogin Corporation Double binding constructs

Also Published As

Publication number Publication date
JP2008515889A (en) 2008-05-15
KR20070073886A (en) 2007-07-10
US20060073152A1 (en) 2006-04-06
US20090123376A1 (en) 2009-05-14
RU2007116973A (en) 2008-11-20
AU2005294723A1 (en) 2006-04-20
MX2007003907A (en) 2007-05-21
CA2583137A1 (en) 2006-04-20
WO2006041641A3 (en) 2006-06-29
IL182261A0 (en) 2007-07-24
EP1796718A2 (en) 2007-06-20
BRPI0516577A (en) 2008-09-16

Similar Documents

Publication Publication Date Title
US20060073152A1 (en) Therapeutic agents with decreased toxicity
CN106604933B (en) anti-PD-L1 antibodies and diagnostic uses thereof
JP2021120382A (en) Site-Specific Antibody Conjugation Methods and Compositions
US9522195B2 (en) Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
TWI438004B (en) Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
US10189910B2 (en) Anti-DPEP3 antibodies and methods of use
CN102791737B (en) The antibody of specific binding EPHA2 acceptor
CN101072581A (en) Therapeutic agents with decreased toxicity
US20040001827A1 (en) Serum albumin binding peptides for tumor targeting
US20170073430A1 (en) Novel anti-rnf43 antibodies and methods of use
EP3107576A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
AU2014312215A1 (en) Site-specific antibody conjugation methods and compositions
US20180112004A1 (en) Engineered site-specific antibodies and methods of use
JP2012100676A (en) Antibody with immune effector activity and that internalizes in endosialin-positive cell
CN114450024A (en) anti-CD 39 antibody compositions and methods
US20240101717A1 (en) Anti-her-2/trop-2 constructs and uses thereof
US20210261670A1 (en) Novel anti-bmpr1b antibodies and methods of use
US20230025600A1 (en) Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
EP3452511A1 (en) Novel anti-tnfrsf21 antibodies and methods of use
KR20230033648A (en) Bispecific Antibody-Drug Conjugates Targeting EGFR and MUC1 and Uses Thereof
US20230235080A1 (en) Trophoblast cell-surface antigen-2 (trop-2) antibodies
TW202404646A (en) Dosage regimen of an anti-cdh6 antibody-drug conjugate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 554161

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 182261

Country of ref document: IL

Ref document number: 2005294723

Country of ref document: AU

Ref document number: 2370/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/003907

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2583137

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007535700

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005810079

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005294723

Country of ref document: AU

Date of ref document: 20050922

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005294723

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007/03478

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020077010255

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007116973

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200580041758.9

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005810079

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0516577

Country of ref document: BR